Compositions and methods for the treatment of tau-related disorders

Abstract

The disclosure provides compositions and methods for the preparation, manufacture and use of an adeno-associated virus (AAV) particle for the vectorized delivery of an antibody molecule that binds to human tau.

Description

VTJ-4010PC COMPOSITIONS AND METHODS FOR THE TREATMENT OF TAU-RELATED DISORDERS RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No.63 / 463,793, filed May 3, 2023, U.S. Provisional Application No.63 / 593638, filed October 27, 2023, and U.S. Provisional Application No.63 / 564127, filed March 12, 2024. The contents of the aforementioned applications are hereby incorporated by reference. FIELD OF THE DISCLOSURE

[0002] Described herein are compositions and methods relating to AAV particles for delivery of an anti-tau antibody molecule for use in the treatment of tau-related disorders (e.g., tauopathies). BACKGROUND

[0003] Tauopathies are a group of neurodegenerative diseases characterized by the dysfunction and / or aggregation of the microtubule associated protein tau. Tau is normaly a very soluble protein known to associate with microtubules based on the extent of its phosphorylation. Tau is considered a critical component of intracelular traficking processes, particularly in neuronal cels, given their unique and extended structure. Hyperphosphorylation of tau depresses its binding to microtubules and microtubule assembly activity. Further, hyperphosphorylation of tau renders it prone to misfolding and aggregation. In tauopathies, the tau becomes hyperphosphorylated, misfolds and aggregates as neurofibrilary tangles (NFT) of paired helical filaments (PHF), twisted ribbons or straight filaments. These NFT are largely considered indicative of impending neuronal cel death and thought to contribute to widespread neuronal cel loss, leading to a variety of behavioral and cognitive deficits.

[0004] Several approaches have been proposed for therapeuticaly interfering with progression of tau pathology and preventing the subsequent molecular and celular consequences. Given that NFT are composed of hyperphosphorylated, misfolded and aggregated forms of tau, interference at each of these stages provides targets that can be pursued. Introducing agents that limit phosphorylation, block misfolding or prevent aggregation are promising strategies. It has also been suggested that introduction of anti-tau antibodies can prevent the trans-neuronal spread of tau pathology.

[0005] There remains a need for anti-tau antibodies for use in tauopathy treatment, diagnostics, and other applications. The present disclosure addresses this need with related compounds and methods described herein.VTJ-4010PC SUMMARY

[0006] The present disclosure addresses the need in the art for improved methods for delivery of antibodies and antibody-based therapeutics targeting tau by providing novel AAV particles comprising an AAV capsid variant comprising viral genomes encoding an anti-tau antibody molecule and / or an antibody-based composition and methods of using the same for the treatment, prevention, diagnosis, and research of diseases, disorders and / or conditions associated with tau pathology.

[0007] Accordingly, in one aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid, e.g., a transgene, encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises an amino acid sequence having the folowing formula: [N1]-[N2]-[N3], wherein: (i) optionaly [N1] comprises X1, X2, and X3, wherein at least one of X1, X2, or X3 is G; (i) [N2] comprises the amino acid sequence of SPH; and (ii) [N3] comprises X4, X5, and X6, wherein at least one of X4, X5, or X6 is a basic amino acid, e.g., a K or R. In some embodiments, position X4 of [N3] is K. In some embodiments, position X5 of [N3] is K. In some embodiments, [N3] is or comprises SKA. In some embodiments [N3] is or comprises KSG. In some embodiments, [N2]-[N3] is present immediately subsequent to position 455, numbered according to SEQ ID NO: 138, 981 or 982. In some embodiments, [N1] is present immediately subsequent to position 452, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138, 981, or 982. In some embodiments, [N1] replaces positions 453- 455 (e.g., G453, S454, and G455), relative to a reference sequence numbered according to SEQ ID NO: 138. In some embodiments, the AAV capsid variant comprises H at position 454 and D at position 455, numbered according to SEQ ID NO: 138 or 982. In some embodiments, the AAV capsid variant comprises S at position 454 and G at position 455, numbered according to SEQ ID NO: 138 or 981. In some embodiments, an insert of 8 amino acids replaces the SG at positions 454-455, numbered according to SEQ ID NO: 138. In some embodiments, an insert of 6 amino acids is present immediately subsequent to position 455, numbered according to SEQ ID NO: 138, 981, or 982.

[0008] In yet another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises an amino acid sequence having the folowing formula: [N1]- [N2]-[N3] (SEQ ID NO: 4729), wherein: (i) [N1] comprises positions X1, X2, and X3, wherein position X2 is S and position X3 is G; (i) [N2] comprises the amino acid sequence SPH; and (ii) [N3] comprises positions X4, X5, and X6, wherein position X5 is K. In some embodiments, [N1]-[N2]-[N3] is presentVTJ-4010PC immediately subsequent to position 452 and replaces positions 453-455, numbered according to SEQ ID NO: 138 or 982. In some embodiments, [N1]-[N2]-[N3] is or comprises GSGSPHSKA (SEQ ID NO: 1671).

[0009] In another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises an amino acid sequence having the folowing formula: [N1]-[N2]-[N3] (SEQ ID NO: 4978), wherein: (i) [N1] comprises positions X1, X2, and X3, wherein position X2 is an amino acid other than S and position X3 is an amino acid other than G; (i) [N2] comprises the amino acid sequence SPH; and (ii) [N3] comprises positions X4, X5, and X6, wherein position X4 is K. In some embodiments, [N1]-[N2]-[N3] is present immediately subsequent to position 452 and replaces positions 453-455, numbered according to SEQ ID NO: 138 or 982. In some embodiments, [N1]-[N2]-[N3] is or comprises GHDSPHKSG (SEQ ID NO: 1672).

[0010] In another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises (a) the amino acid sequence of any of the sequences provided in Tables 2-4, 24-26, 28, or29; (b) an amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17, consecutive amino acids from any one of the sequences provided in Tables 2-4, 24-26, 28, or29; (c) an amino acid sequence comprising at least one, two, or three, but no more than four different amino acids, relative to any one of the sequences provided in Tables 2-4, 24-26, 28, or 29; or (d) an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of any one of the sequences provided in Tables 2-4, 24-26, 28, or29. In some embodiments, the amino acid sequence is present in loop IV. In some embodiments, the amino acid sequence is present immediately subsequent to position 448, 452, 453, 455, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138.

[0011] In yet another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises (a) the amino acid sequence of any of SEQ ID NOs: 945-980 or 985-986; (b) an amino acid sequence comprising at least 3, 4, or 5 consecutive amino acids from any one of SEQ ID NOs: 945-980 or 985-986; (c) an amino acid sequence comprising at least one, two, or three but no more than four diferent amino acids, relative to the amino acid sequence of any one of SEQ ID NOs: 945-980 or 985-986; (d) an amino acid sequence comprising at least one, two, or three but noVTJ-4010PC more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of any one of SEQ ID NOs: 945-980 or 985-986. In some embodiments, the amino acid sequence is present in loop IV. In some embodiments, the amino acid sequence is present immediately subsequent to position 448, 452, 453, 455, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138.

[0012] In yet another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises (a) the amino acid sequence of any of SEQ ID NOs: 2, 200, 201, 941, 943, 204, 208, 404, or 903-909; (b) an amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 consecutive amino acids from any one of SEQ ID NOs: 2, 200, 201, 941, 943, 204, 208, 404, or 903-909; (c) an amino acid sequence comprising at least one, two, or three, but no more than four different amino acids, relative to the amino acid sequence of any one of SEQ ID NOs: 2, 200, 201, 941, 943, 204, 208, 404, or 903-909; or (d) an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of any one of SEQ ID NOs: 2, 200, 201, 941, 943, 204, 208, 404, or 903-909. In some embodiments, the amino acid sequence is present in loop IV. In some embodiments, the amino acid sequence is present immediately subsequent to position 448, 452, 453, 455, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138.

[0013] In yet another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of SPH, wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to the amino acid sequence of any one of SEQ ID NOs: 36-59, 138, 981, or 982.

[0014] In yet another aspect, present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to the amino acid sequence of SEQ ID NO: 138.

[0015] In yet another aspect, present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein theVTJ-4010PC amino acid sequence is present immediately subsequent to position 455, numbered according to the amino acid sequence of SEQ ID NO: 981.

[0016] In yet another aspect, present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the amino acid sequence is present immediately subsequent to position 453, numbered according to the amino acid sequence of SEQ ID NO: 138.

[0017] In yet another aspect, present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the amino acid sequence is present immediately subsequent to position 453, numbered according to the amino acid sequence of SEQ ID NO: 982.

[0018] In yet another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to beta-amyloid, wherein the AAV capsid variant comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941) in hypervariable loop IV. In some embodiments, hypervariable loop IV comprises amino acids 449-460, numbered according to SEQ ID NO: 138. In some embodiments, the amino acid sequence of SEQ ID NO: 941 is present immediately subsequent to position 455, numbered according to SEQ ID NO: 981. In some embodiments, the AAV capsid variant comprises the amino acid E at position 451, numbered according to SEQ ID NO: 981. In some embodiments, the AAV capsid variant comprises the amino acid V at position 453, numbered according to SEQ ID NO: 981. In some embodiments, the AAV capsid variant comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941); the amino acid E at position 451, numbered according to SEQ ID NO: 981; and the amino acid V at position 453, numbered according to SEQ ID NO: 981.

[0019] In yet another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to beta-amyloid, wherein the AAV capsid variant comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941) in hypervariable loop IV. In some embodiments, hypervariable loop IV comprises amino acids 449-460, numbered according to SEQ ID NO: 138. In some embodiments, the amino acid sequence of SEQ ID NO: 941 is present immediately subsequent to position 455, numbered according to SEQ ID NO: 981. In some embodiments, the AAV capsid variant comprises the amino acid E at position 451, numbered according to SEQ ID NO: 981. In some embodiments, the AAV capsid variant comprises the amino acidVTJ-4010PC R at position 452, numbered according to SEQ ID NO: 981. In some embodiments, the AAV capsid variant comprises the amino acid V at position 453, numbered according to SEQ ID NO: 981. In some embodiments, the AAV capsid variant comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941); the amino acid E at position 451, numbered according to SEQ ID NO: 981; the amino acid R at position 452, numbered according to SEQ ID NO: 981; and the amino acid V at position 453, numbered according to SEQ ID NO: 981.

[0020] In yet another aspect, present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises an amino acid sequence comprising at least 3, 4, 5, or 6 consecutive amino acids from the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein: (i) the 3 consecutive amino acids comprise SPH; (i) the 4 consecutive amino acids comprise SPHS (SEQ ID NO: 1673); (ii) the 5 consecutive amino acids comprise SPHSK (SEQ ID NO: 1674); or (iv) the 6 consecutive amino acids comprise SPHSKA (SEQ ID NO: 941); wherein the AAV capsid variant comprises: (a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 138 or SEQ ID NO: 981; (b) a VP2 protein comprising the amino acid sequence of positions 138-736 of SEQ ID NO: 138 or positions 138-742 of SEQ ID NO: 981; (c) a VP3 protein comprising the amino acid sequence of positions 203-736 of SEQ ID NO: 138 or positions 203-742 of SEQ ID NO: 981; or (d) an amino acid sequence with at least 90% (e.g., at least about 95, 96, 97, 98, or 99%) sequence identity to any of the amino acid sequences in (a)-(c). In some embodiments, the amino acid sequence is present immediately subsequent to positions 455, numbered according to SEQ ID NO: 138 or 981.

[0021] In yet another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises one or two, but no more than three substitutions relative to the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the AAV capsid variant comprises: (a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 138 or SEQ ID NO: 981; (b) a VP2 protein comprising the amino acid sequence of positions 138-736 of SEQ ID NO: 138 or positions 138- 742 of SEQ ID NO: 981; (c) a VP3 protein comprising the amino acid sequence of positions 203-736 of SEQ ID NO: 138 or positions 203-742 of SEQ ID NO: 981; or (d) an amino acid sequence with at least 90% (e.g., at least about 95, 96, 97, 98, or 99%) sequence identity to any of the amino acid sequences in (a)-(c). In some embodiments, the amino acid sequence is present immediately subsequent to positions 455, numbered according to SEQ ID NO: 138 or 981.VTJ-4010PC

[0022] In another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises at least 3, 4, 5, or 6 consecutive amino acids from the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein: (i) the 3 consecutive amino acids comprise HDS; (i) the 4 consecutive amino acids comprise HDSP (SEQ ID NO: 1675); (ii) the 5 consecutive amino acids comprise HDSPH (SEQ ID NO: 1676); and / or (iv) the 6 consecutive amino acids comprise HDSPHK (SEQ ID NO: 2); wherein the AAV capsid variant comprises: (a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 138 or SEQ ID NO: 982; (b) a VP2 protein comprising the amino acid sequence of positions 138-736 of SEQ ID NO: 138 or positions 138-742 of SEQ ID NO: 982; (c) a VP3 protein comprising the amino acid sequence of positions 203-736 of SEQ ID NO: 138 or positions 203- 742 of SEQ ID NO: 982; or (d) an amino acid sequence with at least 90% (e.g., at least about 95, 96, 97, 98, or 99%) sequence identity to any of the amino acid sequences in (a)-(c). In some embodiments, the amino acid sequence is present immediately subsequent to positions 453, numbered according to SEQ ID NO: 138 or 982.

[0023] In another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises one or two, but no more than three substitutions relative to the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the AAV capsid variant comprises: (a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 138 or SEQ ID NO: 982; (b) a VP2 protein comprising the amino acid sequence of positions 138-736 of SEQ ID NO: 138 or positions 138-742 of SEQ ID NO: 982; (c) a VP3 protein comprising the amino acid sequence of positions 203-736 of SEQ ID NO: 138 or positions 203-742 of SEQ ID NO: 982; or (d) an amino acid sequence with at least 90% (e.g., at least about 95, 96, 97, 98, or 99%) sequence identity to any of the amino acid sequences in (a)-(c). In some embodiments, the amino acid sequence is present immediately subsequent to positions 453, numbered according to SEQ ID NO: 138 or 982.

[0024] In some embodiments, the anti-tau antibody molecule binds to the N-terminal region, mid- domain region, C-terminal region, microtubule binding domain, or the proline-rich domain of a tau protein (e.g., a human tau protein comprising the amino acid sequence of SEQ ID NO: 9200). In some embodiments, the anti-tau antibody molecule binds to (a) al or a portion of (e.g., one or more residues within) amino acid residues (1) 9-18, (2) 15-25, (3) 25-30, and / or (4) 15-30, numbered according to SEQ ID NO: 9200; (b) al or a portion of (e.g., one or more residues within) amino acid residues (1) 125-131, (2) 204-222, (3) 234-246, (4) 234-259, and / or (5) 235-246, numbered according to SEQ ID NO: 9200; (c)VTJ-4010PC an epitope which includes one or more of pT181, pS199, pS202, pT205, pT212, pS214, pT217, pT231, pS234, pS235, pS258, pS259, pS396, pS404, pS422, and / or pT217, numbered according to SEQ ID NO: 9200; (d) al or a portion of (one or more residues within) amino acid residues (1) 387-408 and / or (2) 409- 436, numbered according to SEQ ID NO: 9200; (e) al or a portion of (e.g., one or more residues within) amino acid residues (1) 32-49, (2) 55-76, (3) 57-72, (4) 159-194, (5) 175-191, (6) 185-200, (7) 219-247, (8) 223-238, (9) 381-426, (10) 383-400, (11) 409-436, and / or (12) 413-430, numbered according to SEQ ID NO: 9200; (f) a conformational epitope which includes al or a portion of (e.g., one or more residues within) amino acid residues (1) 55-76, (2) 159-194, (3) 219-247, and / or (4) 381-426, numbered according to SEQ ID NO: 9200.

[0025] In some embodiments, the anti-tau antibody molecule comprises: (i) a heavy chain variable region comprising one, two, or three heavy chain complementary determining region (HCDR) sequences of any one of the anti-tau antibody molecules described herein (e.g., an antibody molecule listed in Tables 9-19); and / or (i) a light chain variable region comprising one, two, or three light chain complementary determining region (LCDR) sequences of any one of the anti-tau antibody molecules described herein (e.g., an antibody molecule listed in Tables 9-19).

[0026] In some embodiments, the anti-tau antibody molecule comprises: (i) a heavy chain variable region (VH) comprising the amino acid sequence of the VH of any one of the anti-tau antibody molecules described herein (e.g., the VH sequence of an antibody molecule listed in Tables 9-19), or an amino acid sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to the VH sequence of any one of the anti-tau antibody molecules described herein (e.g., the VH sequence of an antibody molecule listed in Tables 9-19), or an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications, to the amino acid sequence of the VH of any of the anti-tau antibody molecules described herein (e.g., the VH sequence of an antibody molecule listed in Tables 9-19); and / or (i) a light chain variable region (VL) comprising the amino acid sequence of the VL of any one of the anti-tau antibody molecules described herein (e.g., the VL sequence of an antibody molecule listed in Tables 9-19), or an amino acid sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to the VL sequence of any one of the anti-tau antibody molecules described herein (e.g., the VL sequence of an antibody molecule listed in Tables 9-19), or an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications, to the amino acid sequence of the VL of any of the anti-tau antibody molecules described herein (e.g., the VL sequenceVTJ-4010PC of an antibody molecule listed in Tables 9-19).

[0027] In some embodiments, the anti-tau antibody molecule comprises (a) the HCDR1, HCDR2, and / or HCDR3 sequences, and / or LCDR1, LCDR2, and / or LCDR3 sequences, (b) the VH and / or VL sequences, or (c) the heavy chain and / or light chain sequences of IPN002, AT8, PT3, UCB, PT76, PHF1, C10.2, V0004, V0009, V0022, V0023, V0024, or V0052 (as described, e.g., in WO2020223276 and WO2021 / 211753), or Ab1, Ab2, Ab3, Ab4, or Ab5. In some embodiments, the anti-tau antibody molecule has at most one, two, or three substitutions (e.g., conservative amino acid substitutions) in a CDR relative to the HCDR1-3 and LCDR1-3 sequences of IPN002, AT8, PT3, UCB, PT76, PHF1, C10.2, V0004, V0009, V0022, V0023, V0024, or V0052. In some embodiments, the anti-tau antibody molecule comprises a VH sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to the VH sequence of any one of IPN002, AT8, PT3, UCB, PT76, PHF1, C10.2, V0004, V0009, V0022, V0023, V0024, V0052, Ab1, Ab2, Ab3, Ab4, or Ab5, and / or a VL sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to the VL sequence of any one of IPN002, AT8, PT3, UCB, PT76, PHF1, C10.2, V0004, V0009, V0022, V0023, V0024, V0052, Ab1, Ab2, Ab3, Ab4, or Ab5. In some embodiments, the anti-tau antibody molecule comprises a VH sequence having at least one, two, or three modifications, but not more than 30, 20, or 10 modifications, relative to the VH sequence of any one of IPN002, AT8, PT3, UCB, PT76, PHF1, C10.2, V0004, V0009, V0022, V0023, V0024, V0052, Ab1, Ab2, Ab3, Ab4, or Ab5, and / or a VL sequence having at least one, two, or three modifications, but not more than 30, 20, or 10 modifications, relative to the VL sequence of any one of IPN002, AT8, PT3, UCB, PT76, PHF1, C10.2, V0004, V0009, V0022, V0023, V0024, V0052, Ab1, Ab2, Ab3, Ab4, or Ab5.

[0028] In yet another aspect, the present disclosure provides an antibody molecule that binds to human tau, which comprises a heavy chain variable region (VH) comprising a heavy chain complementary determining region 1 (HCDR1), a heavy chain complementary determining region 2 (HCDR2), and a heavy chain complementary determining region 3 (HCDR3) and / or a light chain variable region (VL) comprising a light chain complementary determining region 1 (LCDR1), a light chain complementary determining region 2 (LCDR2), and a light chain complementary determining region 3 (LCDR3), wherein (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, 1556, 1557, 1568, RVS,VTJ-4010PC and1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively. In some embodiments, the antibody is a humanized antibody.

[0029] In yet another aspect, the present disclosure provides an antibody molecule that binds to human tau, which comprises a heavy chain variable region (VH) comprising a heavy chain complementary determining region 1 (HCDR1), a heavy chain complementary determining region 2 (HCDR2), and a heavy chain complementary determining region 3 (HCDR3) and / or a light chain variable region (VL) comprising a light chain complementary determining region 1 (LCDR1), a light chain complementary determining region 2 (LCDR2), and a light chain complementary determining region 3 (LCDR3), wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, 1556, 1557, 1568, RVS, and1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; and wherein: (i) the VH comprises an amino acid sequence comprising one, two, three, four, five, six, seven, eight, nine, or al of: an amino acid other than Q at position 5, P at position 7, T at position 9, L at position 11, V at position 12, N at position 19, L at position 20, K at position 67, A at position 68, and / or S at position 76, numbered according to SEQ ID NO: 1562; and / or (i) the VL comprises and amino acid sequence comprising one, two, or al of: an amino acid other than D at position 17, Q at position 18, and / or G at position 68, numbered according to SEQ ID NO:1573.

[0030] In yet another aspect, the present disclosure provides antibody molecule that binds to human tau, which comprises a heavy chain variable region (VH) comprising a heavy chain complementary determining region 1 (HCDR1), a heavy chain complementary determining region 2 (HCDR2), and a heavy chain complementary determining region 3 (HCDR3) and / or a light chain variable region (VL) comprising a light chain complementary determining region 1 (LCDR1), a light chain complementary determining region 2 (LCDR2), and a light chain complementary determining region 3 (LCDR3), wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, andVTJ-4010PC LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, 1556, 1557, 1568, RVS, and1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; and wherein: (i) the VH comprises an amino acid sequence comprising one, two, three, four, five, six, seven, eight, or al of: a V at position 5, an S at position 7, an A at position 9, a V at position 11, a K at position 12, a K at position 19, a V at position 20, an R at position 67, and / or a V at position 68, numbered according to SEQ ID NO: 1562; and / or (i) the VL comprises and amino acid sequence comprising one, two, or al of: Q or E at position 17, P or R at position 18, and / or S at position 68, numbered according to SEQ ID NO: 1573.

[0031] In yet another aspect, the present disclosure provides antibody molecule that binds to human tau, which comprises a heavy chain variable region (VH) comprising a heavy chain complementary determining region 1 (HCDR1), a heavy chain complementary determining region 2 (HCDR2), and a heavy chain complementary determining region 3 (HCDR3) and / or a light chain variable region (VL) comprising a light chain complementary determining region 1 (LCDR1), a light chain complementary determining region 2 (LCDR2), and a light chain complementary determining region 3 (LCDR3), wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, 1556, 1557, 1568, RVS, and1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; and wherein: (i) the VH comprises an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 67-71; and / or (i) the VL comprises an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 72-76.

[0032] In yet another aspect, the present disclosure provides an antibody molecule that binds to human tau, which comprises a heavy chain variable region (VH) comprising a heavy chain complementary determining region 1 (HCDR1), a heavy chain complementary determining region 2 (HCDR2), and a heavy chain complementary determining region 3 (HCDR3) and a light chain variable region (VL) comprising a light chain complementary determining region 1 (LCDR1), a light chain complementary determining region 2 (LCDR2), and a light chain complementary determining region 3 (LCDR3), wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise theVTJ-4010PC amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, 1556, 1557, 1568, RVS, and1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; and wherein: (i) the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or al of: V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; S at position 14; A at position 16; K at position 19; V at position 20; R at position 38; Q at position 39; A at position 40; Q at position 43; R at position 67; V at position 68; I at position 71; R at position 72; D at position 73; T at position 74; T at position 76; T at position 84; and / or L at position 113, numbered according to SEQ ID NO: 1562; and (i) the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or al of: I at position 2; S at position 7; S at position 12; T at position 14; P at position 15; Q at position 17; P at position 18; Q at position 50; S at position 68; V at position 88; Y at position 92; Q at position 105; and / or V at position 109, numbered according to SEQ ID NO: 1573.

[0033] In yet another aspect, the present disclosure provides an antibody molecule that binds to human tau, which comprises a heavy chain variable region (VH) comprising a heavy chain complementary determining region 1 (HCDR1), a heavy chain complementary determining region 2 (HCDR2), and a heavy chain complementary determining region 3 (HCDR3) and / or a light chain variable region (VL) comprising a light chain complementary determining region 1 (LCDR1), a light chain complementary determining region 2 (LCDR2), and a light chain complementary determining region 3 (LCDR3), wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, 1556, 1557, 1568, RVS, and1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; and wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 69, or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 69; and / or (i) the VL comprises the amino acid sequence of SEQ ID NO: 73, or an amino acid sequence atVTJ-4010PC least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 73.

[0034] In yet another aspect, the present disclosure provides an antibody molecule that binds to human tau, which comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 69, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 73.

[0035] In yet another aspect, the present disclosure provides an antibody molecule that binds to human tau, which comprises a heavy chain (HC) comprising the amino acid sequence of SEQ ID NO:172, and a light chain (LC) comprising the amino acid sequence of SEQ ID NO: 176.

[0036] In some embodiments, the anti-tau antibody molecules have a heavy chain constant region and / or light chain constant region listed in Table 20, or a sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to the heavy chain and / or light chain constant region sequences in Table 20, or an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications, to the amino acid sequence of the heavy chain and / or light chain constant region sequences in Table 20.

[0037] In some embodiments, the anti-tau antibody molecule competes for binding to tau with an antibody described herein (e.g., an antibody molecule listed in Tables 9-19). In some embodiments, the anti-tau antibody molecule binds to the same epitope, substantialy the same epitope as, an epitope that overlaps with, or an epitope that substantialy overlaps with an antibody described herein (e.g., an antibody molecule listed in Tables 9-19).

[0038] In some embodiments, the anti-tau antibody molecule comprises one or more of (a) an Fc region or functional variant thereof, e.g., an Fc region with altered effector function (e.g., reduced afinity for Fc receptor, reduced ADCC, reduced CDC), (b) a signal sequence, (c) a linker (e.g., a linker listed in Table 22).

[0039] In some embodiments, the anti-tau antibody molecule is a multispecific antibody molecule comprising at least two antigen-binding domains (e.g., a bispecific antibody molecule).

[0040] In some embodiments, the AAV particle comprises a viral genome comprising one or more of the folowing: a promoter operably linked to the nucleic acid sequence encoding the antibody molecule, a poly A sequence, an inverted terminal repeat (ITR) sequence (positioned 5’ and / or 3’ relative to the encoded antibody molecule), an enhancer, a Kozak sequence (e.g., GCCGCCACCATG (SEQ ID NO: 9021) or GAGGAGCCACC (SEQ ID NO: 9022)), an intron region, and / or an exon region described herein. In some embodiments, the viral genome comprises a nucleotide sequence encoding a miR bindingVTJ-4010PC site described herein.

[0041] In some embodiments, the viral genome is single stranded or self-complementary. In some embodiments, the viral genome further comprises a nucleotide sequence encoding a Rep protein described herein.

[0042] Also provided herein are cels (e.g., a host cel) comprising an AAV particle described herein. In some embodiments, the cel is a mammalian cel (e.g., a cel of a brain region, such as a neuron, astrocyte, or glial cel) or an insect cel.

[0043] In yet another aspect, provided herein is a method of making an AAV particle described herein, comprising (a) providing a host cel comprising a viral genome; and (b) incubating the host cel under conditions suitable to enclose the viral genome in an AAV capsid variant, e.g., an AAV capsid variant described herein, thereby making the AAV particle.

[0044] In yet another aspect, provided herein is a pharmaceutical composition comprising an AAV particle described herein, and a carrier (e.g., a pharmaceuticaly acceptable excipient).

[0045] In yet another aspect, provided herein is a method of delivering a payload to a cel or tissue (e.g., CNS cel or CNS tissue) comprising administering an effective amount of a pharmaceutical composition described herein or an AAV particle described herein. In some embodiments, the cel or tissue is within a subject.

[0046] In yet another aspect, provided herein is a method of treating a subject having or diagnosed with having a neurological disorder (e.g., a neurodegenerative disorder), tau-related disease, or tauopathy, comprising administering to the subject an efective amount of the pharmaceutical composition described herein, or an AAV particle comprising an AAV capsid variant described herein described herein. In some embodiments, the AAV particles, compositions, and methods may, for example, be used for treating a tau-related disorder (e.g., disease associated with expression of tau, neurological (e.g., neurodegenerative) disorders, and / or tauopathies), such as Alzheimer’s disease (AD), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration (FTLD), frontotemporal dementia (FTD), chronic traumatic encephalopathy (CTE), progressive Supranuclear Palsy (PSP), Down’s syndrome, Pick’s disease, corticobasal degeneration (CBD), corticobasal syndrome, amyotrophic lateral sclerosis (ALS), prion diseases, Creutzfeldt-Jakob disease (CJD), multiple system atrophy, tangle-only dementia, and progressive subcortical gliosis.

[0047] In some embodiments, the AAV particle is administered to the subject intravenously, via intra- cisterna magna injection (ICM), intracerebraly, intrathecaly, intracerebroventricularly, via intraparenchymal administration, or intramuscularly, or via focused ultrasound (FUS), e.g., coupled withVTJ-4010PC the intravenous administration of microbubbles (FUS-MB), or MRI-guided FUS coupled with intravenous administration.

[0048] In some embodiments, administration of the AAV particle or pharmaceutical composition described herein results in a decreased presence, level, and / or activity of a tau mRNA, tau protein, or combination thereof. In other embodiments, administration of the AAV particle or pharmaceutical composition described herein results in a increased presence, level, and / or activity of a tau mRNA, tau protein, or combination thereof.

[0049] Those skiled in the art wil recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the folowing enumerated embodiments. Enumerated Embodiments 1. An AAV particle (e.g., isolated AAV particle) comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises an amino acid sequence having the folowing formula: [N1]-[N2]-[N3], wherein: (i) optionaly [N1] comprises X1, X2, and X3, wherein at least one of X1, X2, or X3 is G; (i) [N2] comprises the amino acid sequence of SPH; and (ii) [N3] comprises X4, X5, and X6, wherein at least one of X4, X5, or X6 is a basic amino acid, e.g., a K or R. 2. The AAV particle of embodiment 1, wherein X4, X5, or both of [N3] is a K. 3. The AAV particle of embodiment 1 or 2, wherein X4, X5, or X6 of [N3] is an R. 4. The AAV particle of any one of embodiments 1-3, wherein: (a) position X4 of [N3] is: K, S, A, V, T, G, F, W, V, N, or R; (b) position X5 of [N3] is: S, K, T, F, I, L, Y, H, M, or R; and / or (c) position X6 of [N3] is: G, A, R, M, I, N, T, Y, D, P, V, L, E, W, N, Q, K, or S; optionaly wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(c).VTJ-4010PC 5. The AAV particle of any one of embodiments 1-4, wherein [N3] comprises SK, KA, KS, AR, RM, VK, AS, SR, VK, KR, KK, KN, VR, RS, RK, KT, TS, KF, FG, KI, IG, KL, LG, TT, TY, KY, YG, KD, KP, TR, RG, VR, GA, SL, SS, FL, WK, SA, RA, LR, KW, RR, GK, TK, NK, AK, KV, KG, KH, KM, TG, SE, SV, SW, SN, HG, SQ, LW, MG, MA, or SG. 6. The AAV particle of any one of embodiments 1-5, wherein [N3] is or comprises SKA, KSG, ARM, VKS, ASR, VKI, KKN, VRM, RKA, KTS, KFG, KIG, KLG, KTT, KTY, KYG, SKD, SKP, TRG, VRG, KRG, GAR, KSA, KSR, SKL, SRA, SKR, SLR, SRG, SSR, FLR, SKW, SKS, WKA, VRR, SKV, SKT, SKG, GKA, TKA, NKA, SKL, SKN, AKA, KTG, KSL, KSE, KSV, KSW, KSN, KHG, KSQ, KSK, KLW, WKG, KMG, KMA, or RSG. 7. The AAV particle of any one of embodiments 1-6, wherein [N2]-[N3] comprises SPHSK (SEQ ID NO: 1674), SPHKS (SEQ ID NO: 1677), SPHAR (SEQ ID NO: 1678), SPHVK (SEQ ID NO: 1679), SPHAS (SEQ ID NO: 1680), SPHKK (SEQ ID NO: 1681), SPHVR (SEQ ID NO: 1682), SPHRK (SEQ ID NO: 1683), SPHKT (SEQ ID NO: 1684), SPHKF (SEQ ID NO: 1685), SPHKI (SEQ ID NO: 1686), SPHKL (SEQ ID NO: 1687), SPHKY (SEQ ID NO: 1688), SPHTR (SEQ ID NO: 1689), SPHKR (SEQ ID NO: 1690), SPHGA (SEQ ID NO: 1691), SPHSR (SEQ ID NO: 1692), SPHSL (SEQ ID NO: 1693), SPHSS (SEQ ID NO: 1694), SPHFL (SEQ ID NO: 1695), SPHWK (SEQ ID NO: 1696), SPHGK (SEQ ID NO: 1697), SPHTK (SEQ ID NO: 1698), SPHNK (SEQ ID NO: 1699), SPHAK (SEQ ID NO: 1700), SPHKH (SEQ ID NO: 1701), SPHKM (SEQ ID NO: 1702), or SPHRS (SEQ ID NO: 1703). 8. The AAV particle of any one of embodiments 1-7, wherein [N2]-[N3] is or comprises: (i) SPHSKA (SEQ ID NO: 941), SPHKSG (SEQ ID NO: 946), SPHARM (SEQ ID NO: 947), SPHVKS (SEQ ID NO: 948), SPHASR (SEQ ID NO: 949), SPHVKI (SEQ ID NO: 950), SPHKKN (SEQ ID NO: 954), SPHVRM (SEQ ID NO: 955), SPHRKA (SEQ ID NO: 956), SPHKFG (SEQ ID NO: 957), SPHKIG (SEQ ID NO: 958), SPHKLG (SEQ ID NO: 959), SPHKTS (SEQ ID NO: 963), SPHKTT (SEQ ID NO: 964), SPHKTY (SEQ ID NO: 965), SPHKYG (SEQ ID NO: 966), SPHSKD (SEQ ID NO: 967), SPHSKP (SEQ ID NO: 968), SPHTRG (SEQ ID NO: 972), SPHVRG (SEQ ID NO: 973), SPHKRG (SEQ ID NO: 974), SPHGAR (SEQ ID NO: 975), SPHKSA (SEQ ID NO: 977), SPHKSR (SEQ ID NO: 951), SPHSKL (SEQ ID NO: 960), SPHSRA (SEQ ID NO: 969), SPHSKR (SEQ ID NO: 978), SPHSLR (SEQ ID NO: 952), SPHSRG (SEQ ID NO: 961), SPHSSR (SEQ ID NO: 970), SPHFLR (SEQ ID NO: 979), SPHSKW (SEQ ID NO: 953), SPHSKS (SEQ ID NO: 962) SPHWKA (SEQ ID NO:VTJ-4010PC 971), SPHVRR (SEQ ID NO: 980), SPHSKT (SEQ ID NO: 1704), SPHSKG (SEQ ID NO: 1705), SPHGKA (SEQ ID NO: 1706), SPHNKA (SEQ ID NO: 1707), SPHSKN (SEQ ID NO: 1708), SPHAKA (SEQ ID NO: 1709), SPHSKV (SEQ ID NO: 1710), SPHKTG (SEQ ID NO: 1711), SPHTKA (SEQ ID NO: 1712), SPHKSL (SEQ ID NO: 1713), SPHKSE (SEQ ID NO: 1714), SPHKSV (SEQ ID NO: 1715), SPHKSW (SEQ ID NO: 1716), SPHKSN (SEQ ID NO: 1717), SPHKHG (SEQ ID NO: 1718), SPHKSQ (SEQ ID NO: 1719), SPHKSK (SEQ ID NO: 1720), SPHKLW (SEQ ID NO: 1721), SPHWKG (SEQ ID NO: 1722), SPHKMG (SEQ ID NO: 1723), SPHKMA (SEQ ID NO: 1724), or SPHRSG (SEQ ID NO: 976); (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof; (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i). 9. The AAV particle of any one of embodiments 1-8, wherein the AAV capsid variant comprises an amino acid other than G at position 453 (e.g., V, R, D, E, M, T, I, S, A, N, L, K, H, P, W, or C), an amino acid other than S at position 454 (V, L, N, D, H, R, P, G, T, I, A, E, Y, M, or Q), and / or a G at position 455 (e.g., C, L, D, E, Y, H, V, A, N, P, or S), numbered according to any one of SEQ ID NOs: 36-59, 138, 981 or 982. 10. The AAV particle of any one of embodiments 1-8, wherein the AAV capsid variant comprises the amino acid G at position 453, the amino acid S at position 454, and the amino acid G at position 455, numbered according to SEQ ID NO: 138 or 981. 11. The AAV particle of any one of embodiments 1-9, wherein the AAV capsid variant comprises the amino acid G at position 453, the amino acid H at position 454, and the amino acid D at position 455, numbered according to SEQ ID NO: 138 or 982. 12. The AAV particle of any one of embodiments 1-11, wherein [N1] comprises X1, X2, and X3, wherein at least one of X1, X2, or X3 is G.VTJ-4010PC 13. The AAV particle of any one of embodiments 1-12, wherein: (a) position X1 of [N1] is: G, V, R, D, E, M, T, I, S, A, N, L, K, H, P, W, or C; (b) position X2 of [N1] is: S, V, L, N, D, H, R, P, G, T, I, A, E, Y, M, or Q; and / or (c) position X3 of [N1] is: G, C, L, D, E, Y, H, V, A, N, P, or S; optionaly wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(c). 14. The AAV particle of any one of embodiments 1-13, wherein [N1] comprises GS, SG, GH, HD, GQ, QD, VS, CS, GR, RG, QS, SH, MS, RN, TS, IS, GP, ES, SS, GN, AS, NS, LS, GG, KS, GT, PS, RS, GI, WS, DS, ID, GL, DA, DG, ME, EN, KN, KE, AI, NG, PG, TG, SV, IG, LG, AG, EG, SA, YD, HE, HG, RD, ND, PD, MG, QV, DD, HN, HP, GY, GM, GD, or HS. 15. The AAV particle of any one of embodiments 1-14, wherein [N1] is or comprises GSG, GHD, GQD, VSG, CSG, GRG, CSH, GQS, GSH, RVG, GSC, GLL, GDD, GHE, GNY, MSG, RNG, TSG, ISG, GPG, ESG, SSG, GNG, ASG, NSG, LSG, GGG, KSG, HSG, GTG, PSG, GSV, RSG, GIG, WSG, DSG, IDG, GLG, DAG, DGG, MEG, ENG, GSA, KNG, KEG, AIG, GYD, GHG, GRD, GND, GPD, GMG, GQV, GHN, GHP, or GHS. 16. The AAV particle of any one of embodiments 1-15, wherein [N1]-[N2] comprises (i) SGSPH (SEQ ID NO: 1725), HDSPH (SEQ ID NO: 1676), QDSPH (SEQ ID NO: 1726), RGSPH (SEQ ID NO: 1727), SHSPH (SEQ ID NO: 1728), QSSPH (SEQ ID NO: 1729), DDSPH (SEQ ID NO: 1730), HESPH (SEQ ID NO: 1731), NYSPH (SEQ ID NO: 1732), VGSPH (SEQ ID NO: 1733), SCSPH (SEQ ID NO: 1734), LLSPH (SEQ ID NO: 1735), NGSPH (SEQ ID NO: 1736), PGSPH (SEQ ID NO: 1737), GGSPH (SEQ ID NO: 1738), TGSPH (SEQ ID NO: 1739), SVSPH (SEQ ID NO: 2897), IGSPH (SEQ ID NO: 2907), DGSPH (SEQ ID NO: 2917), LGSPH (SEQ ID NO: 3081), AGSPH (SEQ ID NO: 3238), EGSPH (SEQ ID NO: 3590), SASPH (SEQ ID NO: 3849), YDSPH (SEQ ID NO: 3850), HGSPH (SEQ ID NO: 3851), RDSPH (SEQ ID NO: 3852), NDSPH (SEQ ID NO: 3853), PDSPH (SEQ ID NO: 3854), MGSPH (SEQ ID NO: 3855), QVSPH (SEQ ID NO: 3856), HNSPH (SEQ ID NO: 3857), HPSPH (SEQ ID NO: 3858), or HSSPH (SEQ ID NO: 3859); (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, or 4 amino acids, e.g., consecutive amino acids, thereof;VTJ-4010PC (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i). 17. The AAV particle of any one of embodiments 1-16, wherein [N1]-[N2] is or comprises: (i) GSGSPH (SEQ ID NO: 3860), GHDSPH (SEQ ID NO: 3861), GQDSPH (SEQ ID NO: 3862), VSGSPH (SEQ ID NO: 3863), CSGSPH (SEQ ID NO: 3864), GRGSPH (SEQ ID NO: 3865), CSHSPH (SEQ ID NO: 3866), GQSSPH (SEQ ID NO: 3867), GSHSPH (SEQ ID NO: 3868), GDDSPH (SEQ ID NO: 3869), GHESPH (SEQ ID NO: 3870), GNYSPH (SEQ ID NO: 3871), RVGSPH (SEQ ID NO: 3872), GSCSPH (SEQ ID NO: 3873), GLLSPH (SEQ ID NO: 3874), MSGSPH (SEQ ID NO: 3875), RNGSPH (SEQ ID NO: 3876), TSGSPH (SEQ ID NO: 3877), ISGSPH (SEQ ID NO: 3878), GPGSPH (SEQ ID NO: 3879), ESGSPH (SEQ ID NO: 3880), SSGSPH (SEQ ID NO: 3881), GNGSPH (SEQ ID NO: 3882), ASGSPH (SEQ ID NO: 3883), NSGSPH (SEQ ID NO: 3884), LSGSPH (SEQ ID NO: 3885), GGGSPH (SEQ ID NO: 3886), KSGSPH (SEQ ID NO: 3887), HSGSPH (SEQ ID NO: 3888), GTGSPH (SEQ ID NO: 3889), PSGSPH (SEQ ID NO: 3890), GSVSPH (SEQ ID NO: 3891), RSGSPH (SEQ ID NO: 3892), GIGSPH (SEQ ID NO: 3893), WSGSPH (SEQ ID NO: 3894), DSGSPH (SEQ ID NO: 3895), IDGSPH (SEQ ID NO: 3896), GLGSPH (SEQ ID NO: 3897), DAGSPH (SEQ ID NO: 3898), DGGSPH (SEQ ID NO: 3899), MEGSPH (SEQ ID NO: 3900), ENGSPH (SEQ ID NO: 3901), GSASPH (SEQ ID NO: 3902), KNGSPH (SEQ ID NO: 3903), KEGSPH (SEQ ID NO: 3904), AIGSPH (SEQ ID NO: 3905), GYDSPH (SEQ ID NO: 3906), GHGSPH (SEQ ID NO: 3907), GRDSPH (SEQ ID NO: 3908), GNDSPH (SEQ ID NO: 3909), GPDSPH (SEQ ID NO: 3910), GMGSPH (SEQ ID NO: 3911), GQVSPH (SEQ ID NO: 3912), GHNSPH (SEQ ID NO: 3913), GHPSPH (SEQ ID NO: 3914), or GHSSPH (SEQ ID NO: 3915); (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof; (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i).VTJ-4010PC 18. The AAV particle of any one of embodiments 1-17, wherein [N1]-[N2]-[N3] comprises: (i) SGSPHSK (SEQ ID NO: 3916), HDSPHKS (SEQ ID NO: 3917), SGSPHAR (SEQ ID NO: 3918), SGSPHVK (SEQ ID NO: 3919), QDSPHKS (SEQ ID NO: 3920), SGSPHKK (SEQ ID NO: 3921), SGSPHVR (SEQ ID NO: 3922), SGSPHAS (SEQ ID NO: 3923), SGSPHRK (SEQ ID NO: 3924), SGSPHKT (SEQ ID NO: 3925), SHSPHKS (SEQ ID NO: 3926), QSSPHRS (SEQ ID NO: 3927), RGSPHAS (SEQ ID NO: 3928), RGSPHSK (SEQ ID NO: 3929), SGSPHKF (SEQ ID NO: 3930), SGSPHKI (SEQ ID NO: 3931), SGSPHKL (SEQ ID NO: 3932), SGSPHKY (SEQ ID NO: 3933), SGSPHTR (SEQ ID NO: 3934), SHSPHKR (SEQ ID NO: 3935), SGSPHGA (SEQ ID NO: 3936), HDSPHKR (SEQ ID NO: 3937), DDSPHKS (SEQ ID NO: 3938), HESPHKS (SEQ ID NO: 3939), NYSPHKI (SEQ ID NO: 3940), SGSPHSR (SEQ ID NO: 3941), SGSPHSL (SEQ ID NO: 3942), SGSPHSS (SEQ ID NO: 3943), VGSPHSK (SEQ ID NO: 3944), SCSPHRK (SEQ ID NO: 3945), SGSPHFL (SEQ ID NO: 3946), LLSPHWK (SEQ ID NO: 3947), NGSPHSK (SEQ ID NO: 3948), PGSPHSK (SEQ ID NO: 3949), GGSPHSK (SEQ ID NO: 3950), TGSPHSK (SEQ ID NO: 3951), SVSPHGK (SEQ ID NO: 3952), SGSPHTK (SEQ ID NO: 3953), IGSPHSK (SEQ ID NO: 3954), DGSPHSK (SEQ ID NO: 3955), SGSPHNK (SEQ ID NO: 3956), LGSPHSK (SEQ ID NO: 3957), AGSPHSK (SEQ ID NO: 3958), EGSPHSK (SEQ ID NO: 3959), SASPHSK (SEQ ID NO: 3960), SGSPHAK (SEQ ID NO: 3961), HDSPHKI (SEQ ID NO: 3962), YDSPHKS (SEQ ID NO: 3963), HDSPHKT (SEQ ID NO: 3964), RGSPHKR (SEQ ID NO: 3965), HGSPHSK (SEQ ID NO: 3966), RDSPHKS (SEQ ID NO: 3967), NDSPHKS (SEQ ID NO: 3968), QDSPHKI (SEQ ID NO: 3969), PDSPHKI (SEQ ID NO: 3970), PDSPHKS (SEQ ID NO: 3971), MGSPHSK (SEQ ID NO: 3972), HDSPHKH (SEQ ID NO: 3973), QVSPHKS (SEQ ID NO: 3974), HNSPHKS (SEQ ID NO: 3975), NGSPHKR (SEQ ID NO: 3976), HDSPHKY (SEQ ID NO: 3977), NDSPHKI (SEQ ID NO: 3978), HDSPHKL (SEQ ID NO: 3979), HPSPHWK (SEQ ID NO: 3980), HDSPHKM (SEQ ID NO: 3981), or HSSPHRS (SEQ ID NO: 3982); (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, or 6 amino acids, e.g., consecutive amino acids, thereof; (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i).VTJ-4010PC 19. The AAV particle of any one of embodiments 1-18, wherein [N1]-[N2]-[N3] is or comprises: (i) GSGSPHSKA (SEQ ID NO: 1671), GHDSPHKSG (SEQ ID NO: 1672), GSGSPHARM (SEQ ID NO: 3983), GSGSPHVKS (SEQ ID NO: 3984), GQDSPHKSG (SEQ ID NO: 3985), GSGSPHASR (SEQ ID NO: 3986), GSGSPHVKI (SEQ ID NO: 3987), GSGSPHKKN (SEQ ID NO: 3988), GSGSPHVRM (SEQ ID NO: 3989), VSGSPHSKA (SEQ ID NO: 3990), CSGSPHSKA (SEQ ID NO: 3991), GSGSPHRKA (SEQ ID NO: 3992), CSGSPHKTS (SEQ ID NO: 3993), CSHSPHKSG (SEQ ID NO: 3994), GQSSPHRSG (SEQ ID NO: 3995), GRGSPHASR (SEQ ID NO: 3996), GRGSPHSKA (SEQ ID NO: 3997), GSGSPHKFG (SEQ ID NO: 3998), GSGSPHKIG (SEQ ID NO: 3999), GSGSPHKLG (SEQ ID NO: 4000), GSGSPHKTS (SEQ ID NO: 4001), GSGSPHKTT (SEQ ID NO: 4002), GSGSPHKTY (SEQ ID NO: 4003), GSGSPHKYG (SEQ ID NO: 4004), GSGSPHSKD (SEQ ID NO: 4005), GSGSPHSKP (SEQ ID NO: 4006), GSGSPHTRG (SEQ ID NO: 4007), GSGSPHVRG (SEQ ID NO: 4008), GSHSPHKRG (SEQ ID NO: 4009), GSHSPHKSG (SEQ ID NO: 4010), VSGSPHASR (SEQ ID NO: 4011), VSGSPHGAR (SEQ ID NO: 4012), VSGSPHKFG (SEQ ID NO: 4013), GHDSPHKRG (SEQ ID NO: 4014), GDDSPHKSG (SEQ ID NO: 4015), GHESPHKSA (SEQ ID NO: 4016), GHDSPHKSA (SEQ ID NO: 4017), GNYSPHKIG (SEQ ID NO: 4018), GHDSPHKSR (SEQ ID NO: 4019), GSGSPHSKL (SEQ ID NO: 4020), GSGSPHSRA (SEQ ID NO: 4021), GSGSPHSKR (SEQ ID NO: 4022), GSGSPHSLR (SEQ ID NO: 4023), GSGSPHSRG (SEQ ID NO: 4024), GSGSPHSSR (SEQ ID NO: 4025), RVGSPHSKA (SEQ ID NO: 4026), GSCSPHRKA (SEQ ID NO: 4027), GSGSPHFLR (SEQ ID NO: 4028), GSGSPHSKW (SEQ ID NO: 4029), GSGSPHSKS (SEQ ID NO: 4030), GLLSPHWKA (SEQ ID NO: 4031), GSGSPHVRR (SEQ ID NO: 4032), GSGSPHSKV (SEQ ID NO: 4033), MSGSPHSKA (SEQ ID NO: 4034), RNGSPHSKA (SEQ ID NO: 4035), TSGSPHSKA (SEQ ID NO: 4036), ISGSPHSKA (SEQ ID NO: 4037), GPGSPHSKA (SEQ ID NO: 4038), GSGSPHSKT (SEQ ID NO: 4039), ESGSPHSKA (SEQ ID NO: 4040), SSGSPHSKA (SEQ ID NO: 4041), GNGSPHSKA (SEQ ID NO: 4042), ASGSPHSKA (SEQ ID NO: 4043), NSGSPHSKA (SEQ ID NO: 4044), LSGSPHSKA (SEQ ID NO: 4045), GGGSPHSKA (SEQ ID NO: 4046), KSGSPHSKA (SEQ ID NO: 4047), GGGSPHSKS (SEQ ID NO: 4048), GSGSPHSKG (SEQ ID NO: 4049), HSGSPHSKA (SEQ ID NO: 4050), GTGSPHSKA (SEQ ID NO: 4051), PSGSPHSKA (SEQ ID NO: 4052), GSVSPHGKA (SEQ ID NO: 4053), RSGSPHSKA (SEQ ID NO: 4054), GSGSPHTKA (SEQ ID NO: 4055), GIGSPHSKA (SEQ ID NO: 4056), WSGSPHSKA (SEQ ID NO: 4057), DSGSPHSKA (SEQ ID NO: 4058), IDGSPHSKA (SEQ ID NO: 4059), GSGSPHNKA (SEQ ID NO: 4060), GLGSPHSKS (SEQ ID NO: 4061), DAGSPHSKA (SEQ ID NO: 4063), DGGSPHSKA (SEQ ID NO: 4064), MEGSPHSKAVTJ-4010PC (SEQ ID NO: 4065), ENGSPHSKA (SEQ ID NO: 4066), GSASPHSKA (SEQ ID NO: 4067), GNGSPHSKS (SEQ ID NO: 4068), KNGSPHSKA (SEQ ID NO: 4069), KEGSPHSKA (SEQ ID NO: 4070), AIGSPHSKA (SEQ ID NO: 4071), GSGSPHSKN (SEQ ID NO: 4072), GSGSPHAKA (SEQ ID NO: 4073), GHDSPHKIG (SEQ ID NO: 4074), GYDSPHKSG (SEQ ID NO: 4075), GHESPHKSG (SEQ ID NO: 4076), GHDSPHKTG (SEQ ID NO: 4077), GRGSPHKRG (SEQ ID NO: 4078), GQDSPHKSG (SEQ ID NO: 3985), GHDSPHKSL (SEQ ID NO: 4079), GHGSPHSKA (SEQ ID NO: 4080), GHDSPHKSE (SEQ ID NO: 4082), VSGSPHSKA (SEQ ID NO: 3990), GRDSPHKSG (SEQ ID NO: 4083), GNDSPHKSV (SEQ ID NO: 4084), GQDSPHKIG (SEQ ID NO: 4085), GHDSPHKSV (SEQ ID NO: 4086), GPDSPHKIG (SEQ ID NO: 4087), GPDSPHKSG (SEQ ID NO: 4088), GHDSPHKSW (SEQ ID NO: 4089), GHDSPHKSN (SEQ ID NO: 4090), GMGSPHSKT (SEQ ID NO: 4091), GHDSPHKHG (SEQ ID NO: 4092), GQVSPHKSG (SEQ ID NO: 4093), GDDSPHKSV (SEQ ID NO: 4094), GHNSPHKSG (SEQ ID NO: 4095), GNGSPHKRG (SEQ ID NO: 4096), GHDSPHKYG (SEQ ID NO: 4097), GHDSPHKSQ (SEQ ID NO: 4487), GNDSPHKIG (SEQ ID NO: 4488), GHDSPHKSK (SEQ ID NO: 4489), GHDSPHKLW (SEQ ID NO: 4490), GHPSPHWKG (SEQ ID NO: 4491), GHDSPHKMG (SEQ ID NO: 4492), GHDSPHKMA (SEQ ID NO: 4493), or GHSSPHRSG (SEQ ID NO: 4494); (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, or 8 amino acids, e.g., consecutive amino acids, thereof; (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i). 20. The AAV particle of any one of embodiments 1-19, wherein [N3] comprises SK, KA, KS, or SG. 21. The AAV particle of any one of embodiments 1-20, wherein [N3] is or comprises SKA, KSG, or KYG. 22. The AAV particle of any one of embodiments 1-21, wherein [N2]-[N3] comprises SPHSK (SEQ ID NO: 1674), SPHKS (SEQ ID NO: 1677), or SPHKY (SEQ ID NO: 1688).VTJ-4010PC 23. The AAV particle of any one of embodiments 1-22, wherein [N2]-[N3] is or comprises SPHSKA (SEQ ID NO: 941). 24. The AAV particle of any one of embodiments 1-22, wherein [N2]-[N3] is or comprises SPHKSG (SEQ ID NO: 946). 25. The AAV particle of any one of embodiments 1-22, wherein [N2]-[N3] is or comprises SPHKYG (SEQ ID NO: 966). 26. The AAV particle of any one of embodiments 1-25, wherein [N1] comprises GS, SG, GH, or HD. 27. The AAV particle of any one of embodiments 1-26, wherein [N1] is or comprises GSG. 28. The AAV particle of any one of embodiments 1-26, wherein [N1] is or comprises GHD. 29. The AAV particle of any one of embodiments 1-23 or 26-27, wherein [N1]-[N2]-[N3] comprises SGSPHSK (SEQ ID NO: 3916). 30. The AAV particle of any one of embodiments 1-22, 24, 26, or 28, wherein [N1]-[N2]-[N3] comprises HDSPHKS (SEQ ID NO: 3917). 31. The AAV particle of any one of embodiments 1-22 or 25-27, wherein [N1]-[N2]-[N3] comprises SGSPHKYG (SEQ ID NO: 4495). 32. The AAV particle of any one of embodiments 1-8, 10, 12-23, 26-27, or 29, wherein [N1]-[N2]-[N3] is or comprises GSGSPHSKA (SEQ ID NO: 1671). 33. The AAV particle of any one of embodiments 1-9, 11-22, 24, 26, 28, or 30, wherein [N1]-[N2]-[N3] is or comprises GHDSPHKSG (SEQ ID NO: 1672). 34. The AAV particle of any one of embodiments 1-8, 10, 12-22, 25-27, or 31, wherein [N1]-[N2]-[N3] is or comprises GSGSPHKYG (SEQ ID NO: 4004).VTJ-4010PC 35. The AAV particle of any one of embodiments 1-34, wherein [N1]-[N2]-[N3] replaces positions 453- 455, numbered according to the amino acid sequence of SEQ ID NO: 138. 36. The AAV particle of any one of embodiments 1-35, wherein the AAV capsid variant comprises an amino acid other than Q at position 456 (e.g., W, K, R, G, L, V, S, P, H, K, I, M, A, E, or F), an amino acid other than N at position 457 (e.g., Y, C, K, T, H, R, D, V, S, P, G, W, E, F, A, I, M, Q, or L), an amino acid other than Q at position 458 (e.g., G, K, H, R, T, L, D, A, P, I, F, V, M, W, Y, S, E, N, or Y), and / or an amino acid other than Q at position 459 (e.g., H, L, R, W, K, A, P, E, M, I, S, G, N, Y, C, V, T, D, or V), relative to a reference sequence numbered according to SEQ ID NO: 138. 37. The AAV capsid particle of any one of embodiments 1-36, wherein the AAV capsid variant comprises an amino acid other than Q at position 462 (e.g., W, K, R, G, L, V, S, P, H, K, I, M, A, E, or F), an amino acid other than N at position 463 (e.g., Y, C, K, T, H, R, D, V, S, P, G, W, E, F, A, I, M, Q, or L), an amino acid other than Q at position 464 (e.g., G, K, H, R, T, L, D, A, P, I, F, V, M, W, Y, S, E, N, or Y), and / or an amino acid other than Q at position 465 (e.g., H, L, R, W, K, A, P, E, M, I, S, G, N, Y, C, V, T, D, or V), relative to a reference sequence numbered according to SEQ ID NO: 981, 982, 36, 37, 39, 40, 42-46, 48, 49, 50, 52, 53, 56, or 57. 38. The AAV particle of any one of embodiments 1-37, wherein the AAV capsid variant comprises: (a) the amino acid Q at position 456, the amino acid N at position 457, the amino acid Q at position 458, and / or the amino acid Q at position 459, relative to a reference sequence numbered according to SEQ ID NO: 138; or (b) the amino acid Q at position 462, the amino acid N at position 463, the amino acid Q at position 464, and / or the amino acid Q at position 465, relative to a reference sequence numbered according to SEQ ID NO: 981, 982, 36, 37, 39, 40, 42-46, 48, 49, 50, 52, 53, 56, or 57. 39. The AAV particle of any one of embodiments 1-38, wherein the AAV capsid variant further comprises [N4], wherein [N4] comprises X7 X8 X9 X10, and wherein: (a) position X7 is: Q, W, K, R, G, L, V, S, P, H, K, I, M, A, E, or F; (b) position X8 is: N, Y, C, K, T, H, R, D, V, S, P, G, W, E, F, A, I, M, Q, or L; (c) position X9 is: Q, G, K, H, R, T, L, D, A, P, I, F, V, M, W, Y, S, E, N, or Y; andVTJ-4010PC (d) position X10 is: Q, H, L, R, W, K, A, P, E, M, I, S, G, N, Y, C, V, T, D, or V; optionaly wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(d). 40. The AAV particle of embodiment 39, wherein: (a) position X7 of [N4] is Q or R; (b) position X8 of [N4] is N or R; (c) position X9 of [N4] is Q or R; and (d) position X10 of [N4] is Q, L, or R. 41. The AAV particle of embodiment 39 or 40, wherein [N4] is or comprises: (i) QNQQ (SEQ ID NO: 4496), WNQQ (SEQ ID NO: 4497), QYYV (SEQ ID NO: 4498), RRQQ (SEQ ID NO: 4499), GCGQ (SEQ ID NO: 4508), LRQQ (SEQ ID NO: 4509), RNQQ (SEQ ID NO: 4510), VNQQ (SEQ ID NO: 4511), FRLQ (SEQ ID NO: 4512), FNQQ (SEQ ID NO: 4513), LLQQ (SEQ ID NO: 4514), SNQQ (SEQ ID NO: 4515), RLQQ (SEQ ID NO: 4516), LNQQ (SEQ ID NO: 4517), QRKL (SEQ ID NO: 4518), LRRQ (SEQ ID NO: 4519), QRLR (SEQ ID NO: 4520), QRRL (SEQ ID NO: 4521), RRLQ (SEQ ID NO: 4522), RLRQ (SEQ ID NO: 4523), SKRQ (SEQ ID NO: 4524), QLYR (SEQ ID NO: 4525), QLTV (SEQ ID NO: 4526), QNKQ (SEQ ID NO: 4527), KNQQ (SEQ ID NO: 4528), QKQQ (SEQ ID NO: 4529), QTQQ (SEQ ID NO: 4530), QNHQ (SEQ ID NO: 4531), QHQQ (SEQ ID NO: 4532), QNQH (SEQ ID NO: 4533), QHRQ (SEQ ID NO: 4534), LTQQ (SEQ ID NO: 4536), QNQW (SEQ ID NO: 4541), QNTH (SEQ ID NO: 4542), RRRQ (SEQ ID NO: 4543), QYQQ (SEQ ID NO: 4544), QNDQ (SEQ ID NO: 4546), QNRH (SEQ ID NO: 4547), RDQQ (SEQ ID NO: 4548), PNLQ (SEQ ID NO: 4549), HVRQ (SEQ ID NO: 4550), PNQH (SEQ ID NO: 4551), HNQQ (SEQ ID NO: 4552), QSQQ (SEQ ID NO: 4553), QPAK (SEQ ID NO: 4554), QNLA (SEQ ID NO: 4555), QNQL (SEQ ID NO: 4556), QGQQ (SEQ ID NO: 4557), LNRQ (SEQ ID NO: 4558), QNPP (SEQ ID NO: 4559), QNLQ (SEQ ID NO: 4560), QDQE (SEQ ID NO: 4561), QDQQ (SEQ ID NO: 4562), HWQQ (SEQ ID NO: 4563), PNQQ (SEQ ID NO: 4564), PEQQ (SEQ ID NO: 4565), QRTM (SEQ ID NO: 4566), LHQH (SEQ ID NO: 4567), QHRI (SEQ ID NO: 4568), QYIH (SEQ ID NO: 4569), QKFE (SEQ ID NO: 4570), QFPS (SEQ ID NO: 4571), QNPL (SEQ ID NO: 4572), QAIK (SEQ ID NO: 4573), QNRQ (SEQ ID NO: 4574), QYQH (SEQ ID NO: 4575), QNPQ (SEQ ID NO: 4576), QHQL (SEQ ID NO: 4577), QSPP (SEQ ID NO: 4578), QAKL (SEQ ID NO: 4579), KSQQ (SEQ ID NO: 4580), QDRP (SEQ ID NO: 4581), QNLG (SEQ ID NO: 4582), QAFH (SEQ ID NO: 4583), QNAQ (SEQ ID NO: 4584), HNQL (SEQ ID NO: 4585), QKLN (SEQ ID NO: 4586), QNVQ (SEQVTJ-4010PC ID NO: 4587), QAQQ (SEQ ID NO: 4588), QTPP (SEQ ID NO: 4589), QPPA (SEQ ID NO: 4590), QERP (SEQ ID NO: 4591), QDLQ (SEQ ID NO: 4592), QAMH (SEQ ID NO: 4593), QHPS (SEQ ID NO: 4594), PGLQ (SEQ ID NO: 4595), QGIR (SEQ ID NO: 4596), QAPA (SEQ ID NO: 4597), QIPP (SEQ ID NO: 4598), QTQL (SEQ ID NO: 4599), QAPS (SEQ ID NO: 4600), QNTY (SEQ ID NO: 4601), QDKQ (SEQ ID NO: 4602), QNHL (SEQ ID NO: 4603), QIGM (SEQ ID NO: 4604), LNKQ (SEQ ID NO: 4605), PNQL (SEQ ID NO: 4606), QLQQ (SEQ ID NO: 4607), QRMS (SEQ ID NO: 4608), QGIL (SEQ ID NO: 4609), QDRQ (SEQ ID NO: 4610), RDWQ (SEQ ID NO: 4611), QERS (SEQ ID NO: 4612), QNYQ (SEQ ID NO: 4613), QRTC (SEQ ID NO: 4614), QIGH (SEQ ID NO: 4615), QGAI (SEQ ID NO: 4616), QVPP (SEQ ID NO: 4617), QVQQ (SEQ ID NO: 4618), LMRQ (SEQ ID NO: 4619), QYSV (SEQ ID NO: 4620), QAIT (SEQ ID NO: 4621), QKTL (SEQ ID NO: 4622), QLHH (SEQ ID NO: 4623), QNI (SEQ ID NO: 4624), QGHH (SEQ ID NO: 4625), QSKV (SEQ ID NO: 4626), QLPS (SEQ ID NO: 4627), IGKQ (SEQ ID NO: 4628), QAIH (SEQ ID NO: 4629), QHGL (SEQ ID NO: 4630), QFMC (SEQ ID NO: 4631), QNQM (SEQ ID NO: 4632), QHLQ (SEQ ID NO: 4633), QPAR (SEQ ID NO: 4634), QSLQ (SEQ ID NO: 4635), QSQL (SEQ ID NO: 4636), HSQQ (SEQ ID NO: 4637), QMPS (SEQ ID NO: 4638), QGSL (SEQ ID NO: 4639), QVPA (SEQ ID NO: 4640), HYQQ (SEQ ID NO: 4641), QVPS (SEQ ID NO: 4642), RGEQ (SEQ ID NO: 4643), PGQQ (SEQ ID NO: 4644), LEQQ (SEQ ID NO: 4645), QNQS (SEQ ID NO: 4646), QKVI (SEQ ID NO: 4647), QNND (SEQ ID NO: 4648), QSVH (SEQ ID NO: 4649), QPLG (SEQ ID NO: 4650), HNQE (SEQ ID NO: 4651), QIQQ (SEQ ID NO: 4652), QVRN (SEQ ID NO: 4653), PSNQ (SEQ ID NO: 4654), QVGH (SEQ ID NO: 4655), QRDI (SEQ ID NO: 4656), QMPN (SEQ ID NO: 4657), RGLQ (SEQ ID NO: 4658), PSLQ (SEQ ID NO: 4659), QRDQ (SEQ ID NO: 4660), QAKG (SEQ ID NO: 4661), QSAH (SEQ ID NO: 4662), QSTM (SEQ ID NO: 4663), QREM (SEQ ID NO: 4664), QYRA (SEQ ID NO: 4665), QRQQ (SEQ ID NO: 4666), QWQQ (SEQ ID NO: 4667), QRMN (SEQ ID NO: 4668), GDSQ (SEQ ID NO: 4669), QKIS (SEQ ID NO: 4670), PSMQ (SEQ ID NO: 4671), SPRQ (SEQ ID NO: 4672), MEQQ (SEQ ID NO: 4673), QYQN (SEQ ID NO: 4674), QIRQ (SEQ ID NO: 4675), QSVQ (SEQ ID NO: 4676), RSQQ (SEQ ID NO: 4677), QNKL (SEQ ID NO: 4678), QIQH (SEQ ID NO: 4680), PRQQ (SEQ ID NO: 4681), HTQQ (SEQ ID NO: 4682), QRQH (SEQ ID NO: 4683), RNQE (SEQ ID NO: 4684), QSKQ (SEQ ID NO: 4685), QNQP (SEQ ID NO: 4686), QSPQ (SEQ ID NO: 4687), QTRQ (SEQ ID NO: 4688), QNLH (SEQ ID NO: 4689), QNQE (SEQ ID NO: 4690), LNQP (SEQ ID NO: 4691), QNQD (SEQ ID NO: 4692), QNLL (SEQ ID NO: 4693), QLVI (SEQ ID NO: 4694), RTQE (SEQ ID NO: 4695), QTHQ (SEQ ID NO: 4696), QDQH (SEQ ID NO: 4697), QSQH (SEQ ID NO: 4698), VRQQ (SEQ ID NO: 4699), AWQQ (SEQ ID NO: 4700), QSVP (SEQ ID NO: 4701), QNIQ (SEQ ID NO: 4702), LDQQ (SEQ ID NO: 4703), PDQQ (SEQ ID NO: 4704), ESQQ (SEQ ID NO: 4705), QRQL (SEQ ID NO: 4706), QIV (SEQ ID NO: 4707),VTJ-4010PC QKQS (SEQ ID NO: 4708), QSHQ (SEQ ID NO: 4709), QFVV (SEQ ID NO: 4710), QSQP (SEQ ID NO: 4711), QNEQ (SEQ ID NO: 4712), INQQ (SEQ ID NO: 4713), RNRQ (SEQ ID NO: 4714), RDQK (SEQ ID NO: 4715), QWKR (SEQ ID NO: 4716), ENRQ (SEQ ID NO: 4717), QTQP (SEQ ID NO: 4718), QKQL (SEQ ID NO: 4719), RNQL (SEQ ID NO: 4720), ISIQ (SEQ ID NO: 4721), QTVC (SEQ ID NO: 4722), QQIM (SEQ ID NO: 4723), LNHQ (SEQ ID NO: 4724), QNQA (SEQ ID NO: 4725), QMIH (SEQ ID NO: 4726), RNHQ (SEQ ID NO: 4727), or QKMN (SEQ ID NO: 4728); (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, or 3 amino acids, e.g., consecutive amino acids, thereof; (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i). 42. The AAV particle of any one of embodiments 39-41, wherein [N1]-[N2]-[N3]-[N4] is or comprises: (i) the amino acid sequence of any of SEQ ID NOs: 1800-2241; (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acids, e.g., consecutive amino acids, thereof; (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i). 43. The AAV particle of any one of embodiments 37-42, wherein [N1]-[N2]-[N3]-[N4] is or comprises GSGSPHSKAQNQQ (SEQ ID NO: 1801). 44. The AAV particle of any one of embodiments 37-42, wherein [N1]-[N2]-[N3]-[N4] is or comprises GHDSPHKSGQNQQ (SEQ ID NO: 1800). 45. The AAV particle of any one of embodiments 37-42, wherein [N1]-[N2]-[N3]-[N4] is or comprises GSGSPHKYGQNQQT (SEQ ID NO: 910).VTJ-4010PC 46. The AAV particle of any one of embodiments 1-45, wherein the AAV capsid variant comprises an amino acid other than T at position 450 (e.g., S, Y, M, A, C, I, R, L, D, F, V, Q, N, H, E, or G), an amino acid other than I at position 451 (e.g., M, P, E, N, D, S, A, T, G, Q, F, V, L, C, H, R, W, or L), and / or an amino acid other than N at position 452 (e.g., M, E, G, Y, W, T, I, Q, F, V, A, L, I, P, K, R, H, S, D, or S), relative to a reference sequence numbered according to any one of SEQ ID NOs: 4500-4507, 36-59, 138, 981 or 982. 47. The AAV particle of any one of embodiments 1-46, wherein the AAV capsid variant comprises the amino acid T at position 450, the amino acid I at position 451, and / or the amino acid N at position 452, relative to a reference sequence numbered according to any one of SEQ ID NOs: 138, 981, or 982. 48. The AAV particle of any one of embodiments 1-47, wherein the AAV capsid variant further comprises [N0], wherein [N0] comprises XA XB and XC, and wherein: (a) position XA is: T, S, Y, M, A, C, I, R, L, D, F, V, Q, N, H, E, or G; (b) position XB is: I, M, P, E, N, D, S, A, T, G, Q, F, V, L, C, H, R, W, or L; and (c) position XC is: N, M, E, G, Y, W, T, I, Q, F, V, A, L, I, P, K, R, H, S, D, or S; and optionaly wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(c). 49. The AAV particle of embodiment 48, wherein [N0] is or comprises TIN, SMN, TIM, YLS, GLS, MPE, MEG, MEY, AEW, CEW, ANN, IPE, ADM, IEY, ADY, IET, MEW, CEY, RIN, MEI, LEY, ADW, IEI, DIM, FEQ, MEF, CDQ, LPE, IEN, MES, AEI, VEY, IN, TSN, IEV, MEM, AEV, MDA, VEW, AEQ, LEW, MEL, MET, MEA, IES, MEV, CEI, ATN, MDG, QEV, ADQ, NMN, IEM, ISN, TGN, QQQ, HDW, IEG, TII, TFP, TEK, EIN, TVN, TFN, SIN, TER, TSY, ELH, AIN, SVN, TDN, TFH, TVH, TEN, TSS, TID, TCN, NIN, TEH, AEM, AIK, TDK, TFK, SDQ, TEI, NTN, TET, SIK, TEL, TEA, TAN, TIY, TFS, TES, TTN, TED, TNN, EVH, TIS, TVR, TDR, TIK, NHI, TIP, ESD, TDL, TVP, TVI, AEH, NCL, TVK, NAD, TIT, NCV, TIR, NAL, VIN, TIQ, TEF, TRE, QGE, SEK, NVN, GGE, EFV, SDK, TEQ, EVQ, TEY, NCW, TDV, SDI, NSI, NSL, EVV, TEP, SEL, TWQ, TEV, AVN, GVL, TLN, TEG, TRD, NAI, AEN, AET, ETA, NNL, or any dipeptide thereof. 50. The AAV particle of embodiment 48 or 49, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises:VTJ-4010PC (i) the amino acid sequence of any one of SEQ ID NOs: 2242-2886; (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids, e.g., consecutive amino acids, thereof; (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i). 51. The AAV particle of any one of embodiments 48-50, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises TINGSGSPHSKAQNQQ (SEQ ID NO: 2242). 52. The AAV particle of any one of embodiments 48-50, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises TINGHDSPHKSGQNQQ (SEQ ID NO: 2243). 53. The AAV particle of any one of embodiments 48-50, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises TINGSGSPHKYGQNQQT (SEQ ID NO: 5246). 54. The AAV particle of any one of embodiments 1-53, wherein [N1]-[N2]-[N3] is present in loop IV of the AAV capsid variant. 55. The AAV particle of any one of embodiments 48-54, wherein [N0] and [N4] are present in loop IV of the AAV capsid variant. 56. The AAV particle of any one of embodiments 48-55, wherein [N0] is present immediately subsequent to position 449, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 57. The AAV particle of any one of embodiments 48-55, wherein [N0] is present immediately subsequent to position 449, relative to a reference sequence numbered according to the amino acid sequence of any one of SEQ ID NO: 4500-4507, 36-59, 981, or 982.VTJ-4010PC 58. The AAV particle of any one of embodiments 48-57, wherein [N0] replaces positions 450, 451, and 452 (e.g., T450, I451, and N452), relative to a reference sequence numbered according to SEQ ID NO: 138. 59. The AAV particle of any one of embodiments 48-58, wherein [N0] replaces positions 450-452 (e.g., T450, I451, and N452), relative to a reference sequence numbered according to any one of SEQ ID NOs: 4500-4507, 36-59, 981, or 982. 60. The AAV particle of any one of embodiments 48-59, wherein [N0] coresponds to positions 450-452 of any one of SEQ ID NOs: 4500-4507, 36-59, 138, 981 or 982. 61. The AAV particle of any one of embodiments 48-60, wherein [N0] is present immediately subsequent to position 449 and wherein [N0] replaces positions 450-452 (e.g., T450, I451, and N452), relative to a reference sequence numbered according to SEQ ID NO: 138. 62. The AAV particle of any one of embodiments 48-61, wherein [N0] is present immediately subsequent to position 449 and wherein [N0] replaces positions 450-452 (e.g., T450, I451, and N452), relative to a reference sequence numbered according to any one of SEQ ID NOs: 4500-4507, 36-59, 981 or 982. 63. The AAV particle of any one of embodiments 1-62, wherein [N1] is present immediately subsequent to position 452, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 64. The AAV particle of any one of embodiments 1-63, wherein [N1] is present immediately subsequent to position 452, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 981 or 982. 65. The AAV particle of any one of embodiments 1-64, wherein [N1] replaces positions 453- 455 (e.g., G453, S454, and G455), relative to a reference sequence numbered according to SEQ ID NO: 138. 66. The AAV particle of any one of embodiments 1-65, wherein [N1] replaces positions 453 (e.g., G453), relative to a reference sequence numbered according to SEQ ID NO: 138.VTJ-4010PC 67. The AAV particle of any one of embodiments 1-66, wherein [N1] replaces positions 453- 455 (e.g., G453, S454, and G455), relative to a reference sequence numbered according to SEQ ID NO: 981. 68. The AAV particle of any one of embodiments 1-66 or 67, wherein [N1] replaces positions 453- 455, relative to a reference sequence numbered according to SEQ ID NO: 982. 69. The AAV particle of any one of embodiments 1-68, wherein [N1] is present immediately subsequent to position 452 and wherein [N1] replaces positions 453-455 (e.g., G453, S454, and G455), relative to a reference sequence numbered according to SEQ ID NO: 138. 70. The AAV particle of any one of embodiments 1-64, or 66, wherein [N1] is present immediately subsequent to position 452 and wherein [N1] replaces positions 453 (e.g., G453), relative to a reference sequence numbered according to SEQ ID NO: 138. 71. The AAV particle of any one of embodiments 1-64, 66, or 70, wherein [N1] is present immediately subsequent to position 452 and wherein [N1] replaces positions 453-455, relative to a reference sequence numbered according to SEQ ID NO: 981 or 982. 72. The AAV particle of any one of embodiments 1-71, wherein [N1] corresponds to positions 453-455 of any one of SEQ ID NOs: 4500-4507, 36-59, 981 or 982. 73. The AAV particle of any one of embodiment 1-72, wherein the AAV capsid variant comprises an amino acid other than S at position 454 and / or an amino acid other than G at position 455, numbered according to SEQ ID NO: 138, 981, or 982. 74. The AAV particle of any one of embodiments 1-73, wherein the AAV capsid variant comprises the amino acid H at position 454 and the amino acid D at position 455, numbered according to SEQ ID NO: 138. 75. The AAV particle of any one of embodiments 1-74, wherein the AAV capsid variant comprises a substitution at position 454 (e.g., S454H) and / or a substitution at position 455 (e.g., G455D), numbered according to SEQ ID NO: 138 or 982.VTJ-4010PC 76. The AAV particle of any one of embodiments 1-75, wherein the AAV capsid variant comprises the amino acid H at position 454 and the amino acid D at position 455, and further comprises the amino acid sequence SPHSKA (SEQ ID NO: 941) immediately subsequent to position 455, relative to a reference sequence numbered according to SEQ ID NO: 138. 77. The AAV particle of any one of embodiments 1-71, wherein the AAV capsid variant comprises the amino acid H at position 454 and the amino acid D at position 455, relative to a reference sequence numbered according to SEQ ID NO: 982. 78. The AAV particle of any one of embodiments 1-77, wherein the AAV capsid variant comprises the amino acid H at position 454 and the amino acid D at position 455, and further comprises the amino acid sequence SPHSKA (SEQ ID NO: 941) immediately subsequent to position 455, relative to a reference sequence numbered according to SEQ ID NO: 982. 79. The AAV particle of any one of embodiments 1-71, wherein the AAV capsid variant comprises the amino acid S at position 454 and the amino acid G at position 455, relative to a reference sequence numbered according to SEQ ID NO: 138. 80. The AAV particle of any one of embodiments 1-71 or 79, wherein the AAV capsid variant comprises the amino acid S at position 454 and the amino acid G at position 455, and further comprises the amino acid sequence SPHSKA (SEQ ID NO: 941) immediately subsequent to position 455, relative to a reference sequence numbered according to SEQ ID NO: 138. 81. The AAV particle of any one of embodiments 1-71, 79, or 80, wherein the AAV capsid variant comprises the amino acid S at position 454 and the amino acid G at position 455, relative to a reference sequence numbered according to SEQ ID NO: 981. 82. The AAV particle of any one of embodiments 1-71 or 79-81, wherein the AAV capsid variant comprises the amino acid S at position 454 and the amino acid G at position 455, and further comprises the amino acid sequence SPHSKA (SEQ ID NO: 941) immediately subsequent to position 455, relative to a reference sequence numbered according to SEQ ID NO: 981.VTJ-4010PC 83. The AAV particle of any one of embodiments 1-82, wherein [N2] is present immediately subsequent to position 455, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 84. The AAV particle of any one of embodiments 1-82, wherein [N2] corresponds to positions 456-458 (e.g., S456, P457, H458) of SEQ ID NO: 981 or 982. 85. The AAV particle of any one of embodiments 1-84, wherein [N2] corresponds to positions 456-458 (e.g., S456, P457, H458) of any one of SEQ ID NOs: 4500-4507, or 36-59. 86. The AAV particle of any one of embodiments 1-85, wherein [N2]-[N3] is present immediately subsequent to position 455, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 87. The AAV particle of any one of embodiments 1-86, wherein [N2] is present immediately subsequent to position 455, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 981 or 982. 88. The AAV particle of any one of embodiments 1-87, wherein [N2]-[N3] is present immediately subsequent to position 455, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 981 or 982. 89. The AAV particle of any one of embodiments 1-88, wherein [N2]-[N3] coresponds to positions 456-461 (e.g., S456, P457, H458, S459, K460, A461) of SEQ ID NO: 981. 90. The AAV particle of any one of embodiments 1-88, wherein [N2]-[N3] coresponds to positions 456-461 (e.g., S456, P457, H458, K459, S460, G461) of SEQ ID NO: 982. 91. The AAV particle of any one of embodiments 1-88, wherein [N2] is present immediately subsequent to [N1].VTJ-4010PC 92. The AAV particle of any one of embodiments 1-64, 66, 70, or 71, wherein [N3] is present immediately subsequent to [N2] and replaces positions 454 and 455 (e.g., S454 and G455), numbered according to SEQ ID NO: 138. 93. The AAV particle of any one of embodiments 1-64, 66, 70, 71, or 92, wherein [N3] is present immediately subsequent to [N1]-[N2] and replaces positions 454 and 455 (e.g., S454 and G455), numbered according to SEQ ID NO: 138. 94. The AAV particle of any one of embodiments 39-93, wherein [N4] is present immediately subsequent to position 455, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 95. The AAV particle of any one of embodiments 39-94, wherein [N4] replaces positions 456-459 (e.g., Q456, N457, Q458, and Q459), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 96. The AAV particle of any one of embodiments 39-95, wherein [N4] coresponds to positions 462-465 (e.g., Q462, N463, Q464, Q465) of SEQ ID NO: 981 or 982. 97. The AAV particle of any one of embodiments 39-96, wherein [N2]-[N3]-[N4] replaces positions 456- 459 (e.g., Q456, N457, Q458, and Q459), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 98. The AAV particle of any one of embodiments 39-97, wherein [N2]-[N3]-[N4] is present immediately subsequent to position 455, and wherein [N2]-[N3]-[N4] replaces positions 456-459 (e.g., Q456, N457, Q458, and Q459), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 99. The AAV particle of any one of embodiments 39-98, wherein [N2]-[N3]-[N4] corresponds to positions 456-465 (e.g., S456, P457, H458, S459, K460, A461, Q462, N463, Q464, Q465) of SEQ ID NO: 981.VTJ-4010PC 100. The AAV particle of any one of embodiments 39-99, wherein [N2]-[N3]-[N4] coresponds to positions 456-465 (e.g., S456, P457, H458, K459, S460, G461, Q462, N463, Q464, Q465) of SEQ ID NO: 982. 101. The AAV particle of any one of embodiments 39-100, wherein [N2]-[N3]-[N4] corresponds to positions 456-465 of any one of SEQ ID NOs: 4500-4507, or 36-59. 102. The AAV particle of any one of embodiments 39-101, wherein [N1]-[N2]-[N3]-[N4] replaces positions 453-459 (e.g., G453, S454, G455, Q456, N457, Q458, and Q459), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 103. The AAV particle of any one of embodiments 39-102, wherein [N1]-[N2]-[N3]-[N4] is present immediately subsequent to position 452, and wherein [N1]-[N2]-[N3]-[N4] replaces positions 453-459 (e.g., G453, S454, G455, Q456, N457, Q458, and Q459), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 104. The AAV particle of any one of embodiments 39-99, 102, or 103, wherein [N1]-[N2]-[N3]-[N4] corresponds to positions 453-465 (e.g., G453, S454, G455, S456, P457, H458, S459, K460, A461, Q462, N463, Q464, Q465) of SEQ ID NO: 981. 105. The AAV particle of any one of embodiments 39-98 or 100-103, wherein [N1]-[N2]-[N3]-[N4] corresponds to positions 453-465 (e.g., G453, H454, D455, S456, P457, H458, K459, S460, G461, Q462, N463, Q464, Q465) of SEQ ID NO: 982. 106. The AAV particle of any one of embodiments 39-98, or 101-103, wherein [N1]-[N2]-[N3]-[N4] corresponds to positions 453-465 of any one of SEQ ID NOs: 4500-4507, or 36-59. 107. The AAV particle of any one of embodiments 1-98 or 102-104 wherein [N1]-[N2]-[N3] coresponds to positions 453-461 (e.g., G453, S454, G455, S456, P457, H458, S459, K460, A461) of SEQ ID NO: 981. 108. The AAV particle of any one of embodiments 1-98, 100, 102, 103, or 105, wherein [N1]-[N2]-[N3] corresponds to positions 453-461 (e.g., G453, H454, D455, S456, P457, H458, K459, S460, G461) of SEQ ID NO: 982.VTJ-4010PC 109. The AAV particle of any one of embodiments 40-98, 101-103, or 106, wherein [N1]-[N2]-[N3] corresponds to positions 453-461 of any one of SEQ ID NOs: 4500-4507, or 36-59. 110. The AAV particle of any one of embodiments 39-109, wherein [N0]-[N1]-[N2]-[N3]-[N4] replaces positions 450-459 (e.g., T450, I451, N452, G453, S454, G455, Q456, N457, Q458, and Q459), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 111. The AAV particle of any one of embodiments 39-110, wherein [N0]-[N1]-[N2]-[N3]-[N4] is present immediately subsequent to position 449, and wherein [N0]-[N1]-[N2]-[N3]-[N4] replaces positions 450-459 (e.g., T450, I451, N452, G453, S454, G455, Q456, N457, Q458, and Q459), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 112. The AAV particle of any one of embodiments 39-99, 102-104, 110 or 111, wherein [N0]-[N1]-[N2]- [N3]-[N4] coresponds to positions 450-465 (e.g., T450, I451, N452, G453, S454, G455, S456, P457, H458, S459, K460, A461, Q462, N463, Q464, Q465) of SEQ ID NO: 981. 113. The AAV particle of any one of embodiments 39-98, 100-103, or 105-111, wherein [N0]-[N1]-[N2]- [N3]-[N4] coresponds to positions 450-465 (e.g., T450, I451, N452, G453, H454, D455, S456, P457, H458, K459, S460, G461, Q462, N463, Q464, Q465) of SEQ ID NO: 982. 114. The AAV particle of any one of embodiments 48-98, 101-103, 106, or 109, wherein [N0]-[N1]-[N2]- [N3]-[N4] coresponds to positions 450-465 of any one of SEQ ID NOs: 4500-4507, or 36-59. 115. The AAV particle of any one of embodiments 39-113, wherein [N4] replaces positions 462-465 (e.g., Q462, N463, Q464, and Q465), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 981 or 982. 116. The AAV particle of any one of embodiments 39-115, wherein [N2]-[N3]-[N4] replaces positions 462- 465 (e.g., Q462, N463, Q464, and Q465), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 981 or 982.VTJ-4010PC 117. The AAV particle of any one of embodiments 39-116, wherein [N2]-[N3]-[N4] is present immediately subsequent to position 455, and wherein [N2]-[N3]-[N4] replaces positions 462-465 (e.g., Q462, N463, Q464, and Q465), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 981 or 982. 118. The AAV particle of any one of embodiments 1-117, wherein [N3] is present immediately subsequent to [N2]. 119. The AAV particle of any one of embodiments 1-118, wherein the AAV capsid variant comprises from N-terminus to C-terminus, [N2]-[N3]. 120. The AAV particle of any one of embodiments 1-119, wherein the AAV capsid variant comprises from N-terminus to C-terminus, [N1]-[N2]-[N3]. 121. The AAV particle of any one of embodiments 28-120, wherein the AAV capsid variant comprises from N-terminus to C-terminus, [N0]-[N1]-[N2]-[N3]. 122. The AAV particle of any one of embodiments 25-121, wherein the AAV capsid variant comprises from N-terminus to C-terminus, [N1]-[N2]-[N3]-[N4]. 123. The AAV particle of any one of embodiments 25-122, wherein the AAV capsid variant comprises from N-terminus to C-terminus, [N0]-[N1]-[N2]-[N3]-[N4]. 124. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid other T at position 460 (e.g., N, I, C, H, R, L, D, Y, A, M, Q, I, E, K, P, G or S), numbered according to the amino acid sequence of SEQ ID NO: 138. 125. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises the amino acid N, I, C, H, R, L, D, Y, A, M, Q, I, E, K, P, G or S at position 460, numbered according to the amino acid sequence of SEQ ID NO: 138.VTJ-4010PC 126. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid other T at position 466 (e.g., N, I, C, H, R, L, D, Y, A, M, Q, I, E, K, P, G or S), numbered according to the amino acid sequence of any one of SEQ ID NOs: 4500-4507, 36-59, 981 or 982. 127. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises the amino acid N, I, C, H, R, L, D, Y, A, M, Q, I, E, K, P, G or S at position 466, numbered according to the amino acid sequence of any one of SEQ ID NOs: 4500-4507, 36-59, 981 or 982. 128. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid other K at position 449 (e.g., an E, an N, or a T), numbered according to the amino acid sequence of any one of SEQ ID NOs: 4500-4507, 36-59, 138, 981, or 982. 129. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises the amino E, N, or T at position 449, numbered according to the amino acid sequence of any one of SEQ ID NOs: 4500-4507, 36-59, 138, 981 or 982. 130. An AAV particle (e.g., isolated AAV particle) comprising an AAV capsid variant and a nucleic acid encoding an antibodymolecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises an amino acid sequence having the folowing formula: [N1]-[N2]-[N3] (SEQ ID NO: 4729), wherein: (i) [N1] comprises positions X1, X2, and X3, wherein position X2 is S and position X3 is G; (i) [N2] comprises the amino acid sequence SPH; and (ii) [N3] comprises positions X4, X5, and X6, wherein position X5 is K. 131. The AAV particle of embodiment 130, wherein: (i) X4 of [N3] is S, T, N, or A; and (i) X5 of [N3] is A, V, T, S, G, R, L, or N; optionaly wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (i) or (i). 132. The AAV particle of embodiment 130 or 131, wherein X4 is S and / or X5 is A.VTJ-4010PC 133. The AAV particle of any one of embodiments 130-132, wherein [N3] comprises SK, TK, NK, AK, KA, KV, KT, KS, KG, KR, KL, or KN. 134. The AAV particle of any one of embodiments 130-133, wherein [N3] is or comprises SKA, SKV, SKT, SKS, SKG, SKR, TKA, NKA, SKL, SKN, or AKA. 135. The AAV particle of any one of embodiments 130-134, wherein [N3] is or comprises SKA. 136. The AAV particle of any one of embodiments 130-135, wherein [N2]-[N3] comprises SPHSK (SEQ ID NO: 1674), SPHTK (SEQ ID NO: 1698), SPHNK (SEQ ID NO: 1699), or SPHAK (SEQ ID NO: 1700). 137. The AAV particle of any one of embodiments 130-136, wherein [N2]-[N3] is or comprises: (i) SPHSKA (SEQ ID NO: 941), SPHSKV (SEQ ID NO: 1710), SPHSKT (SEQ ID NO: 1704), SPHSKS (SEQ ID NO: 962), SPHSKG (SEQ ID NO: 1705), SPHSKR (SEQ ID NO: 978), SPHTKA (SEQ ID NO: 1712), SPHNKA (SEQ ID NO: 1707), SPHSKL (SEQ ID NO: 960), SPHSKN (SEQ ID NO: 1708), or SPHAKA (SEQ ID NO: 1709); (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof; (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i). 138. The AAV particle of any one of embodiments 130-137, wherein [N2]-[N3] is or comprises SPHSKA (SEQ ID NO: 941). 139. The AAV particle of any one of embodiments 130-138, which comprises an amino acid other than G at position 453 (e.g., M, T, I, E, S, A, N, V, L, K, H, P, R, W, or D), numbered according to SEQ ID NO: 138 or 981.VTJ-4010PC 140. The AAV particle of any one of embodiments 130-139, which comprises the amino acid G at position 453, numbered according to SEQ ID NO: 138 or 981. 141. The AAV particle of any one of embodiments 130-140, wherein X1 of [N1] is chosen from: G, M, T, I, E, S, A, N, V, L, K, H, P, R, W, or D; optionaly wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids. 142. The AAV particle of any one of embodiments 130-141, wherein [N1] comprises SG, GS, MS, TS, IS, ES, SS, AS, NS, VS, LS, KS, HS, PS, RS, WS, or DS. 143. The AAV particle of any one of embodiments 130-142, wherein [N1] is or comprises: GSG, MSG, TSG, ISG, ESG, SSG, ASG, NSG, VSG, LSG, KSG, HSG, PSG, RSG, WSG, or DSG. 144. The AAV particle of any one of embodiments 130-143, wherein [N1] is or comprises GSG. 145. The AAV particle of any one of embodiments 130-144, wherein [N1]-[N2] comprises SGSPH (SEQ ID NO: 1725). 146. The AAV particle of any one of embodiments 130-145, wherein [N1]-[N2] is or comprises: (i) GSGSPH (SEQ ID NO: 3860), MSGSPH (SEQ ID NO: 3875), TSGSPH (SEQ ID NO: 3877), ISGSPH (SEQ ID NO: 3878), ESGSPH (SEQ ID NO: 3880), SSGSPH (SEQ ID NO: 3881), ASGSPH (SEQ ID NO: 3883), NSGSPH (SEQ ID NO: 3884), VSGSPH (SEQ ID NO: 3863), LSGSPH (SEQ ID NO: 3885), KSGSPH (SEQ ID NO: 3887), HSGSPH (SEQ ID NO: 3888), PSGSPH (SEQ ID NO: 3890), RSGSPH (SEQ ID NO: 3892), WSGSPH (SEQ ID NO: 3894), DSGSPH (SEQ ID NO: 3895); (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof; (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i).VTJ-4010PC 147. The AAV particle of any one of embodiments 130-146, wherein [N1]-[N2]-[N3] is or comprises: (i) GSGSPHSKA (SEQ ID NO: 1671), GSGSPHSKV (SEQ ID NO: 4033), MSGSPHSKA (SEQ ID NO: 4034), TSGSPHSKA (SEQ ID NO: 4036), ISGSPHSKA (SEQ ID NO: 4037), GSGSPHSKT (SEQ ID NO: 4039), ESGSPHSKA (SEQ ID NO: 4040), SSGSPHSKA (SEQ ID NO: 4041), GSGSPHSKS (SEQ ID NO: 4030), ASGSPHSKA (SEQ ID NO: 4043), NSGSPHSKA (SEQ ID NO: 4044), VSGSPHSKA (SEQ ID NO: 3990), LSGSPHSKA (SEQ ID NO: 4045), KSGSPHSKA (SEQ ID NO: 4047), GSGSPHSKG (SEQ ID NO: 4049), GSGSPHSKR (SEQ ID NO: 4022), HSGSPHSKA (SEQ ID NO: 4050), PSGSPHSKA (SEQ ID NO: 4052), RSGSPHSKA (SEQ ID NO: 4054), GSGSPHTKA (SEQ ID NO: 4055), WSGSPHSKA (SEQ ID NO: 4057), DSGSPHSKA (SEQ ID NO: 4058), GSGSPHNKA (SEQ ID NO: 4060), GSGSPHSKL (SEQ ID NO: 4020), GSGSPHSKN (SEQ ID NO: 4072), or GSGSPHAKA (SEQ ID NO: 4073); (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, or 9 amino acids, e.g., consecutive amino acids, thereof; (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i). 148. The AAV particle of any one of embodiments 130-147, wherein [N1]-[N2]-[N3] is or comprises GSGSPHSKA (SEQ ID NO: 1671). 149. The AAV particle of any one of embodiments 130-148, wherein the AAV capsid variant comprises an amino acid other than Q at position 456 (e.g., R, P, H, L, K, I, G, S, M, or E), an amino acid other than N at position 457 (e.g., D, V, S, P, T, G, Y, W, E, R, H, K, F, A, I, L, or M), an amino acid other than Q at position 458 (e.g., R, L, A, P, H, T, I, F, K, V, M, G, W, Y, S, E, N, or D), an amino acid other than Q at position 459 (e.g., H, K, A, L, P, E, M, I, S, N, R, Y, C, V, T, W, D, G), and / or an amino acid other than T at position 460 (e.g., I, N, S, H, R, L, D, Y, A, or Q), relative to a reference sequence numbered according to SEQ ID NO: 138. 150. The AAV parrticle of any one of embodiments 130-149, wherein the AAV capsid variant comprises an amino acid other than Q at position 462 (e.g., R, P, H, L, K, I, G, S, M, or E), an amino acid other than N atVTJ-4010PC position 463 (e.g., D, V, S, P, T, G, Y, W, E, R, H, K, F, A, I, L, or M), an amino acid other than Q at position 464 (e.g., R, L, A, P, H, T, I, F, K, V, M, G, W, Y, S, E, N, or D), an amino acid other than Q at position 465 (e.g., H, K, A, L, P, E, M, I, S, N, R, Y, C, V, T, W, D, G), and / or an amino acid other than T at position 466 (e.g., I, N, S, H, R, L, D, Y, A, or Q), relative to a reference sequence numbered according to SEQ ID NO: 981. 151. The AAV particle of any one of embodiments 130-150, wherein the AAV capsid variant comprises the amino acid Q at position 456, the amino acid N at position 457, the amino acid Q at position 458, the amino acid Q at position 459, and / or the amino acid T at position 460, relative to a reference sequence numbered according to SEQ ID NO: 138. 152. The AAV particle of any one of embodiments 130-151, wherein the AAV capsid variant comprises the amino acid Q at position 462, the amino acid N at position 463, the amino acid Q at position 464, the amino acid Q at position 465, and / or the amino acid T at position 466, numbered according to SEQ ID NO: 981 153. The AAV particle of any one of embodiments 130-152, wherein the AAV capsid variant further comprises [N4] wherein [N4] comprises X7, X8, X9, X10, and X11, wherein: (a) X7 is Q, R, P, H, L, K, I, G, S, M, or E; (b) X8 is N, D, V, S, P, T, G, Y, W, E, R, H, K, F, A, I, L, or M; (c) X9 is Q, R, L, A, P, H, T, I, F, K, V, M, G, W, Y, S, E, N, D; (d) X10 is Q, H, K, A, L, P, E, M, I, S, N, R, Y, C, V, T, W, D, G; and (e) X11 is T, I, N, S, H, R, L, D, Y, A, Q; optionaly wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(e). 154. The AAV particle of embodiment 153, wherein [N4] is or comprises: (i) QNQQT (SEQ ID NO: 4730), QNRHT (SEQ ID NO: 4731), RDQQT (SEQ ID NO: 4732), PNLQT (SEQ ID NO: 4733), HVRQT (SEQ ID NO: 4734), PNQHT (SEQ ID NO: 4735), QSQQT (SEQ ID NO: 4736), QNQQI (SEQ ID NO: 4737), QPAKT (SEQ ID NO: 4738), QTQQN (SEQ ID NO: 4739), QNLAT (SEQ ID NO: 4740), QNQLT (SEQ ID NO: 4741), QGQQT (SEQ ID NO: 4742), LNRQS (SEQ ID NO: 4743), HNQQT (SEQ ID NO: 4744), QNPPT (SEQ ID NO: 4745), QNLQT (SEQ ID NO: 4746), QYQQT (SEQ ID NO: 4747), QDQET (SEQ ID NO: 4748), QNHQT (SEQ ID NO: 4749), QDQQT (SEQVTJ-4010PC ID NO: 4750), HWQQT (SEQ ID NO: 4751), PNQQT (SEQ ID NO: 4752), QNQLI (SEQ ID NO: 4753), PEQQT (SEQ ID NO: 4754), QRTMT (SEQ ID NO: 4755), QNQQH (SEQ ID NO: 4756), LHQHT (SEQ ID NO: 4757), QHRIT (SEQ ID NO: 4758), QYIHT (SEQ ID NO: 4759), QKFET (SEQ ID NO: 4760), QFPST (SEQ ID NO: 4761), HNQQR (SEQ ID NO: 4762), QAIKT (SEQ ID NO: 4763), QNRQT (SEQ ID NO: 4764), QYQHT (SEQ ID NO: 4765), QNPQS (SEQ ID NO: 4766), QHQLT (SEQ ID NO: 4767), QSPPT (SEQ ID NO: 4768), QAKLT (SEQ ID NO: 4769), KSQQT (SEQ ID NO: 4770), QDRPT (SEQ ID NO: 4771), QSQQL (SEQ ID NO: 4772), QAFHT (SEQ ID NO: 4773), QKQQD (SEQ ID NO: 4774), QNAQT (SEQ ID NO: 4775), HNQLT (SEQ ID NO: 4776), QNQQY (SEQ ID NO: 4777), QKLNT (SEQ ID NO: 4778), QNVQT (SEQ ID NO: 4779), QAQQT (SEQ ID NO: 4780), QNLQA (SEQ ID NO: 4781), QTPPT (SEQ ID NO: 4782), QYQHA (SEQ ID NO: 4783), QGQQA (SEQ ID NO: 4784), QPPAT (SEQ ID NO: 4785), QERPT (SEQ ID NO: 4786), QDLQT (SEQ ID NO: 4787), QAMHT (SEQ ID NO: 4788), LNQQT (SEQ ID NO: 4789), QHPST (SEQ ID NO: 4790), PGLQT (SEQ ID NO: 4791), QGIRT (SEQ ID NO: 4792), QAPAT (SEQ ID NO: 4793), QSQQI (SEQ ID NO: 4794), QIPPT (SEQ ID NO: 4795), QTQLT (SEQ ID NO: 4796), QAPST (SEQ ID NO: 4797), QNTYA (SEQ ID NO: 4798), QNQHI (SEQ ID NO: 4799), QNHLT (SEQ ID NO: 4800), QIGMT (SEQ ID NO: 4801), LNKQT (SEQ ID NO: 4802), QLQQT (SEQ ID NO: 4803), QRMST (SEQ ID NO: 4804), QGILT (SEQ ID NO: 4805), QDRQT (SEQ ID NO: 4806), RDWQT (SEQ ID NO: 4807), QNTHD (SEQ ID NO: 4808), PNLQI (SEQ ID NO: 4809), QERST (SEQ ID NO: 4810), QNYQT (SEQ ID NO: 4811), QRTCT (SEQ ID NO: 4812), QIGHT (SEQ ID NO: 4813), QGAIT (SEQ ID NO: 4814), QVPPT (SEQ ID NO: 4815), QVQQI (SEQ ID NO: 4816), LMRQT (SEQ ID NO: 4817), QYSVT (SEQ ID NO: 4818), QAITT (SEQ ID NO: 4819), QKTLT (SEQ ID NO: 4820), QNQWT (SEQ ID NO: 4821), QLHHT (SEQ ID NO: 4822), QNII (SEQ ID NO: 4823), QGHHT (SEQ ID NO: 4824), QSKVT (SEQ ID NO: 4825), QLPST (SEQ ID NO: 4826), IGKQT (SEQ ID NO: 4827), QAIHT (SEQ ID NO: 4828), QHGLT (SEQ ID NO: 4829), QFMCT (SEQ ID NO: 4830), QHLQT (SEQ ID NO: 4831), QNHQN (SEQ ID NO: 4832), QPART (SEQ ID NO: 4833), QSLQT (SEQ ID NO: 4834), QSQLT (SEQ ID NO: 4835), QDRQS (SEQ ID NO: 4836), QMPST (SEQ ID NO: 4837), QGSLT (SEQ ID NO: 4838), QVPAT (SEQ ID NO: 4839), QDKQT (SEQ ID NO: 4840), HYQQT (SEQ ID NO: 4841), QVPST (SEQ ID NO: 4842), RGEQT (SEQ ID NO: 4843), PGQQT (SEQ ID NO: 4844), QSLQI (SEQ ID NO: 4845), LEQQT (SEQ ID NO: 4846), QNQST (SEQ ID NO: 4847), QKVIT (SEQ ID NO: 4848), QNNDQ (SEQ ID NO: 4849), QSVHT (SEQ ID NO: 4850), QPLGT (SEQ ID NO: 4851), HNQET (SEQ ID NO: 4852), QNLQI (SEQ ID NO: 4853), QIQQT (SEQ ID NO: 4854), QVRNT (SEQ ID NO: 4855), PSNQT (SEQ ID NO: 4856), QVGHT (SEQ ID NO: 4857), QRDIT (SEQ ID NO: 4858), QMPNT (SEQ ID NO: 4859), RGLQT (SEQ ID NO: 4860), QKQQT (SEQ ID NO: 4861), PSLQT (SEQVTJ-4010PC ID NO: 4862), QRDQT (SEQ ID NO: 4863), QAKGT (SEQ ID NO: 4864), QSAHT (SEQ ID NO: 4865), QSTMT (SEQ ID NO: 4866), QREMT (SEQ ID NO: 4867), QYRAT (SEQ ID NO: 4868), QWQQT (SEQ ID NO: 4869), QRMNT (SEQ ID NO: 4870), GDSQT (SEQ ID NO: 4871), QKIST (SEQ ID NO: 4872), PSMQT (SEQ ID NO: 4873), SPRQT (SEQ ID NO: 4874), MEQQT (SEQ ID NO: 4875), QYQNT (SEQ ID NO: 4876), QHQQT (SEQ ID NO: 4877), INQQT (SEQ ID NO: 4878), PNQQH (SEQ ID NO: 4879), ENRQT (SEQ ID NO: 4880), QTQQA (SEQ ID NO: 4881), or QNQAT (SEQ ID NO: 4882); (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, or 4 amino acids, e.g., consecutive amino acids, thereof; (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i). 155. The AAV particle of embodiment 153 or 154, wherein [N1]-[N2]-[N3]-[N4] is or comprises: (i) the amino acid sequence of any of SEQ ID NOs: 200 or 2887-3076; (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 amino acids, e.g., consecutive amino acids, thereof; (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i). 156. The AAV particle of any one of embodiments 153-155, wherein [N1]-[N2]-[N3]-[N4] is or comprises GSGSPHSKAQNQQT (SEQ ID NO: 200). 157. The AAV particle of any one of embodiments 153-155, wherein [N1]-[N2]-[N3]-[N4] is or comprises VSGSPHSKAQNQQT (SEQ ID NO: 903). 158. The AAV particle of any one of embodiments 130-157, wherein the AAV capsid variant comprises an amino acid other than K at position 449 (e.g., T, E, or N), T at position 450 (e.g., S, E, A, N, V, Q, or G), anVTJ-4010PC amino acid other than I at position 451 (e.g., F, E, V, L, D, S, C, T, A, N, H, R, G, or W), and / or an amino acid other than N at position 452 (e.g., I, P, K, R, H, S, M, Q, D, T, L, A, Y, V, F, E, W, or G), relative to a reference sequence numbered according to SEQ ID NO: 138. 159. The AAV particle of any one of embodiments 130-157, wherein the AAV capsid variant comprises the amino acid K at position 449, the amino acid T at position 450, the amino acid I at position 451, and / or the amino acid N at position 452, relative to a reference sequence numbered according to SEQ ID NO: 138 or 981. 160. The AAV particle of any one of embodiments 130-159, wherein the AAV capsid variant further comprises [N0], wherein [N0] comprises XA, XB, XC, and XD, wherein: (a) XA is K, T, E, or N; (b) Xb is T, S, E, A, N, V, Q, or G; (c) XC is I, F, E, V, L, D, S, C, T, A, N, H, R, G, or W; and (d) XD is N, I, P, K, R, H, S, M, Q, D, T, L, A, Y, V, F, E, W, or G; optionaly wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(d). 161. The AAV particle of embodiment 160, wherein [N0] is or comprises: (i) KTI (SEQ ID NO: 4883), KTFP (SEQ ID NO: 4884), KTEK (SEQ ID NO: 4885), KTVN (SEQ ID NO: 4886), KTFN (SEQ ID NO: 4887), KTIN (SEQ ID NO: 4888), TTIN (SEQ ID NO: 4889), KSIN (SEQ ID NO: 4890), KTER (SEQ ID NO: 4891), KELH (SEQ ID NO: 4892), KAIN (SEQ ID NO: 4893), KTDN (SEQ ID NO: 4894), KTFH (SEQ ID NO: 4895), KTSN (SEQ ID NO: 4896), ETIN (SEQ ID NO: 4897), NTIN (SEQ ID NO: 4898), KTEN (SEQ ID NO: 4899), KTSS (SEQ ID NO: 4900), KTCN (SEQ ID NO: 4901), KTEH (SEQ ID NO: 4902), KAEM (SEQ ID NO: 4903), KATN (SEQ ID NO: 4904), KAIK (SEQ ID NO: 4905), KTDK (SEQ ID NO: 4906), KTFK (SEQ ID NO: 4907), KSDQ (SEQ ID NO: 4908), KTEI (SEQ ID NO: 4909), KTID (SEQ ID NO: 4910), KNTN (SEQ ID NO: 4911), KTET (SEQ ID NO: 4912), KTEL (SEQ ID NO: 4913), KNIN (SEQ ID NO: 4914), KTEA (SEQ ID NO: 4915), KTAN (SEQ ID NO: 4916), NTIY (SEQ ID NO: 4917), KTFS (SEQ ID NO: 4918), KTES (SEQ ID NO: 4919), KTTN (SEQ ID NO: 4920), KTED (SEQ ID NO: 4921), KTNN (SEQ ID NO: 4922), KEVH (SEQ ID NO: 4923), KTIS (SEQ ID NO: 4924), KTVR (SEQ ID NO: 4925), KTDR (SEQ ID NO: 4926), ETIK (SEQ ID NO: 4927), KNHI (SEQ ID NO: 4928), KESD (SEQ ID NO: 4929), KTIK (SEQ ID NO: 4930), KTDL (SEQ IDVTJ-4010PC NO: 4931), KTVP (SEQ ID NO: 4932), KTVI (SEQ ID NO: 4933), KAEH (SEQ ID NO: 4934), KNCL (SEQ ID NO: 4935), KTVK (SEQ ID NO: 4936), KNAD (SEQ ID NO: 4937), KTIT (SEQ ID NO: 4938), KNCV (SEQ ID NO: 4939), KNAL (SEQ ID NO: 4940), KVIN (SEQ ID NO: 4941), KTEF (SEQ ID NO: 4942), KTRE (SEQ ID NO: 4943), KQGE (SEQ ID NO: 4944), KSEK (SEQ ID NO: 4945), KNVN (SEQ ID NO: 4946), KGGE (SEQ ID NO: 4947), KEFV (SEQ ID NO: 4948), KSDK (SEQ ID NO: 4949), KTEQ (SEQ ID NO: 4950), KEVQ (SEQ ID NO: 4951), KTEY (SEQ ID NO: 4952), KNCW (SEQ ID NO: 4953), KTDV (SEQ ID NO: 4954), KSDI (SEQ ID NO: 4955), KNSI (SEQ ID NO: 4956), KNSL (SEQ ID NO: 4957), KEVV (SEQ ID NO: 4958), KTEP (SEQ ID NO: 4959), KSEL (SEQ ID NO: 4960), KTWQ (SEQ ID NO: 4961), KTEV (SEQ ID NO: 4962), KAVN (SEQ ID NO: 4963), KGVL (SEQ ID NO: 4964), KTEG (SEQ ID NO: 4965), KTRD (SEQ ID NO: 4966), KTGN (SEQ ID NO: 4967), KNAI (SEQ ID NO: 4968), KAEN (SEQ ID NO: 4969), KAET (SEQ ID NO: 4970), KTVH (SEQ ID NO: 4971), KETA (SEQ ID NO: 4972), KNNL (SEQ ID NO: 4973), EAIN (SEQ ID NO: 4974), KSLN (SEQ ID NO: 4975), KTIP (SEQ ID NO: 4976), or KTIH (SEQ ID NO: 4977); (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, or 3 amino acids, e.g., consecutive amino acids, thereof; (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i). 162. The AAV particle of embodiment 160 or 161, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises: (i) the amino acid sequence of any one of SEQ ID NOs: 3239-3526 or 3591-3605; (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 amino acids, e.g., consecutive amino acids, thereof; (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i).VTJ-4010PC 163. The AAV particle of any one of embodiments 160-162, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises KTINGSGSPHSKAQNQQT (SEQ ID NO: 5660). 164. The AAV particle of any one of embodiments 160-162, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises KTERVSGSPHSKAQNQQT (SEQ ID NO: 3589). 165. An AAV particle (e.g., isolated AAV particle) comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises an amino acid sequence having the folowing formula: [N1]-[N2]-[N3] (SEQ ID NO: 4978), wherein: (i) [N1] comprises positions X1, X2, and X3, wherein position X2 is an amino acid other than S and position X3 is an amino acid other than G; (i) [N2] comprises the amino acid sequence SPH; and (ii) [N3] comprises positions X4, X5, and X6, wherein position X4 is K. 166. The AAV particle of embodiment 165, wherein: (i) X5 of [N3] is S, I, T, R, H, Y, L, or M; and (i) X6 of [N3] is G, A, L, E, V, R, W, N, Q, or K; optionaly wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (i) or (i). 167. The AAV particle of embodiment 165 or 166, wherein X5 is S and / or X6 is G. 168. The AAV particle of any one of embodiments 165-167, wherein [N3] comprises KS, KI, KT, KR, KH, KY, KL, KM, SG, IG, TG, RG, SA, SL, SE, SV, SR, SW, SN, HG, YG, SQ, IV, SK, LW, MG, or MA. 169. The AAV particle of any one of embodiments 165-168, wherein [N3] is or comprises KSG, KIG, KTG, KRG, KSA, KSL, KSE, KSV, KSR, KSW, KSN, KHG, KYG, KSQ, KIV, KSK, KLW, KMG, or KMA. 170. The AAV particle of any one of embodiments 165-169, wherein [N3] is or comprises KSG.VTJ-4010PC 171. The AAV particle of any one of embodiments 165-170, wherein [N2]-[N3] comprises SPHKS (SEQ ID NO: 1677), SPHKI (SEQ ID NO: 1686), SPHKT (SEQ ID NO: 1684), SPHKR (SEQ ID NO: 1690), NPHKS (SEQ ID NO: 4979), SPHKH (SEQ ID NO: 1701), SPHKY (SEQ ID NO: 1688), SPHKL (SEQ ID NO: 1687), or SPHKM (SEQ ID NO: 1702). 172. The AAV particle of any one of embodiments 165-171, wherein [N2]-[N3] is or comprises: (i) SPHKSG (SEQ ID NO: 946), SPHKIG (SEQ ID NO: 958), SPHKTG (SEQ ID NO: 1711), SPHKRG (SEQ ID NO: 974), NPHKSG (SEQ ID NO: 4980), SPHKSA (SEQ ID NO: 977), SPHKSL (SEQ ID NO: 1713), SPHKSE (SEQ ID NO: 1714), SPHKSV (SEQ ID NO: 1715), SPHKSR (SEQ ID NO: 951), SPHKSW (SEQ ID NO: 1716), SPHKSN (SEQ ID NO: 1717), SPHKHG (SEQ ID NO: 1718), SPHKYG (SEQ ID NO: 966), SPHKSQ (SEQ ID NO: 1719), SPHKIV (SEQ ID NO: 4981), SPHKSK (SEQ ID NO: 1720), SPHKLW (SEQ ID NO: 1721), SPHKMG (SEQ ID NO: 1723), or SPHKMA (SEQ ID NO: 1724); (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof; (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i). 173. The AAV particle of any one of embodiments 165-172, wherein [N2]-[N3] is or comprises SPHKSG (SEQ ID NO: 946). 174. The AAV particle of any one of embodiments 165-173, wherein the AAV capsid variant comprises an amino acid other than G at position 453 (e.g., A, K, W, R, L, I, M, N, T, E, Q, Y, H, F, or V), numbered according to SEQ ID NO: 138 or 981. 175. The AAV particle of any one of embodiments 165-173, wherein the AAV capsid variant comprises the amino acid G at position 453, numbered according to SEQ ID NO: 138 or 981. 176. The AAV particle of any one of embodiments 165-175, wherein: (i) position X1 of [N1] is G, A, K, W, R, L, I, M, N, T, E, Q, Y, H, F, or V;VTJ-4010PC (i) position X2 of [N1] is H, Y, R, Q, N, P, or D; (ii) position X3 of [N1] is D, E, G, V, or N; optionaly wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (i), (i), or (ii). 177. The AAV particle of any one of embodiments 165-176, wherein position X2 of [N1] is H and position X3 of [N1] is D. 178. The AAV particle of any one of embodiments 165-177, wherein position X1 of [N1] is G, position X2 of [N1] is H and position X3 of [N1] is D. 179. The AAV particle of any one of embodiments 165-178, wherein [N1] comprises GH, HD, GY, GR, GQ, AH, GN, KH, GP, WH, RH, LH, IH, MH, GD, NH, TH, EH, QH, YH, HH, FH, VH, YD, HE, RG, QD, RD, ND, PD, QV, DD, HN, or NG 180. The AAV particle of any one of embodiments 165-179, wherein [N1] is or comprises GHD, GYD, GHE, GRG, GQD, GRD, AHD, GND, KHD, GPD, WHD, RHD, LHD, GQV, IHD, MHD, GDD, GHN, NHD, THD, GNG, EHD, QHD, YHD, HHD, FHD, or VHD. 181. The AAV particle of any one of embodiments 165-180, wherein [N1] is or comprises GHD. 182. The AAV particle of any one of embodiments 165-181, wherein [N1]-[N2] comprises HDSPH (SEQ ID NO: 1676). 183. The AAV particle of any one of embodiments 165-182, wherein [N1]-[N2] is or comprises: (i) GHDSPH (SEQ ID NO: 3861), GYDSPH (SEQ ID NO: 3906), GHESPH (SEQ ID NO: 3870), GRGSPH (SEQ ID NO: 3865), GHDNPH (SEQ ID NO: 4982), GQDSPH (SEQ ID NO: 3862), GRDSPH (SEQ ID NO: 3908), AHDSPH (SEQ ID NO: 4983), GNDSPH (SEQ ID NO: 3909), KHDSPH (SEQ ID NO: 4984), GPDSPH (SEQ ID NO: 3910), WHDSPH (SEQ ID NO: 4985), RHDSPH (SEQ ID NO: 4986), LHDSPH (SEQ ID NO: 4987), GQVSPH (SEQ ID NO: 3912), IHDSPH (SEQ ID NO: 4988), MHDSPH (SEQ ID NO: 4989), GDDSPH (SEQ ID NO: 3869), GHNSPH (SEQ ID NO: 3913), NHDSPH (SEQ ID NO: 4990), THDSPH (SEQ ID NO: 4991), GNGSPH (SEQ ID NO: 3882), EHDSPH (SEQ ID NO: 4992),VTJ-4010PC QHDSPH (SEQ ID NO: 4993), YHDSPH (SEQ ID NO: 4994), HHDSPH (SEQ ID NO: 4995), FHDSPH (SEQ ID NO: 4996), or VHDSPH (SEQ ID NO: 4997); (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof; (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i). 184. The AAV particle of any one of embodiments 165-183, wherein [N1]-[N2]-[N3] is or comprises: (i) GHDSPHKSG (SEQ ID NO: 1672), GHDSPHKIG (SEQ ID NO: 4074), GYDSPHKSG (SEQ ID NO: 4075), GHESPHKSG (SEQ ID NO: 4076), GHDSPHKTG (SEQ ID NO: 4077), GRGSPHKRG (SEQ ID NO: 4078), GHDNPHKSG (SEQ ID NO: 4998), GQDSPHKSG (SEQ ID NO: 3985), GHDSPHKSA (SEQ ID NO: 4017), GHDSPHKSL (SEQ ID NO: 4079), GHDSPHKSE (SEQ ID NO: 4082), GRDSPHKSG (SEQ ID NO: 4083), AHDSPHKSG (SEQ ID NO: 4999), GNDSPHKSV (SEQ ID NO: 4084), AHDSPHKIG (SEQ ID NO: 5000), GHESPHKSA (SEQ ID NO: 4016), GQDSPHKIG (SEQ ID NO: 4085), GHDSPHKSV (SEQ ID NO: 4086), GHDSPHKSR (SEQ ID NO: 4019), KHDSPHKSG (SEQ ID NO: 5001), GPDSPHKIG (SEQ ID NO: 4087), GPDSPHKSG (SEQ ID NO: 4088), GHDSPHKSW (SEQ ID NO: 4089), WHDSPHKSG (SEQ ID NO: 5002), RHDSPHKSG (SEQ ID NO: 5003), GHDSPHKSN (SEQ ID NO: 4090), GHDSPHKRG (SEQ ID NO: 4014), GHDSPHKHG (SEQ ID NO: 4092), LHDSPHKSG (SEQ ID NO: 5004), GQVSPHKSG (SEQ ID NO: 4093), IHDSPHKSG (SEQ ID NO: 5005), MHDSPHKSG (SEQ ID NO: 5006), GDDSPHKSV (SEQ ID NO: 4094), GHNSPHKSG (SEQ ID NO: 4095), NHDSPHKSG (SEQ ID NO: 5007), THDSPHKSG (SEQ ID NO: 5008), GNGSPHKRG (SEQ ID NO: 4096), EHDSPHKSG (SEQ ID NO: 5009), GHDSPHKYG (SEQ ID NO: 4097), GHDSPHKSQ (SEQ ID NO: 4487), QHDSPHKSG (SEQ ID NO: 5010), RHDSPHKIV (SEQ ID NO: 5011), YHDSPHKSG (SEQ ID NO: 5012), GNDSPHKIG (SEQ ID NO: 4488), HHDSPHKSG (SEQ ID NO: 5013), GHDSPHKSK (SEQ ID NO: 4489), FHDSPHKSG (SEQ ID NO: 5014), GHDSPHKLW (SEQ ID NO: 4490), VHDSPHKSG (SEQ ID NO: 5015), GHDSPHKMG (SEQ ID NO: 4492), GHDSPHKMA (SEQ ID NO: 4493), or GDDSPHKSG (SEQ ID NO: 4015); (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, or 9 amino acids, e.g., consecutive amino acids, thereof;VTJ-4010PC (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i). 185. The AAV particle of any one of embodiments 165-184, wherein [N1]-[N2]-[N3] is or comprises GHDSPHKSG (SEQ ID NO: 1672). 186. The AAV particle of any one of embodiments 165-185, wherein the AAV capsid variant comprises an amino acid other than Q at position 456 (e.g., R, P, H, K, L, V, A, E, or I), an amino acid other than N at position 457 (e.g., I, K, S, H, R, T, D, Y, L, W, F, A, Q, or M), an amino acid other than Q at position 458 (e.g., R, V, K, P, Y, H, L, I, E, or M), an amino acid other than Q at position 459 (e.g., H, L, E, P, W, D, I, V, S, K, R, C, M, or N), and / or an amino acid other than T at position 460 (e.g., A, E, K, S, I, P, G, or N), relative to a reference sequence numbered according to SEQ ID NO: 138. 187. The AAV particle of any one of embodiments 165-186, wherein the AAV capsid variant comprises an amino acid other than Q at position 462 (e.g., R, P, H, K, L, V, A, E, or I), an amino acid other than N at position 463 (e.g., I, K, S, H, R, T, D, Y, L, W, F, A, Q, or M), an amino acid other than Q at position 464 (e.g., R, V, K, P, Y, H, L, I, E, or M), an amino acid other than Q at position 465 (e.g., H, L, E, P, W, D, I, V, S, K, R, C, M, or N), and / or an amino acid other than T at position 466 (e.g., A, E, K, S, I, P, G, or N), relative to a reference sequence numbered according to SEQ ID NO: 982. 188. The AAV particle of any one of embodiments 165-187, wherein the AAV capsid variant comprises the amino acid Q at position 456, the amino acid N at position 457, the amino acid Q at position 458, the amino acid Q at position 459, and / or the amino acid T at position 460, relative to a reference sequence numbered according to SEQ ID NO: 138. 189. The AAV particle of any one of embodiments 165-188, wherein the AAV capsid variant comprises the amino acid Q at position 462, the amino acid N at position 463, the amino acid Q at position 464, the amino acid Q at position 465, and / or the amino acid T at position 466, relative to a reference sequence numbered according to SEQ ID NO: 982.VTJ-4010PC 190. The AAV particle of any one of embodiments 165-189, wherein the AAV capsid variant further comprises [N4] wherein [N4] comprises X7, X8, X9, X10, and X11, wherein: (a) X7 is Q, R, P, H, L, K, I, G, S, M, or E; (b) X8 is N, D, V, S, P, T, G, Y, W, E, R, H, K, F, A, I, L, or M; (c) X9 is Q, R, L, A, P, H, T, I, F, K, V, M, G, W, Y, S, E, N, D; (d) X10 is Q, H, K, A, L, P, E, M, I, S, N, R, Y, C, V, T, W, D, G; and (e) X11 is T, I, N, S, H, R, L, D, Y, A, Q; optionaly wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(e). 191. The AAV particle of embodiment 190, wherein [N4] is or comprises: (i) QNQQT (SEQ ID NO: 4730), QIRQT (SEQ ID NO: 5016), QNQHA (SEQ ID NO: 5017), QKQQT (SEQ ID NO: 4861), QSVQT (SEQ ID NO: 5018), RSQQT (SEQ ID NO: 5019), QNKLE (SEQ ID NO: 5020), QNQQK (SEQ ID NO: 5021), QHQQA (SEQ ID NO: 5022), QIQHT (SEQ ID NO: 5023), PRQQT (SEQ ID NO: 5024), HTQQT (SEQ ID NO: 5025), QRQHT (SEQ ID NO: 5026), QSQQT (SEQ ID NO: 4736), QNQQS (SEQ ID NO: 5027), RNQET (SEQ ID NO: 5028), QTQLT (SEQ ID NO: 4796), KNQQT (SEQ ID NO: 5029), QDQQT (SEQ ID NO: 4750), HNQQT (SEQ ID NO: 4744), QNQLT (SEQ ID NO: 4741), QTQQT (SEQ ID NO: 5030), QTQQI (SEQ ID NO: 5031), QSKQA (SEQ ID NO: 5032), QNQPP (SEQ ID NO: 5033), QSPQT (SEQ ID NO: 5034), QNYQT (SEQ ID NO: 4811), QNHQT (SEQ ID NO: 4749), QNRQT (SEQ ID NO: 4764), QNQQG (SEQ ID NO: 5035), QNHLT (SEQ ID NO: 4800), QYQHT (SEQ ID NO: 4765), QNQWT (SEQ ID NO: 4821), QNQHT (SEQ ID NO: 5036), QTRQT (SEQ ID NO: 5037), QNLHT (SEQ ID NO: 5038), LNQQT (SEQ ID NO: 4789), QNQET (SEQ ID NO: 5039), QHLQT (SEQ ID NO: 4831), LNQPT (SEQ ID NO: 5040), QNQDT (SEQ ID NO: 5041), RNQQT (SEQ ID NO: 5042), QNLLT (SEQ ID NO: 5043), QLVIT (SEQ ID NO: 5044), RTQET (SEQ ID NO: 5045), QTHQT (SEQ ID NO: 5046), QNQPA (SEQ ID NO: 5047), QDQHT (SEQ ID NO: 5048), QSQHT (SEQ ID NO: 5049), RNQQI (SEQ ID NO: 5050), VRQQT (SEQ ID NO: 5051), QNQHS (SEQ ID NO: 5052), AWQQT (SEQ ID NO: 5053), QSVPT (SEQ ID NO: 5054), QNIQP (SEQ ID NO: 5055), QNHLN (SEQ ID NO: 5056), LDQQT (SEQ ID NO: 5057), PDQQS (SEQ ID NO: 5058), ESQQT (SEQ ID NO: 5059), QNKQT (SEQ ID NO: 5060), QRQLT (SEQ ID NO: 5061), QIVT (SEQ ID NO: 5062), QKQST (SEQ ID NO: 5063), QSHQT (SEQ ID NO: 5064), QFVVT (SEQ ID NO: 5065), QNLQT (SEQ ID NO: 4746), QNQQI (SEQ ID NO: 4737), QSQPT (SEQ ID NO: 5066), QNEQT (SEQ ID NO: 5067), QSLQT (SEQ IDVTJ-4010PC NO: 4834), RNRQT (SEQ ID NO: 5068), QSKQT (SEQ ID NO: 5069), QNPLT (SEQ ID NO: 5070), RDQKT (SEQ ID NO: 5071), HNQQN (SEQ ID NO: 5072), QWKRT (SEQ ID NO: 5073), QSQQI (SEQ ID NO: 4794), QAQQT (SEQ ID NO: 4780), QNHQI (SEQ ID NO: 5074), QNQQA (SEQ ID NO: 5075), QNQLN (SEQ ID NO: 5076), QTQPT (SEQ ID NO: 5077), INQQT (SEQ ID NO: 4878), QKQLT (SEQ ID NO: 5078), RNQLA (SEQ ID NO: 5079), RNQQS (SEQ ID NO: 5080), ISIQT (SEQ ID NO: 5081), QNQQN (SEQ ID NO: 5082), QSQQS (SEQ ID NO: 5083), QTVCT (SEQ ID NO: 5084), QYQQI (SEQ ID NO: 5085), QQIMT (SEQ ID NO: 5086), QNEQS (SEQ ID NO: 5087), LNHQT (SEQ ID NO: 5088), QMIHT (SEQ ID NO: 5089), RNHQS (SEQ ID NO: 5090), QKMNT (SEQ ID NO: 5091), QSQQN (SEQ ID NO: 5092), QYQHA (SEQ ID NO: 4783); (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, or 4 amino acids, e.g., consecutive amino acids, thereof; (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i). 192. The AAV particle of embodiment 190 or 191, wherein [N1]-[N2]-[N3]-[N4] is or comprises: (i) the amino acid sequence of any of SEQ ID NOs: 201 or 3160-3237; (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 amino acids, e.g., consecutive amino acids, thereof; (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i). 193. The AAV particle of any one of embodiments 190-192, wherein [N1]-[N2]-[N3]-[N4] is or comprises GHDSPHKSGQNQQT (SEQ ID NO: 201). 194. The AAV particle of any one of embodiments 165-193, wherein the AAV capsid variant comprises an amino acid other than K at position 449 (e.g., T), T at position 450 (e.g., A, S, I, V, N, E, Y, C, G, W, or Q),VTJ-4010PC an amino acid other than I at position 451 (e.g., E, V, S, T, N, D, C, G, Q, L, P, A), and / or an amino acid other than N at position 452 (e.g., S, Y, I, K, F, T, D, E, G, V, L, A, M, Q, H, P, or R), relative to a reference sequence numbered according to SEQ ID NO: 138 or 982. 195. The AAV particle of any one of embodiments 165-193, wherein the AAV capsid variant comprises the amino acid K at position 449, the amino acid T at position 450, the amino acid I at position 451, and / or the amino acid N at position 452, relative to a reference sequence numbered according to SEQ ID NO: 138. 196. The AAV particle of any one of embodiments 165-195, wherein the AAV capsid variant further comprises [N0], wherein [N0] comprises XA, XB, XC, and XD, wherein: (a) XA is K or T; (b) Xb is T, A, S, I, V, N, E, Y, C, G, W, or Q; (c) XC is I, E, V, S, T, N, D, C, G, Q, L, P, A; and (d) XD is N, S, Y, I, K, F, T, D, E, G, V, L, A, M, Q, H, P, or R; optionaly wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(d). 197. The AAV particle of embodiment 196, wherein [N0] is or comprises: (i) KAIN (SEQ ID NO: 4893), KTIN (SEQ ID NO: 4888), KTES (SEQ ID NO: 4919), TTIN (SEQ ID NO: 4889), KSIN (SEQ ID NO: 4890), KTVN (SEQ ID NO: 4886), KSIY (SEQ ID NO: 5093), KTSN (SEQ ID NO: 4896), KTTN (SEQ ID NO: 4920), KIN (SEQ ID NO: 5094), KTIS (SEQ ID NO: 4924), KAI (SEQ ID NO: 5095), KTIK (SEQ ID NO: 4930), KTEF (SEQ ID NO: 4942), KTIT (SEQ ID NO: 4938), KTNN (SEQ ID NO: 4922), KTID (SEQ ID NO: 4910), KAIS (SEQ ID NO: 5096), KTVD (SEQ ID NO: 5097), KTIE (SEQ ID NO: 5098), KTEG (SEQ ID NO: 4965), KVIN (SEQ ID NO: 4941), KAVN (SEQ ID NO: 4963), KTIY (SEQ ID NO: 5099), KTDN (SEQ ID NO: 4894), KTCN (SEQ ID NO: 4901), KNVV (SEQ ID NO: 5100), KTEL (SEQ ID NO: 4913), KTDA (SEQ ID NO: 5101), KTEV (SEQ ID NO: 4962), KSEL (SEQ ID NO: 4960), KTEM (SEQ ID NO: 5102), KTEQ (SEQ ID NO: 4950), KTI (SEQ ID NO: 4883), KIVN (SEQ ID NO: 5103), KTEK (SEQ ID NO: 4885), KTEN (SEQ ID NO: 4899), KIGN (SEQ ID NO: 5104), KEVM (SEQ ID NO: 5105), KYQV (SEQ ID NO: 5106), KTEA (SEQ ID NO: 4915), KATN (SEQ ID NO: 4904), KTEH (SEQ ID NO: 4902), KTVE (SEQ ID NO: 5107), KAID (SEQ ID NO: 5108), KTIM (SEQ ID NO: 5109), KEVG (SEQ ID NO: 5110), KSEM (SEQ ID NO: 5111), KAQQ (SEQ ID NO: 5112), KCGE (SEQ ID NO: 5113), KASN (SEQ ID NO: 5114), KTET (SEQ ID NO: 4912), KTIGVTJ-4010PC (SEQ ID NO: 5115), KTDP (SEQ ID NO: 5116), KELV (SEQ ID NO: 5117), KELM (SEQ ID NO: 5118), KNEI (SEQ ID NO: 5119), KTPN (SEQ ID NO: 5120), KITN (SEQ ID NO: 5121), KTDI (SEQ ID NO: 5122), KTDQ (SEQ ID NO: 5123), KGIN (SEQ ID NO: 5124), KSEI (SEQ ID NO: 5125), KSEK (SEQ ID NO: 4945), KWSA (SEQ ID NO: 5126), KELA (SEQ ID NO: 5127), KQTQ (SEQ ID NO: 5128), KGAD (SEQ ID NO: 5129), KVGE (SEQ ID NO: 5130), KANE (SEQ ID NO: 5131), KTDT (SEQ ID NO: 5132), KTCI (SEQ ID NO: 5133), KELR (SEQ ID NO: 5134), KCQI (SEQ ID NO: 5135), KGVM (SEQ ID NO: 5136), KACD (SEQ ID NO: 5137), KNEL (SEQ ID NO: 5138), KAAE (SEQ ID NO: 5139), KGQN (SEQ ID NO: 5141), KNEF (SEQ ID NO: 5142), KTSI (SEQ ID NO: 5143), KAEH (SEQ ID NO: 4934), KCDQ (SEQ ID NO: 5144), KEIL (SEQ ID NO: 5145), KTER (SEQ ID NO: 4891), KNAI (SEQ ID NO: 4968), KTDK (SEQ ID NO: 4906), KTPD (SEQ ID NO: 5146), KTIH (SEQ ID NO: 4977), or KTEI (SEQ ID NO: 4909); (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, or 3 amino acids, e.g., consecutive amino acids, thereof; (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i). 198. The AAV particle of embodiment 196 or 197, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises: (i) the amino acid sequence of any one of SEQ ID NOs: 3606-3836; (i) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 amino acids, e.g., consecutive amino acids, thereof; (ii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four diferent amino acids, relative to any one of the amino acid sequences in (i). 199. The AAV particle of any one of embodiments 196-198, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises KTINGHDSPHKSGQNQQT (SEQ ID NO: 5828).VTJ-4010PC 200. The AAV particle of any one of embodiments 196-198, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises KAEIGHDSPHKSGQNQQT (SEQ ID NO: 1754). 201. The AAV particle of any one of embodiments 196-198, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises KTEKMSGSPHSKAQNQQT (SEQ ID NO: 3241). 202. The AAV particle of any one of embodiments 130-200, wherein [N1]-[N2]-[N3] is present in loop IV of the AAV capsid variant. 203. The AAV particle of any one of embodiments 160-164 or 196-202, wherein [N0] and [N4] are present in loop IV of the AAV capsid variant. 204. The AAV particle of any one of embodiments 160-164 or 196-203, wherein [N0] is present immediately subsequent to position 448, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138, 981, or 982. 205. The AAV particle of any one of embodiments 160-164 or 196-204, wherein [N0] replaces positions 449-452 (e.g., K449, T450, I451, and N452), relative to a reference sequence numbered according to SEQ ID NO: 138, 981, or 982. 206. The AAV particle of any one of embodiments 160-164 or 196-205, wherein [N0] is present immediately subsequent to position 448 and wherein [N0] replaces positions 449-452 (e.g., K449, T450, I451, and N452), relative to a reference sequence numbered according to SEQ ID NO: 138, 981, or 982. 207. The AAV particle of any one of embodiments 160-164 or 196-206, wherein [N0] corresponds to positions 449-452 (e.g., K449, T450, I451, and N452) of SEQ ID NO: 981 or 982. 208. The AAV particle of any one of embodiments 130-207, wherein [N1] is present immediately subsequent to position 452, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138, 981, or 982.VTJ-4010PC 209. The AAV particle of any one of embodiments 130-208, wherein [N1] replaces positions 453- 455 (e.g., G453, S454, and G455), relative to a reference sequence numbered according to SEQ ID NO: 138, 981, or 982. 210. The AAV particle of any one of embodiments 130-208, wherein [N1] replaces position 453 (e.g., G453), relative to a reference sequence numbered according to SEQ ID NO: 138, 981, or 982. 211. The AAV particle of any one of embodiments 130-164 or 200-209, wherein: (i) position X1 of [N1] replaces position 453 (e.g., G453); (i) position X2 of [N1] coresponds to position 454 (e.g., S454); and (ii) position X3 of [N1] corresponds to position 455 (e.g., G455), wherein (i), (i), and (ii) are numbered according to SEQ ID NO: 138 or SEQ ID NO: 981. 212. The AAV particle of any one of embodiments 130-164 or 200-209, wherein: (i) position X1 of [N1] corresponds to position 453 (e.g., G453); (i) position X2 of [N1] coresponds to position 454 (e.g., S454); and (ii) position X3 of [N1] corresponds to position 455 (e.g., G455), wherein (i), (i), and (ii) are numbered according to SEQ ID NO: 138 or SEQ ID NO: 981. 213. The AAV particle of any one of embodiments 165-209, wherein: (i) position X1 of [N1] corresponds to position 453 (e.g., G453); (i) position X2 of [N1] replaces position 454 (e.g., S454); and (ii) position X3 of [N1] replaces position 455 (e.g., G455); wherein (i), (i), and (ii) are numbered according to SEQ ID NO: 138 or SEQ ID NO: 982. 214. The AAV particle of any one of embodiments 165-209, wherein [N1] coresponds to positions 453-455 (e.g., G453, H454, D455) of SEQ ID NO 982. 215. The AAV particle of any one of embodiments 165-209, wherein [N1] coresponds to positions 453-455 (e.g., G453, S454, G455) of SEQ ID NO: 138 or 981.VTJ-4010PC 216. The AAV particle of any one of embodiments 130-215, wherein [N2] is present immediately subsequent to position 455, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138, 981, or 982. 217. The AAV particle of any one of embodiments 130-216, wherein [N2] coresponds to positions 456-458 (e.g., S456, P457, and H458) of SEQ ID NO: 981 or 982. 218. The AAV particle of any one of embodiments 130-216, wherein [N2] coresponds to positions 456-458 (e.g., S456, P457, and H458) of any one of SEQ ID NOs: 4500-4507, or 36-59. 219. The AAV particle of any one of embodiments 130-218, wherein [N2] is present immediately subsequent to [N1]. 220. The AAV particle of any one of embodiments 130-219, wherein [N3] coresponds to positions 459-460 (e.g., S459, K460, A461) of SEQ ID NO 981. 221. The AAV particle of any one of embodiments 130-220, wherein [N3] coresponds to positions 459-460 (e.g., S459, K460, A461) of SEQ ID NO: 36, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 57, or 59 222. The AAV particle of any one of embodiments 130-220, wherein [N2]-[N3] is present immediately subsequent to position 455, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138, 981, or 982. 223. The AAV particle of any one of embodiments 130-164 or 200-222, wherein [N2]-[N3] is present immediately subsequent to position 455, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 981. 224. The AAV particle of any one of embodiments 130-164 or 200-223, wherein [N2]-[N3] coresponds to positions 456-461 (e.g., S456, P457, H458, S459, K460, A461) of SEQ ID NO: 981.VTJ-4010PC 225. The AAV particle of any one of embodiments 130-164 or 200-223, wherein [N2]-[N3] coresponds to positions 456-461 (e.g., S456, P457, H458, S459, K460, A461) of any one of SEQ ID NOs: 36, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 57, or 59. 226. The AAV particle of any one of embodiments 165-222, wherein [N3] coresponds to positions 459-460 (e.g., K459, S460, G461) of SEQ ID NO: 982. 227. The AAV particle of any one of embodiments 165-219 or 222-226, wherein [N3] corresponds to positions 459-460 (e.g., K459, S460, G461) of SEQ ID NO: 37. 228. The AAV particle of any one of embodiments 165-222 or 227, wherein [N2]-[N3] is present immediately subsequent to position 455, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 982. 229. The AAV particle of any one of embodiments 165-228, wherein [N3] replaces positions 454 and 455 (e.g., S454 and G455), numbered according to SEQ ID NO: 138. 230. The AAV particle of any one of embodiments 165-229, wherein [N3] is present immediately subsequent to [N2] and replaces positions 454 and 455 (e.g., S454 and G455), numbered according to SEQ ID NO: 138. 231. The AAV particle of any one of embodiments 165-230, wherein [N3] is present immediately subsequent to [N1]-[N2] and replaces positions 454 and 455 (e.g., S454 and G455), numbered according to SEQ ID NO: 138. 232. The AAV particle of any one of embodiments 165-222, 226, or 228, wherein [N2]-[N3] coresponds to positions 456-461 (e.g., S456, P457, H458, K459, S460, G461) of SEQ ID NO: 982. 233. The AAV particle of any one of embodiments 165-222, 226, or 228, wherein [N2]-[N3] coresponds to positions 456-461 (e.g., S456, P457, H458, K459, S460, G461) of SEQ ID NO: 37.VTJ-4010PC 234. The AAV particle of any one of embodiments 153-164 or 190-233, wherein [N4] is present immediately subsequent to position 455, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 235. The AAV particle of any one of embodiments 153-164 or 190-234, wherein [N4] replaces positions 456-460 (e.g., Q456, N457, Q458, Q459, and T460), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 236. The AAV particle of any one of embodiments 153-164 or 190-235, wherein [N4] corresponds to positions 462-466 (e.g., Q462, N463, Q464, Q465, and T466) of SEQ ID NO: 981 or 982. 237. The AAV particle of any one of embodiments 153-164 or 190-235, wherein [N4] corresponds to positions 462-466 of any one of SEQ ID NOs: 4500-4507, or 36-59. 238. The AAV particle of any one of embodiments 153-164 or 190-235, wherein [N4] corresponds to positions 456-460 (e.g., Q456, N457, Q458, Q459, and T460) of SEQ ID NO: 138. 239. The AAV particle of any one of embodiments 153-164 or 190-236, wherein [N2]-[N3]-[N4] replaces positions 456-460 (e.g., Q456, N457, Q458, Q459, and T460), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 240. The AAV particle of any one of embodiments 153-164 or 190-239, wherein [N2]-[N3]-[N4] is present immediately subsequent to position 455, and wherein [N2]-[N3]-[N4] replaces positions 456-460 (e.g., Q456, N457, Q458, Q459, and T460), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 241. The AAV particle of any one of embodiments 153-164 or 190-240, wherein [N1]-[N2]-[N3]-[N4] replaces positions 453-460 (e.g., G453, S454, G455, Q456, N457, Q458, Q459, and T460), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 242. The AAV particle of any one of embodiments 153-164 or 190-241, wherein [N1]-[N2]-[N3]-[N4] is present immediately subsequent to position 452, and wherein [N1]-[N2]-[N3]-[N4] replaces positions 453-VTJ-4010PC 460 (e.g., G453, S454, G455, Q456, N457, Q458, Q459, and T460), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 243. The AAV particle of any one of embodiments 153-164 or 190-242, wherein [N1]-[N2]-[N3]-[N4] corresponds to positions 453-466 (e.g., G453, S454, G455, S456, P457, H458, S459, K460, A461, Q462, N463, Q464, Q465, Q466) of SEQ ID NO: 981. 244. The AAV particle of any one of embodiments 153-164 or 190-243, wherein [N1]-[N2]-[N3] corresponds to positions 453-461 (e.g., G453, S454, G455, S456, P457, H458, S459, K460, A461) of SEQ ID NO: 981. 245. The AAV particle of any one of embodiments 153-164 or 190-242, wherein [N1]-[N2]-[N3]-[N4] corresponds to positions 453-466 (e.g., G453, H454, D455, S456, P457, H458, K459, S460, G461, Q462, N463, Q464, Q465, T466) of SEQ ID NO: 982. 246. The AAV particle of any one of embodiments 153-164, 190-242, or 245, wherein [N1]-[N2]-[N3] corresponds to positions 453-461 (e.g., G453, H454, D455, S456, P457, H458, K459, S460, G461) of SEQ ID NO: 982. 247. The AAV particle of any one of embodiments 153-164, 190-242, or 245, wherein [N1]-[N2]-[N3]-[N4] corresponds to positions 453-466 of any one of SEQ ID NOs: 4500-4507 or 36-59. 248. The AAV particle of any one of embodiments 160-164 or 196-245, wherein [N0]-[N1]-[N2]-[N3]-[N4] replaces positions 449-460 (e.g., K449, T450, I451, N452, G453, S454, G455, Q456, N457, Q458, Q459, T460), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 249. The AAV particle of any one of embodiments 160-164 or 196-248, wherein [N0]-[N1]-[N2]-[N3]-[N4] is present immediately subsequent to position 448, and wherein [N0]-[N1]-[N2]-[N3]-[N4] replaces positions 449-460 (e.g., K449, T450, I451, N452, G453, S454, G455, Q456, N457, Q458, Q459, T460), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138.VTJ-4010PC 250. The AAV particle of any one of embodiments 160-164 or 202-249, wherein [N0]-[N1]-[N2]-[N3]-[N4] corresponds to positions 449-466 (e.g., K449, T450, I451, N452, G453, S454, G455, S456, P457, H458, S459, K460, A461, Q462, N463, Q464, Q465, T466) of SEQ ID NO: 981. 251. The AAV particle of any one of embodiments 202-249, wherein [N0]-[N1]-[N2]-[N3]-[N4] corresponds to positions 449-466 (e.g., K449, T450, I451, N452, G453, H454, D455, S456, P457, H458, K459, S460, G461, Q462, N463, Q464, Q465, T466) of SEQ ID NO: 982. 252. The AAV particle of any one of embodiments 202-249, wherein [N0]-[N1]-[N2]-[N3]-[N4] corresponds to positions 449-466 of any one of SEQ ID NOs: 4500-4507 or 36-59. 253. The AAV particle of any one of embodiments 153-164 or 190-251, wherein [N4] is present immediately subsequent to position 461, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 981 or 982. 254. The AAV particle of any one of embodiments 153-164 or 190-253, wherein [N4] replaces positions 462-466 (e.g., Q462, N463, Q464, Q465, and T466), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 981 or 982. 255. The AAV particle of any one of embodiments 153-164 or 190-254, wherein [N2]-[N3]-[N4] replaces positions 462-466 (e.g., Q462, N463, Q464, Q465, and T466), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 981 or 982. 256. The AAV particle of any one of embodiments 153-164 or 190-255, wherein [N2]-[N3]-[N4] is present immediately subsequent to position 455, and wherein [N2]-[N3]-[N4] replaces positions 462-466 (e.g., Q462, N463, Q464, Q465, and T466), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 981 or 982. 257. The AAV particle of any one of embodiments 130-256, wherein the AAV capsid variant comprises from N-terminus to C-terminus, [N2]-[N3].VTJ-4010PC 258. The AAV particle of any one of embodiments 130-257, wherein the AAV capsid variant comprises from N-terminus to C-terminus, [N1]-[N2]-[N3]. 259. The AAV particle of any one of embodiments 130-258, wherein the AAV capsid variant comprises from N-terminus to C-terminus, [N0]-[N1]-[N2]-[N3]. 260. The AAV particle of any one of embodiments 130-259, wherein the AAV capsid variant comprises from N-terminus to C-terminus, [N1]-[N2]-[N3]-[N4]. 261. The AAV particle of any one of embodiments 130-260, wherein the AAV capsid variant comprises from N-terminus to C-terminus, [N0]-[N1]-[N2]-[N3]-[N4]. 262. An AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant: (i) is enriched, e.g., at least about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 190, 200, 205, or 210- fold, in the brain of at least two to three species, e.g., a non-human primate and rodent (e.g., mouse), e.g., as compared to a reference sequence of SEQ ID NO: 138, optionaly wherein the at least two to three species are Macaca fascicularis, Chlorocebus sabaeus, Calithrix jacchus, and / or mouse (e.g., BALB / c mice, C57Bl / 6 mice, and / or CD-1 outbred mice); and / or (i) is capable of transducing neuronal and non-neuronal cels, e.g., glial cels, oligodendrocytes (e.g., Olig2 positive oligodendrocytes), and / or astrocytes (e.g., Olig2 positive astrocytes). 263. An AAV particle (e.g., isolated AAV particle) comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises: (a) the amino acid sequence of any of the sequences provided in Tables 2-4, 24-26, 28, or 29; (b) an amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 consecutive amino acids from any one of the sequences provided in Tables 2-4, 24-26, 28, or 29; or (c) an amino acid sequence comprising at least one, two, or three but no more than four different amino acids, relative to any one of the sequences provided in Tables 2-4, 24-26, 28, or 29; orVTJ-4010PC (d) an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of any one of the sequences provided in Tables 2-4, 24-26, 28, or 29. 264. An AAV particle (e.g., isolated AAV particle) comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises: (a) the amino acid sequence of any of SEQ ID NOs: 945-980 or 985-986; (b) an amino acid sequence comprising at least 3, 4, or 5 consecutive amino acids from any one of SEQ ID NOs: 945-980 or 985-986; or (c) an amino acid sequence comprising at least one, two, or three but no more than four different amino acids, relative to the amino acid sequence of any one of SEQ ID NOs: 945-980 or 985-986; (d) an amino sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of any one of SEQ ID NOs: 945-980 or 985-986. 265. An AAV particle (e.g., isolated AAV particle) comprising an AAV capsid variant and a nucleic acid encoding a an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises: (a) the amino acid sequence of any of SEQ ID NOs: 2, 200, 201, 941, 943, 204, 208, 404, or 903- 909; (b) an amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 consecutive amino acids from any one of SEQ ID NOs: 2, 200, 201, 941, 943, 204, 208, 404, or 903-909; (c) an amino acid sequence comprising at least one, two, or three but no more than four different amino acids, relative to the amino acid sequence of any one of SEQ ID NOs: 2, 200, 201, 941, 943, 204, 208, 404, or 903-909; or (d) an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of any one of SEQ ID NOs: 2, 200, 201, 941, 943, 204, 208, 404, or 903-909.VTJ-4010PC 266. The AAV particle of any one of embodiments 225, 226, 228, 262, 263 or 265, wherein the AAV capsid variant comprises an amino acid sequence comprising at least 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 consecutive amino acids from any one of SEQ ID NOs: 2, 200, 201, 941, 943, 204, 208, 404, or 903-909. 267. The AAV particle of any one of embodiments 262-266, wherein the 3 consecutive amino acids comprise SPH. 268. The AAV particle of any one of embodiments 262-267, wherein the 4 consecutive amino acids comprise SPHS (SEQ ID NO: 1673). 269. The AAV particle of any one of embodiments 262-268, wherein the 5 consecutive amino acids comprise SPHSK (SEQ ID NO: 1674). 270. The AAV particle of any one of embodiments 262-269, wherein the 6 consecutive amino acids comprise SPHSKA (SEQ ID NO: 941). 271. The AAV particle of embodiment 262-266, wherein the 3 consecutive amino acids comprise HDS. 272. The AAV particle of any one of embodiments 262-266 or 271, wherein the 4 consecutive amino acids comprise HDSP (SEQ ID NO: 1675). 273. The AAV particle of any one of embodiments 262-266, 271, or 272, wherein the 5 consecutive amino acids comprise HDSPH (SEQ ID NO: 1676). 274. The AAV particle of any one of embodiments 262-266 or 271-273, wherein the 6 consecutive amino acids comprise HDSPHK (SEQ ID NO: 2). 275. The AAV particle of any one of embodiments 262-267, wherein: (i) the 3 consecutive amino acids comprise SPH; (i) the 4 consecutive amino acids comprise SPHK (SEQ ID NO: 5147); (ii) the 5 consecutive amino acids comprise SPHKY (SEQ ID NO: 1688); and / or (iv) the 6 consecutive amino acids comprise SPHKYG (SEQ ID NO: 966).VTJ-4010PC 276. The AAV particle of embodiment 262, 263, 265, or 266, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of any one of SEQ ID NOs: 2, 200, 201, 941, 943, 204, 208, 404, or 903-909. 277. The AAV particle of any one of embodiments 262-270 or 276, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of SPHSKA (SEQ ID NO: 941). 278. The AAV particle of any one of embodiments 262-266, 271-274, or 276, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of HDSPHK (SEQ ID NO: 2). 279. The AAV particle of any one of embodiments 262-267, 275, or 276, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of SPHKYG (SEQ ID NO: 966). 280. The AAV particle of embodiment 262 or 263, wherein the AAV capsid variant comprises: (i) an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of KTENVSGSPHSKAQNQQT (SEQ ID NO: 3272); (i)an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of KTERVSGSPHSKAQNQQT (SEQ ID NO: 3589); (i) an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of KAEIGHDSPHKSGQNQQT (SEQ ID NO: 1754);VTJ-4010PC (ii) an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of KTEKMSGSPHSKAQNQQT (SEQ ID NO: 3241); (iv) an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of KTINGHDSPHSKAQNLQT (SEQ ID NO: 4100); or (v) an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of KTVNGHDSPHSKAQNQQT (SEQ ID NO: 4062). 281. The AAV particle of any one of embodiments 262, 263, 265, 266, or 276, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two, or three but no more than four diferent amino acids relative to the amino acid sequence of any one of SEQ ID NOs: 200, 201, 941, 943, 204, 208, 404, or 903-909. 282. The AAV particle of any one of embodiments 262-270, 276, 277, or 281, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two, or three but no more than four diferent amino acids relative to the amino acid sequence of SPHSKA (SEQ ID NO: 941). 283. The AAV particle of any one of embodiments 262-266, 271-275, 276, 278, or 281, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two, or three but no more than four different amino acids relative to the amino acid sequence of HDSPHK (SEQ ID NO: 2). 284. The AAV particle of any one of embodiments 262-267, 275, 276, or 281, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two, or three but no more than four diferent amino acids relative to the amino acid sequence of SPHKYG (SEQ ID NO: 966). 285. The AAV particle of any one of embodiments 262, 263 or 280, wherein the AAV capsid variant comprises: (i) an amino acid sequence comprising at least one, two, or three but no more than four different amino acids relative to the amino acid sequence of KTERVSGSPHSKAQNQQT (SEQ ID NO: 3589);VTJ-4010PC (i) an amino acid sequence comprising at least one, two, or three but no more than four different amino acids relative to the amino acid sequence of KAEIGHDSPHKSGQNQQT (SEQ ID NO: 1754); (ii) an amino acid sequence comprising at least one, two, or three but no more than four diferent amino acids relative to the amino acid sequence of KTEKMSGSPHSKAQNQQT (SEQ ID NO: 3241); (iv) an amino acid sequence comprising at least one, two, or three but no more than four diferent amino acids relative to the amino acid sequence of KTINGHDSPHSKAQNLQT (SEQ ID NO: 4100); (v) an amino acid sequence comprising at least one, two, or three but no more than four different amino acids relative to the amino acid sequence of KTVNGHDSPHSKAQNQQT (SEQ ID NO: 4062); (vi) an amino acid sequence comprising at least one, two, or three but no more than four diferent amino acids relative to the amino acid sequence of KTENVSGSPHSKAQNQQT (SEQ ID NO: 3272); (vi) an amino acid sequence comprising at least one, two, or three but no more than four diferent amino acids relative to the amino acid sequence of KTEKVSGSPHSKAQNQQT (SEQ ID NO: 3274); (vii) an amino acid sequence comprising at least one, two, or three but no more than four diferent amino acids relative to the amino acid sequence of KTINGSGSPHKSGQNKTS (SEQ ID NO: 4406); (ix) an amino acid sequence comprising at least one, two, or three but no more than four diferent amino acids relative to the amino acid sequence of KTSNASGSPHSKAHNQQT (SEQ ID NO: 3382); (x) an amino acid sequence comprising at least one, two, or three but no more than four different amino acids relative to the amino acid sequence of KNSIGSGSPHSKAQNQQT (SEQ ID NO: 3421); (xi) an amino acid sequence comprising at least one, two, or three but no more than four diferent amino acids relative to the amino acid sequence of KTVNGHDSPHKSGQRPST (SEQ ID NO: 4478); (xi) an amino acid sequence comprising at least one, two, or three but no more than four diferent amino acids relative to the amino acid sequence of KAENGSGSPHSKAQNQQT (SEQ ID NO: 3487); or (xii) an amino acid sequence comprising at least one, two, or three but no more than four diferent amino acids relative to the amino acid sequence of KTINGSGSPHKSGQNQQP (SEQ ID NO: 4081). 286. The AAV particle of any one of embodiments 1-129, 262, 263, 265-279, or 281-284, wherein the AAV capsid variant comprises the amino acid sequence of any of SEQ ID NOs: 200, 201, 941, 943, 204, 208, 404, or 903-909. 287. The AAV particle of any one of embodiments 262, 263, 267-270, 276, 277, 280-282, 285, or 286, wherein the AAV capsid variant comprises the amino acid sequence of ERVSGSPHSKA (SEQ ID NO:VTJ-4010PC 5148), optionaly wherein the amino acid sequence is present immediately subsequent to position 450 and replaces positions 451-455, numbered according to SEQ ID NO: 138. 288. The AAV particle of any one of embodiments 262, 263, 267-270, 276, 277, 280-282, or 285-287, wherein the AAV capsid variant comprises the amino acid sequence of KTERVSGSPHSKAQNQQT (SEQ ID NO: 3589), optionaly wherein the amino acid sequence is present immediately subsequent to position 448 and replaces positions 449-460, numbered according to SEQ ID NO: 138. 289. The AAV particle of any one of embodiments 262, 263, 271-274, 276, 278, 280, 281, 283, 285, or 286, wherein the AAV capsid variant comprises the amino acid sequence of AEIGHDSPHKSG (SEQ ID NO: 5149), optionaly wherein the amino acid sequence is present immediately subsequent to position 449 and replaces positions 450-455, numbered according to SEQ ID NO: 138. 290. The AAV particle of any one of embodiments 262, 263, 271-274, 276, 278, 280, 281, 283, 285, 286, or 289, wherein the AAV capsid variant comprises the amino acid sequence of KAEIGHDSPHKSGQNQQT (SEQ ID NO: 1754), optionaly wherein the amino acid sequence is present immediately subsequent to position 448 and replaces positions 449-460, (e.g., K449, T450, I451, N452, G453, S454, G455, Q456, N457, Q458, Q459, T460), numbered according to SEQ ID NO: 138. 291. The AAV particle of any one of embodiments 262, 263, 271-274, 276, 278, 280, 281, 283, 285, or 286, which comprises the amino acid sequence of EKMSGSPHSKA (SEQ ID NO: 6401), optionaly wherein the amino acid sequence is present immediately subsequent to position 450 and replaces positions 451-455 (e.g., I451, N452, G453, S454, G455), numbered according to SEQ ID NO: 138. 292. The AAV particle of any one of embodiments 262, 263, 271-274, 276, 278, 280, 281, 283, 285, 286, or 291, wherein the AAV capsid variant comprises the amino acid sequence of KTEKMSGSPHSKAQNQQT (SEQ ID NO: 3241), optionaly wherein the amino acid sequence is present immediately subsequent to position 448 and replaces positions 449-460 (e.g., K449, T450, I451, N452, G453, S454, G455, Q456, N457, Q458, Q459, T460), numbered according to SEQ ID NO: 138. 293. The AAV particle of any one of embodiments 262, 263, 271-274, 276, 278, 280, 281, 283, 285, or 286, wherein the AAV capsid variant comprises the amino acid sequence of HDSPHSKAQNL (SEQ ID NO:VTJ-4010PC 6402), optionaly wherein the amino acid sequence is present immediately subsequent to position 453 and replaces positions 456-458 (e.g., Q456, N457, Q458), numbered according to SEQ ID NO: 138. 294. The AAV particle of any one of embodiments 262, 263, 271-274, 276, 278, 280, 281, 283, 285, 286, or 293, wherein the AAV capsid variant comprises the amino acid sequence of KTINGHDSPHSKAQNLQT (SEQ ID NO: 4100), optionaly wherein the amino acid sequence is present immediately subsequent to position 448 and replaces positions 449-460 (e.g., K449, T450, I451, N452, G453, S454, G455, Q456, N457, Q458, Q459, T460), numbered according to SEQ ID NO: 138. 295. The AAV particle of any one of embodiments 262, 263, 271-274, 276, 278, 280, 281, 283, 285, or 286, wherein the AAV capsid variant comprises the amino acid sequence of VNGHDSPHSKA (SEQ ID NO: 6403), optionaly wherein the amino acid sequence is present immediately subsequent to position 450 and replaces positions 451-455 (e.g., I451, N452, G453, S454, G455), numbered according to SEQ ID NO: 138. 296. The AAV particle of any one of embodiments 262, 263, 271-274, 276, 278, 280, 281, 283, 285, 286, or 295, wherein the AAV capsid variant comprises the amino acid sequence of KTVNGHDSPHSKAQNQQT (SEQ ID NO: 4062), optionaly wherein the amino acid sequence is present immediately subsequent to position 448 and replaces positions 449-460 (e.g., K449, T450, I451, N452, G453, S454, G455, Q456, N457, Q458, Q459, T460), numbered according to SEQ ID NO: 138. 297. The AAV particle of any one of embodiments 262, 263, 271-274, 276, 278, 280, 281, 283, 285, or 286, wherein the AAV capsid variant comprises the amino acid sequence of ENVSGSPHSKA (SEQ ID NO: 5150), optionaly wherein the amino acid sequence is present immediately subsequent to position 450 and replaces positions 451-455 (e.g., I451, N452, G453, S454, G455), numbered according to SEQ ID NO: 138; corresponds to positions 451 to 461 of SEQ ID NO: 4500; or is present at positions 451 to 461 numbered according to SEQ ID NO: 4500 or 981. 298. The AAV particle of any one of embodiments 262, 263, 271-274, 276, 278, 280, 281, 283, 285, 286, or 295, wherein the AAV capsid variant comprises the amino acid sequence of KTENVSGSPHSKAQNQQT (SEQ ID NO: 3272), optionaly wherein the amino acid sequence is present immediately subsequent to position 448 and replaces positions 449-460 (e.g., K449, T450, I451, N452, G453, S454, G455, Q456,VTJ-4010PC N457, Q458, Q459, T460), numbered according to SEQ ID NO: 138; coresponds to positions 449 to 466 of SEQ ID NO: 4500; or is present at positions 449 to 466 numbered according to SEQ ID NO: 4500 or 981. 299. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-71, 79-89, 94-99, 102- 104, 106-112, 115-164, 203-209, 212, 216-224, 234-243, 248-250, 253-270, 276, 277, 281, 282, or 286-288, wherein the AAV capsid variant comprises an amino acid sequence encoded by: the nucleotide sequence of SEQ ID NO: 942; a nucleotide sequence comprising at least one, two, three, four, five, six, or seven modifications, e.g., substitutions (e.g., conservative substitutions), but no more than ten modifications, e.g., substitutions (e.g., conservative substitutions), relative to the nucleotide sequence of SEQ ID NO: 942; or a nucleotide sequence comprising at least one, two, three, four, five, six, or seven, but no more than ten diferent nucleotides relative to the nucleotide sequence of SEQ ID NO: 942. 300. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-78, 83-88, 90-98, 100-103, 105-111, 113-129, 165-211, 213-222, 226-242, 245-249, 251-266, 271-274, 276, 278, 280, 281, 283, 285, 286, 289, or 290, wherein the AAV capsid variant comprises an amino acid sequence encoded by: the nucleotide sequence of SEQ ID NO: 3; a nucleotide sequence comprising at least one, two, three, four, five, six, or seven modifications, e.g., substitutions (e.g., conservative substitutions), but no more than ten modifications, e.g., substitutions (e.g., conservative substitutions), relative to the nucleotide sequence of SEQ ID NO: 3; or a nucleotide sequence comprising at least one, two, three, four, five, six, or seven, but no more than ten different nucleotides relative to the nucleotide sequence of SEQ ID NO: 3. 301. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-71, 79-89, 94-99, 102- 104, 106-112, 115-164, 203-209, 212, 216-224, 234-243, 248-250, 253-270, 276, 277, 281, 282, 286-288, or 299, wherein the nucleotide sequence encoding the AAV capsid variant comprises the nucleotide sequence of SEQ ID NO: 942; a nucleotide sequence comprising at least one, two, three, four, five, six, or seven modifications, e.g., substitutions (e.g., conservative substitutions), but no more than ten modifications, e.g., substitutions (e.g., conservative substitutions), relative to the nucleotide sequence of SEQ ID NO: 942; or a nucleotide sequence comprising at least one, two, three, four, five, six, or seven, but no more than ten diferent nucleotides relative to the nucleotide sequence of SEQ ID NO: 942.VTJ-4010PC 302. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-78, 83-88, 90-98, 100-103, 105-111, 113-129, 165-211, 213-222, 226-242, 245-249, 251-266, 271-274, 276, 278, 280, 281, 283, 285, 286, 289, 290, or 300, wherein the nucleotide sequence encoding the AAV capsid variant comprises the nucleotide sequence of SEQ ID NO: 3; a nucleotide sequence comprising at least one, two, three, four, five, six, or seven modifications, e.g., substitutions (e.g., conservative substitutions), but no more than ten modifications, e.g., substitutions (e.g., conservative substitutions), relative to the nucleotide sequence of SEQ ID NO: 3; or a nucleotide sequence comprising at least one, two, three, four, five, six, or seven, but no more than ten diferent nucleotides relative to the nucleotide sequence of SEQ ID NO: 3. 303. The AAV particle of any one of embodiments 262-302, wherein the amino acid sequence is present in loop IV of the AAV capsid variant. 304. The AAV particle of any one of embodiments 262-303, wherein the amino acid sequence is present immediately subsequent to position 448, 449, 450, 451, 452, 453, 454, or 455, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 305. The AAV particle of any one of embodiments 262-304, wherein the amino acid sequence replaces amino acids 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, and / or 460 (e.g., K449, T450, I451, N452, G453, S454, G455, Q456, N457, Q458, Q459, and / or T460), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 306. The AAV particle of any one of embodiments 262-305, wherein the amino acid sequence is present immediately subsequent to position 455, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 307. The AAV particle of any one of embodiments 262-306, wherein the amino acid sequence is present immediately subsequent to position 453, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 308. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-71, 79-89, 94-99, 102- 104, 106-112, 115-164, 203-209, 212, 216-224, 234-243, 248-250, 253-270, 276, 277, 281, 282, 286-288,VTJ-4010PC 299, 301, or 303-307, wherein the AAV capsid variant comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 309. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-71, 79-89, 94-99, 102- 104, 106-112, 115-164, 203-209, 212, 216-224, 234-243, 248-250, 253-270, 276, 277, 281, 282, 286-288, 299, 301, or 303-308, wherein the AAV capsid variant comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455 (e.g., present at positions 456-461), numbered according to the amino acid sequence of SEQ ID NO: 981. 310. The AAV particle of embodiment 308 or 309, wherein the AAV capsid variant further comprises an amino acid other than I at position 451, an amino acid other than N at position 452, and an amino acid other than G at position 453, numbered according to any one of SEQ ID NOs: 36, 138, or 981. 311. The AAV particle of any one of embodiments 308-310, wherein the AAV capsid variant further comprises E at position 451, R at position 452, and V at position 453, numbered according to any one of SEQ ID NOs: 36, 138, or 981. 312. The AAV particle of any one of embodiments 308-311, wherein the AAV capsid variant further comprises the substitutions I451E, N452R, and G453V, numbered according to any one of SEQ ID NOs: 36, 138, or 981. 313. The AAV particle of any one of embodiments 308-312, wherein the AAV capsid variant comprises: (i) E at position 451, R at position 452, and V at position 453, numbered according to any one of SEQ ID NOs: 36, 138, or 981; and (i) the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to any one of SEQ ID NOs: 36, 138, or 981 (e.g., at amino acids 456-461, numbered according to SEQ ID NO: 36 or 981). 314. The AAV particle of embodiment 308 or 309, which further comprises an amino acid other than I at position 451, an amino acid other than N at position 452, and / or G at position 453, numbered according to SEQ ID NO: 39 or 138.VTJ-4010PC 315. The AAV particle of any one of embodiments 308, 309, or 314, which further comprises E at position 451, K at position 452, and / or M at position 453, numbered according to SEQ ID NO: 138 or 39. 316. The AAV particle of any one of embodiments 308, 309, 314, or 315, which further comprises the substitutions I451E, N452K, and G453M, numbered according to SEQ ID NO: 39 or 138. 317. The AAV particle of any one of embodiments 308, 309, or 314-316, which comprises: (i) E at position 451, K at position 452, and M at position 453, numbered according to SEQ ID NO: 39 or 138; and (i) the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to SEQ ID NO: 39 or 138. 318. The AAV particle of embodiment 308 or 309, which further comprises an amino acid other than S at position 454, an amino acid other than G at position 455, and / or Q at position 458, numbered according to SEQ ID NO: 138. 319. The AAV particle of any one of embodiments 308, 309, or 318, which further comprises H at position 454, D at position 455, and / or L at position 458, numbered according to SEQ ID NO: 138. 320. The AAV particle of any one of embodiments 308, 309, 318, or 319, which further comprises the substitutions S454H, G455D, and Q458L, numbered according to SEQ ID NO: 138. 321. The AAV particle of any one of embodiments 308, 309, or 318-320, which comprises: (i) H at position 454, D at position 455, and / or L at position 458, numbered according to SEQ ID NO: 138; and (i) the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to SEQ ID NO: 138. 322. The AAV particle of embodiment 308 or 309, which further comprises an amino acid other than I at position 451, an amino acid other than S at position 454, and / or an amino acid other than G at position 455, numbered according to SEQ ID NO: 52 or 138.VTJ-4010PC 323. The AAV particle of any one of embodiments 308, 309, or 322, which further comprises V at position 451, H at position 454, and / or D at position 455, numbered according to SEQ ID NO: 52 or 138. 324. The AAV particle of any one of embodiments 308, 309, 322, or 323, wherein the AAV capsid variant further comprises the substitutions I451V, S454H, and / or G455D, numbered according to SEQ ID NO: 52 or 138. 325. The AAV particle of any one of embodiments 308, 309, or 322-324, wherein the AAV capsid variant comprises: (i) V at position 451, H at position 454, and / or D at position 455, numbered according to SEQ ID NO: 52 or 138; and (i) the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to SEQ ID NO: 52 or 138. 326. The AAV particle of embodiment 308 or 309, wherein the AAV capsid variant comprises an amino acid other than I at position 451 and / or G at position 453, numbered according to SEQ ID NO: 138. 327. The AAV particle of any one of embodiments 308, 309, or 326, wherein the AAV capsid variant comprises E at position 451 and / or V at position 453, numbered according to SEQ ID NO: 138 or 4500. 328. The AAV particle of any one of embodiments 308, 309, 326, or 327, wherein the AAV capsid variant comprises: (i) E at position 451 and V at position 453, numbered according to SEQ ID NO: 4500 or 138; and (i) the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, at positions 456-461, numbered according to SEQ ID NO: 4500 or 138. 329. The AAV particle of embodiment 308 or 309, wherein the AAV capsid variant comprises: (i) E at position 451, K at position 452, and V at position 453, numbered according to SEQ ID NO: 4501 or 138; and the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequenceVTJ-4010PC is present immediately subsequent to position 455, at positions 456-461, numbered according to SEQ ID NO: 4501 or 138; (i) S at position 451, A at position 453, and H at position 462, numbered according to SEQ ID NO: 4503; and the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, at positions 456-461, numbered according to SEQ ID NO: 4503 or 138; (ii) N at position 450, S at position 451, and I at position 452, numbered according to SEQ ID NO: 4504 or 138; and the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, at positions 456-461, numbered according to SEQ ID NO: 4504 or 138; or (iv) A at position 450 and E at position 451, numbered according to SEQ ID NO: 4506 or 138; and the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, at positions 456-461, numbered according to SEQ ID NO: 4506 or 138. 330. The AAV particle of any one of embodiments 308, 309, or 329, wherein the AAV capsid variant comprises the amino acid sequence of any one of SEQ ID NOs: 3241, 3272, 3274, 3382, 3421, 3487, 3589, 4100, optionaly wherein: (i) the amino acid sequence is present immediately subsequent to position 448 and replaces positions 449-460 (e.g., K449, T450, I451, N452, G453, S454, G455, Q456, N457, Q458, Q459, and T460), numbered according to SEQ ID NO: 138; or (i) the amino acid sequence is present at positions 449-466, numbered according to any one of SEQ ID NOs: 4500-4507, 36-59, 981, or 982. 331. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-78, 83-88, 90-98, 100-103, 105-111, 113-129, 165-211, 213-222, 226-242, 245-249, 251-266, 271-274, 276, 278, 280, 281, 283, 285, 286, 289, 290, 300, or 302-307, wherein the AAV capsid variant comprises the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the amino acid sequence is present immediately subsequent to position 453 (e.g., at positions 454-459), numbered relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138.VTJ-4010PC 332. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-78, 83-88, 90-98, 100-103, 105-111, 113-129, 165-211, 213-222, 226-242, 245-249, 251-266, 271-274, 276, 278, 280, 281, 283, 285, 286, 289, 290, 300, 302-307, or 331, wherein the AAV capsid variant comprises the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the amino acid sequence is present immediately subsequent to position 453, numbered relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 982. 333. The AAV particle of embodiment 332, wherein the AAV capsid variant comprises: (i) V at position 451, R at position 463, P at position 464, and S at position 465, numbered according to SEQ ID NO: 4505 or 982; (i) the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the amino acid sequence is present immediately subsequent to position 453, at positions 454-459, numbered relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 4505 or 982. 334. The AAV particle of embodiment 332 or 333, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 1754, 4062, 4100, or 4478, optionaly wherein: (i) the amino acid sequence is present immediately subsequent to position 448 and replaces positions 449-460 (e.g., K449, T450, I451, N452, G453, S454, G455, Q456, N457, Q458, Q459, and T460), numbered according to SEQ ID NO: 138; or (i) the amino acid sequence is present at positions 449-466, numbered according to any one of SEQ ID NOs: 4500-4507, 36-59, 981 or 982. 335. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-78, 83-88, 90-98, 100-103, 105-111, 113-129, 165-211, 213-222, 226-242, 245-249, 251-266, 271-274, 276, 278, 280, 281, 283, 285, 286, 289, 290, 300, 302-307, 331, or 332, wherein the AAV capsid variant comprises the amino acid sequence of SPHKSG (SEQ ID NO: 946), wherein the amino acid sequence is present immediately subsequent to position 455 (e.g., at positions 456-461), numbered relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 982. 336. The AAV particle of embodiment 335, wherein the AAV capsid variant comprises: (i) K at position 464, T at position 465, and S at position 466, numbered according SEQ ID NO: 4502; and the amino acid sequence of SPHKSG (SEQ ID NO: 946), wherein the amino acid sequence isVTJ-4010PC present immediately subsequent to position 455, at positions 456-461, numbered relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 4502; or (i) P at position 466, numbered according SEQ ID NO: 4507; and the amino acid sequence of SPHKSG (SEQ ID NO: 946), wherein the amino acid sequence is present immediately subsequent to position 455, at positions 456-461, numbered relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 4507. 337. The AAV particle of embodiment 335 or 336, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 4081 or 4406, optionaly wherein: (i) the amino acid sequence is present immediately subsequent to position 448 and replaces positions 449-460 (e.g., K449, T450, I451, N452, G453, S454, G455, Q456, N457, Q458, Q459, and T460), numbered according to SEQ ID NO: 138; or (i) the amino acid sequence is present at positions 449-466, numbered according to any one of SEQ ID NOs: 4500-4507, 36-59, 981 or 982. 338. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-78, 83-88, 90-98, 100-103, 105-111, 113-129, 165-211, 213-222, 226-242, 245-249, 251-266, 271-274, 276, 278, 280, 281, 283, 285, 286, 289, 290, 300, 302-307, or 331-337, wherein the AAV capsid variant comprises: (i) the amino acid sequence of HDSPHSKA (SEQ ID NO: 4486), which is present immediately subsequent to position 453; and (i) a deletion of amino acids SG at position 454 and 455; wherein (i) and (i) are numbered according to SEQ ID NO: 138. 339. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-78, 83-88, 90-98, 100-103, 105-111, 113-129, 165-211, 213-222, 226-242, 245-249, 251-266, 271-274, 276, 278, 280, 281, 283, 285, 286, 289, 290, 300, 302-307, or 331-338, wherein the AAV capsid variant comprises the amino acids HD at position 454 and 455, and further comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941), which is present immediately subsequent to position 455, numbered relative to SEQ ID NO: 138.VTJ-4010PC 340. The AAV particle of any one of embodiments 331-339, wherein the AAV capsid variant further comprises an amino acid other than T at position 450, an amino acid other than I at position 451, and an amino acid other than N at position 452, numbered according to SEQ ID NO: 138 or 982. 341. The AAV particle of any one of embodiments 331-340, wherein the AAV capsid variant further comprises A at position 450, E at position 451, and I at position 452, numbered according to SEQ ID NO: 138 or 982. 342. The AAV particle of any one of embodiments 331-341, wherein the AAV capsid variant further comprises the substitutions T450A, I451E, and N452I, numbered according to SEQ ID NO: 138 or 982. 343. The AAV particle of any one of embodiments 331-342, wherein the AAV capsid variant comprises: (i) A at position 450, E at position 451, and I at position 452, numbered according to SEQ ID NO: 138 or 982; and (i) the amino acid sequence of HDSPHK (SEQ ID NO: 2), which is present immediately subsequent to positions 453, numbered according to SEQ ID NO: 138 or 982. 344. The AAV particle of any one of embodiments 1-22, 25-27, 31, 34-42, 45-50, 51-63, 69, 79, 83-86, 94-98, 102, 103, 110, 111, 118-129, 262-267, 275, 276, 281, 284, 286, or 303-307, wherein the AAV capsid variant comprises the amino acid sequence of SPHKYG (SEQ ID NO: 966), wherein the amino acid sequence is present immediately subsequent to position 455, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 345. An AAV particle (e.g., isolated AAV particle) comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the amino acid sequence is present immediately subsequent to position 453, numbered according to the amino acid sequence of SEQ ID NO: 982. 346. An AAV particle (e.g., isolated AAV particle) comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence isVTJ-4010PC present immediately subsequent to position 455, numbered according to the amino acid sequence of SEQ ID NO: 981. 347. An AAV particle (e.g., isolated AAV particle) comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the amino acid sequence is present immediately subsequent to position 453, numbered according to the amino acid sequence of SEQ ID NO: 37, and optionaly further comprising: (i) one, two, or al of an amino acid other than T at position 450, an amino acid other than I at position 541, and / or an amino acid other than N at position 452, numbered according to SEQ ID NO: 138 or 37; (i) one, two, or al of A at position 450, E at position 451, and / or I at position 452, numbered according to SEQ ID NO: 138 or 37. 348. An AAV particle (e.g., isolated AAV particle) comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to the amino acid sequence of any one of SEQ ID NO: 4500, 36, 38-55, 57, or 59. 349. The AAV particle of embodiment 348, which comprises: (a) the amino acid E at position 451, (b) the amino acid V at position 453, (c) the amino acid E at position 451 and the amino acid V at position 453, (d) the amino acid R at amino acid 452; and / or (e) the amino acid E at position 451, the amino acid R at position 452, and the amino acid V at position 453, wherein the amino acids are numbered according to SEQ ID NO: 4500, 981, or 138. 350. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant further comprises:VTJ-4010PC (i) a modification, e.g., an insertion, substitution (e.g., conservative substitution), and / or deletion, in loop I, I, VI and / or VII; and / or (i) a substitution at position K449, e.g., a K449R substitution, numbered according to SEQ ID NO: 138. 351. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises: (i) an amino acid sequence comprising at least one, two or three modifications, e.g., substitutions (e.g., conservative substitutions), but not more than 30, 20 or 10 modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of SEQ ID NO: 138; or (i) an amino acid sequence comprising at least one, two or three, but no more than 30, 20 or 10 diferent amino acids relative to the amino acid sequence of SEQ ID NO: 138. 352. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 138, or an amino acid sequence with at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 353. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 137, or a sequence with at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 354. The AAV particle of any one of the preceding embodiments, wherein the nucleotide sequence encoding the AAV capsid variant comprises the nucleotide sequence of SEQ ID NO: 137, or a sequence with at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 355. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises a VP1 protein, a VP2 protein, a VP3 protein, or a combination thereof. 356. The AAV particle of any one of embodiments 1-355, wherein the AAV capsid variant comprises the amino acid sequence coresponding to positions 138-742, e.g., a VP2, of SEQ ID NO: 981, 982, 4500-4507,VTJ-4010PC or 36-59, or a sequence with at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 357. The AAV particle of any one of embodiments 1-355, wherein the AAV capsid variant comprises the amino acid sequence coresponding to positions 203-742, e.g., a VP3, of SEQ ID NO: 981, 982, 4500-4507, or 36-59, or a sequence with at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 358. The AAV particle of any one of embodiments 1-355, wherein the AAV capsid variant comprises the amino acid sequence coresponding to positions 138-736, e.g., a VP2, of SEQ ID NO: 138, or a sequence with at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 359. The AAV particle of any one of embodiments 1-355, wherein the AAV capsid variant comprises the amino acid sequence coresponding to positions 203-736, e.g., a VP3, of SEQ ID NO: 138, or a sequence with at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 360. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-71, 79-89, 94-99, 102- 104, 106-112, 115-164, 203-209, 212, 216-224, 234-243, 248-250, 253-270, 276, 277, 281, 282, 286-288, 299, 301, 303-309, or 349, wherein the AAV capsid variant comprises an amino acid sequence comprising at least 3, 4, 5, or 6 consecutive amino acids from the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein: (i) the 3 consecutive amino acids comprise SPH; (i) the 4 consecutive amino acids comprise SPHS (SEQ ID NO: 1673); (ii) the 5 consecutive amino acids comprise SPHSK (SEQ ID NO: 1674); or (iv) the 6 consecutive amino acids comprise SPHSKA (SEQ ID NO: 941); wherein the AAV capsid variant comprises: (a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 138 or SEQ ID NO: 981; (b) a VP2 protein comprising the amino acid sequence of positions 138-736 of SEQ ID NO: 138 or positions 138-742 of SEQ ID NO: 981; (c) a VP3 protein comprising the amino acid sequence of positions 203-736 of SEQ ID NO: 138 or positions 203-742 of SEQ ID NO: 981; or (d) an amino acid sequence with at least 90% (e.g., at least about 95, 96, 97, 98, or 99%) sequence identity to any of the amino acid sequences in (a)-(c).VTJ-4010PC 361. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-71, 79-89, 94-99, 102- 104, 106-112, 115-164, 203-209, 212, 216-224, 234-243, 248-250, 253-270, 276, 277, 281, 282, 286-288, 299, 301, 303-309, 349, or 360, wherein the AAV capsid variant comprises an amino acid sequence comprising at least 3, 4, 5, or 6 consecutive amino acids from the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein: (i) the 3 consecutive amino acids comprise SPH; (i) the 4 consecutive amino acids comprise SPHS (SEQ ID NO: 1673); (ii) the 5 consecutive amino acids comprise SPHSK (SEQ ID NO: 1674); or (iv) the 6 consecutive amino acids comprise SPHSKA (SEQ ID NO: 941); wherein the AAV capsid variant comprises an amino acid sequence at least 90% (e.g., at least about 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 981. 362. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-71, 79-89, 94-99, 102- 104, 106-112, 115-164, 203-209, 212, 216-224, 234-243, 248-250, 253-270, 276, 277, 281, 282, 286-288, 299, 301, 303-309, 349, 360, or 361, wherein the AAV capsid variant comprises one or two, but no more than three substitutions relative to the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the AAV capsid variant comprises: (a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 138 or SEQ ID NO: 981; (b) a VP2 protein comprising the amino acid sequence of positions 138-736 of SEQ ID NO: 138 or positions 138-742 of SEQ ID NO: 981; (c) a VP3 protein comprising the amino acid sequence of positions 203-736 of SEQ ID NO: 138 or positions 203-742 of SEQ ID NO: 981; or (d) an amino acid sequence with at least 90% (e.g., at least about 95, 96, 97, 98, or 99%) sequence identity to any of the amino acid sequences in (a)-(c). 363. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-71, 79-89, 94-99, 102- 104, 106-112, 115-164, 203-209, 212, 216-224, 234-243, 248-250, 253-270, 276, 277, 281, 282, 286-288, 299, 301, 303-309, 349, or 360-362, wherein the AAV capsid variant comprises one or two, but no more than three substitutions relative to the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the AAV capsid variant comprises an amino acid sequence at least 90% (e.g., at least about 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 138 or SEQ ID NO: 981.VTJ-4010PC 364. The AAV particle of any one of embodiments 360-363, wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to SEQ ID NO: 138 or 981. 365. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-78, 83-88, 90-98, 100-103, 105-111, 113-129, 165-211, 213-222, 226-242, 245-249, 251-266, 271-274, 276, 278, 280, 281, 283, 285, 286, 289, 290, 300, 302-307, 331-339, or 349, wherein the AAV capsid variant comprises an amino acid sequence comprising at least 3, 4, 5, or 6 consecutive amino acids from the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein: (i) the 3 consecutive amino acids comprise HDS; (i) the 4 consecutive amino acids comprise HDSP (SEQ ID NO: 1675); (ii) the 5 consecutive amino acids comprise HDSPH (SEQ ID NO: 1676); or (iv) the 6 consecutive amino acids comprise HDSPHK (SEQ ID NO: 2); wherein the AAV capsid variant comprises: (a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 138 or SEQ ID NO: 982; (b) a VP2 protein comprising the amino acid sequence of positions 138-736 of SEQ ID NO: 138 or positions 138-742 of SEQ ID NO: 982; (c) a VP3 protein comprising the amino acid sequence of positions 203-736 of SEQ ID NO: 138 or positions 203-742 of SEQ ID NO: 982; or (d) an amino acid sequence with at least 90% (e.g., at least about 95, 96, 97, 98, or 99%) sequence identity to any of the amino acid sequences in (a)-(c). 366. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-78, 83-88, 90-98, 100-103, 105-111, 113-129, 165-211, 213-222, 226-242, 245-249, 251-266, 271-274, 276, 278, 280, 281, 283, 285, 286, 289, 290, 300, 302-307, 331-339, 349, or 365, wherein the AAV capsid variant comprises an amino acid sequence comprising at least 3, 4, 5, or 6 consecutive amino acids from the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein: (i) the 3 consecutive amino acids comprise HDS; (i) the 4 consecutive amino acids comprise HDSP (SEQ ID NO: 1675); (ii) the 5 consecutive amino acids comprise HDSPH (SEQ ID NO: 1676); or (iv) the 6 consecutive amino acids comprise HDSPHK (SEQ ID NO: 2); wherein the AAV capsid variant comprises an amino acid sequence at least 90% (e.g., at least about 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 982.VTJ-4010PC 367. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-78, 83-88, 90-98, 100-103, 105-111, 113-129, 165-211, 213-222, 226-242, 245-249, 251-266, 271-274, 276, 278, 280, 281, 283, 285, 286, 289, 290, 300, 302-307, 331-339, 349, 365, or 366, wherein the AAV capsid variant comprises one or two, but no more than three substitutions relative to the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the AAV capsid variant comprises: (a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 138 or SEQ ID NO: 982; (b) a VP2 protein comprising the amino acid sequence of positions 138-736 of SEQ ID NO: 138 or positions 138-742 of SEQ ID NO: 982; (c) a VP3 protein comprising the amino acid sequence of positions 203-736 of SEQ ID NO: 138 or positions 203-742 of SEQ ID NO: 982; or (d) an amino acid sequence with at least 90% (e.g., at least about 95, 96, 97, 98, or 99%) sequence identity to any of the amino acid sequences in (a)-(c). 368. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-78, 83-88, 90-98, 100-103, 105-111, 113-129, 165-211, 213-222, 226-242, 245-249, 251-266, 271-274, 276, 278, 280, 281, 283, 285, 286, 289, 290, 300, 302-307, 331-339, 349, 365-367, wherein the AAV capsid variant comprises one or two, but no more than three substitutions relative to the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the AAV capsid variant comprises an amino acid sequence at least 90% (e.g., at least about 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 982. 369. The AAV particle of any one of embodiments 365-368, wherein the amino acid sequence is present immediately subsequent to position 453, numbered according to SEQ ID NO: 138 or 982. 370. The AAV particle of any one of embodiments 1-368, wherein the AAV capsid variant comprises the amino acid sequence of any one of SEQ ID NO: 981 or 982, or an amino acid sequence with at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 371. The AAV particle of any one of embodiments 1-370, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two or three modifications, e.g., substitutions (e.g., conservative substitutions), but not more than 30, 20 or 10 modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of SEQ ID NO: 981 or 982.VTJ-4010PC 372. The AAV particle of any one of embodiments, 1-371, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 different amino acids, relative to the amino acid sequence of SEQ ID NO: 981 or 982. 373. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-71, 79-89, 94-99, 102- 104, 106-112, 115-164, 203-209, 212, 216-224, 234-243, 248-250, 253-270, 276, 277, 281, 282, 286-288, 299, 301, 303-309, 349, 360-363, or 370-372, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 981, or an amino acid sequence with at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 374. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-71, 79-89, 94-99, 102- 104, 106-112, 115-164, 203-209, 212, 216-224, 234-243, 248-250, 253-270, 276, 277, 281, 282, 286-288, 299, 301, 303-309, 349, 360-363, or 370-372, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two or three modifications, e.g., substitutions (e.g., conservative substitutions), but not more than 30, 20 or 10 modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of SEQ ID NO: 981. 375. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-71, 79-89, 94-99, 102- 104, 106-112, 115-164, 203-209, 212, 216-224, 234-243, 248-250, 253-270, 276, 277, 281, 282, 286-288, 299, 301, 303-309, 349, 360-363, or 370-374, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 diferent amino acids, relative to the amino acid sequence of SEQ ID NO: 981. 376. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-78, 83-88, 90-98, 100-103, 105-111, 113-129, 165-211, 213-222, 226-242, 245-249, 251-266, 271-274, 276, 278, 280, 281, 283, 285, 286, 289, 290, 300, 302-307, 331-339, 349, or 365-372, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 982, or an amino acid sequence with at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 377. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-78, 83-88, 90-98, 100-103, 105-111, 113-129, 165-211, 213-222, 226-242, 245-249, 251-266, 271-274, 276, 278, 280, 281, 283, 285, 286, 289, 290, 300, 302-307, 331-339, 349, 365-372, or 376, wherein theVTJ-4010PC AAV capsid variant comprises an amino acid sequence comprising at least one, two or three modifications, e.g., substitutions (e.g., conservative substitutions), but not more than 30, 20 or 10 modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of SEQ ID NO: 982. 378. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-78, 83-88, 90-98, 100-103, 105-111, 113-129, 165-211, 213-222, 226-242, 245-249, 251-266, 271-274, 276, 278, 280, 281, 283, 285, 286, 289, 290, 300, 302-307, 331-339, 349, 365-372, 376, or 377, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 diferent amino acids, relative to the amino acid sequence of SEQ ID NO: 982. 379. The AAV particle of any one of embodiments 1-378, wherein the AAV capsid variant comprises an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 983 or 984, or a nucleotide sequence with at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 380. The AAV particle of any one of the preceding embodiments 1-379, wherein the nucleotide sequence encoding the AAV capsid variant comprises the nucleotide sequence of SEQ ID NOs: 983 or 984, or a nucleotide sequence with at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 381. The AAV particle of any one of the preceding embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-71, 79- 89, 94-99, 102-104, 106-112, 115-164, 203-209, 212, 216-224, 234-243, 248-250, 253-270, 276, 277, 281, 282, 286-288, 299, 301, 303-309, 349, 360-363, 370-375, 379, or 380, wherein the nucleotide sequence encoding the AAV capsid variant comprises the nucleotide sequence of SEQ ID NO: 983, or a nucleotide sequence with at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 382. The AAV particle of any one of the preceding embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-78, 83-88, 90-98, 100-103, 105-111, 113-129, 165-211, 213-222, 226-242, 245-249, 251- 266, 271-274, 276, 278, 280, 281, 283, 285, 286, 289, 290, 300, 302-307, 331-339, 349, 365-372, 376, or 377-380, wherein the nucleotide sequence encoding the AAV capsid variant comprises the nucleotide sequence of SEQ ID NO: 984, or a nucleotide sequence with at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto.VTJ-4010PC 383. The AAV particle of any one of the preceding embodiments, wherein the nucleotide sequence encoding the AAV capsid variant is codon optimized. 384. An AAV particle (e.g., isolated AAV particle) comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein AAV capsid variant comprising the amino acid sequence of SEQ ID NO: 981. 385. The AAV particle of embodiment 384, wherein the nucleotide sequence encoding the AAV capsid variant comprises the nucleotide sequence of SEQ ID NO: 983, or a nucleotide sequence at least 90%, 95%, or 99% identical thereto. 386. An AAV particle (e.g., isolated AAV particle) comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein AAV capsid variant comprising the amino acid sequence of SEQ ID NO: 982. 387. The AAV particle of embodiment 386, wherein the nucleotide sequence encoding the AAV capsid variant comprises the nucleotide sequence of SEQ ID NO: 984, or a nucleotide sequence at least 90%, 95%, or 99% identical thereto. 388. An AAV particle (e.g., isolated AAV particle) comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of any one of SEQ ID NOs: 36-59 or 4500-4507. 389. An AAV particle (e.g., isolated AAV particle) comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), comprising an amino acid sequence encoded by the nucleotide sequence of any one of SEQ ID NOs: 77, 79, 81, 82, 83, 84, 85, 86, 87, 88, or 22-35, or a nucleotide sequence at least 95% identical thereto. 390. The AAV particle of embodiment 388 or 389, wherein the nucleotide sequence encoding the AAV capsid variant comprises the nucleotide sequence of any one of SEQ ID NOs: 77, 79, 81, 82, 83, 84, 85, 86, 87, 88, or 22-35, or a nucleotide sequence at least 95% identical thereto.VTJ-4010PC 391. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant has an increased tropism for a CNS cel or tissue, e.g., a brain cel, brain tissue, spinal cord cel, or spinal cord tissue, relative to the tropism of a reference sequence comprising the amino acid sequence of SEQ ID NO: 138. 392. The AAV particle of any one of embodiments 1-391, wherein the AAV capsid variant transduces a brain region, e.g., a midbrain region (e.g., the hippocampus, or thalamus) or the brain stem, optionaly wherein the level of transduction is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, or 65-fold greater as compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay, e.g., an immunohistochemistry assay or a qPCR assay, e.g., as described in Example 2. 393. The AAV particle of any one of embodiments 1-392, wherein the AAV capsid variant transduces a brain region, e.g., a midbrain region (e.g., the hippocampus, or thalamus) or the brain stem, optionaly wherein the level of transduction is at least 30, 35, 40, 45, 50, 55, 60, or 65-fold greater as compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay, e.g., an immunohistochemistry assay or a qPCR assay, e.g., as described in Example 2. 394. The AAV particle of any one of embodiments 1-393, wherein the AAV capsid variant is enriched at least about 3, 4, 5, 6, 7, 8, 9, or 10-fold, in the brain compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1. 395. The AAV particle of any one of embodiments 1-394, wherein the AAV capsid variant is enriched at least about 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80 or 85-fold, in the brain compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1. 396. The AAV particle of any one of embodiments 1-395, wherein the AAV capsid variant is enriched in the brain of at least two to three species, e.g., a non-human primate and rodent (e.g., mouse), e.g., as compared to a reference sequence of SEQ ID NO: 138. 397. The AAV particle of any one of embodiments 1-396, wherein the AAV capsid variant is enriched at least about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 190, 200, 205, or 210-fold, in the brain of at leastVTJ-4010PC two to three species, e.g., a non-human primate and rodent (e.g., mouse), compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1 or 4. 398. The AAV particle of embodiment 396 or 397, wherein the at least two to three species are Macaca fascicularis, Chlorocebus sabaeus, Calithrix jacchus, and / or mouse (e.g., BALB / c mice, C57Bl / 6 mice, and / or CD-1 outbred mice). 399. The AAV particle of any one of embodiments 1-398, wherein the AAV capsid variant delivers an increased level of a payload to a brain region, optionaly wherein the level of the payload is increased by at least 10, 12, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, or 70-fold, as compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay, e.g., a qRT-PCR or a qPCR assay (e.g., as described in Example 2 or 6). 400. The AAV particle of any one of embodiments 1-399, wherein the AAV capsid variant delivers an increased level of viral genomes to a brain region, optionaly wherein the level of viral genomes is increased by at least 5, 10, 15, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50-fold, as compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay, e.g., a qRT-PCR or a qPCR assay (e.g., as described in Example 2 or 6). 401. The AAV particle of embodiment 399 or 400, wherein the brain region is a midbrain region (e.g., the hippocampus or thalamus), frontal cortex, temporal cortex, motor cortex, cerebral cortex, caudate, putamen, dentate nucleus, substantia nigra, or the brainstem. 402. The AAV particle of any one of embodiments 1-401, wherein the AAV capsid variant is enriched at least about 5, 10, 15, 20, 25, 30, or 35-fold, in the spinal cord compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1 or 6, optionaly wherein the region of the spinal cord is a thoracic spinal cord region, cervical spinal cord region, C5 ventral horn region, lumbar spinal cord region, or L5 ventral horn region. 403. The AAV particle of any one of embodiments 1-402, wherein the AAV capsid variant shows preferential transduction in a brain region relative to the transduction in the dorsal root ganglia (DRG).VTJ-4010PC 404. The AAV particle of any one of embodiments 1-403, wherein the AAV capsid variant shows preferential transduction in a brain region relative to the liver. 405. The AAV particle of any one of embodiments 1-404, wherein the AAV capsid variant shows preferential transduction in a brain region relative to the transduction in the heart. 406. The AAV particle of any one of embodiments 1-405, wherein the AAV capsid variant shows preferential transduction in a brain region relative to the transduction in the dorsal root ganglia (DRG) and the heart. 407. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant is capable of transducing non-neuronal cels, e.g., glial cels (e.g., oligodendrocytes or astrocytes). 408. The AAV particle of embodiment 407, wherein the non-neuronal cels comprise glial cels, oligodendrocytes (e.g., Olig2 positive oligodendrocytes), or astrocytes (e.g., Olig2 positive astrocytes), optionaly wherein the AAV capsid variant is capable of transducing Olig2 positive cels, e.g., Olig2 positive astrocytes or Olig2 positive oligodendrocytes. 409. The AAV particle of any one of the preceding embodiments, wherein the antibody molecule binds to the N-terminal region or an epitope within the N-terminal region of a tau protein (e.g., human tau). 410. The AAV particle of embodiment 409, wherein the antibody molecule binds to al or a portion of (e.g., one or more residues within) amino acid residues (a) 9-18, (b) 15-25, (c) 25-30, and / or (d) 15-30 of a tau protein, numbered according to SEQ ID NO: 9200. 411. The AAV particle of any one of embodiments 1-408, wherein the antibody molecule binds to the mid-domain region or an epitope within the mid-domain region of a tau protein (e.g., human tau). 412. The AAV particle of embodiment 411, wherein the antibody molecule binds to al or a portion of (e.g., one or more residues within) amino acid residues (a) 125-131, (b) 204-222, (c) 234-246, (d) 234- 259, and / or (e) 235-246, numbered according to SEQ ID NO: 9200.VTJ-4010PC 413. The AAV particle of embodiment 412, wherein the antibody molecule binds to an epitope which includes one or more of pS422, pT181, pS199, pS202, pT205, pT212, pS214, pT217, pT231, pS234, pS235, pS258, pS259, pS396, pS404, and pS409, numbered according to SEQ ID NO: 9200. 414. The AAV particle of embodiment 413, wherein the antibody molecule binds to an epitope which includes (a) pS202 and pT205, (b) pT212 and pS214, (c) pT212 and pT217, (c) pT217 and pT231, (d) pT231 and pT234 (or pT235), (e) pS234 and pS259 (or pS258), and (f) pS396 and pS404, numbered according to SEQ ID NO: 9200. 415. The AAV particle of any one of embodiments 1-408, wherein the antibody molecule binds to the C- terminal region or an epitope within the C-terminal region of a tau protein (e.g., human tau). 416. The AAV particle of embodiment 415, wherein the antibody molecule binds to al or a portion of (e.g., one or more residues within) amino acid residues (a) 387-408 and / or (b) 409-436, numbered according to SEQ ID NO: 9200. 417. The AAV particle of embodiment 415, wherein the antibody molecule binds to an epitope which includes pS409, numbered according to SEQ ID NO: 9200. 418. The AAV particle of embodiment 415, wherein the antibody molecule binds to an epitope which includes pS422, numbered according to SEQ ID NO: 9200. 419. The AAV particle of any one of embodiments 1-408, wherein the antibody molecule binds to the microtubule-binding domain or an epitope within the microtubule-binding domain of a tau protein (e.g., human tau). 420. The AAV particle of any one of embodiments 1-408, wherein the antibody molecule binds to the proline rich domain or an epitope within the proline rich domain of a tau protein (e.g., human tau). 421. The AAV particle of any one of embodiments 1-408, wherein the antibody molecule binds to a region that overlaps with the N-terminal domain and the mid-domain of a tau protein (e.g., human tau).VTJ-4010PC 422. The AAV particle of any one of embodiments 1-408, wherein the antibody molecule binds to a region that overlaps with the mid-domain and the microtubule-binding domain of a tau protein (e.g., human tau). 423. The AAV particle of any one of embodiments 1-408, wherein the antibody molecule binds to a region that overlaps with the mid-domain and the C-terminal domain of a tau protein (e.g., human tau). 424. The AAV particle of any one of embodiments 1-408, wherein the antibody molecule binds to al or a portion of (e.g., one or more residues within) amino acid residues (a) 32-49, (b) 55-76, (c) 57-72, (d) 159-194, (e) 175-191, (f) 185-200, (g) 219-247, (h) 223-238, (i) 381-426, (j) 383-400, (k) 409-436, and / or (l) 413-430, numbered according to SEQ ID NO: 9200. 425. The AAV particle of embodiment 424, wherein the antibody molecule binds to al or a portion of (e.g., one or more residues within) amino acid residues (a) 55-76, (b) 159-194, (c) 219-247, and / or (d) 381-426, numbered according to SEQ ID NO: 9200. 426. The AAV particle of embodiment 424, wherein the antibody molecule binds to al or a portion of (e.g., one or more residues within) amino acid residues (a) 57-72, (b) 175-191, (c) 223-238, and / or (d) 383-400, numbered according to SEQ ID NO: 9200. 427. The AAV particle of embodiment 424 and 426, wherein the antibody molecule binds to al or a portion of (e.g., one or more residues within) amino acid residues 223-238, numbered according to SEQ ID NO: 9200. 428. The AAV particle of embodiment 427, wherein the antibody molecule binds a conformational epitope which includes al or a portion of (e.g., one or more residues within) amino acid residues (a) 55- 76, (b) 159-194, (c) 219-247, and / or (d) 381-426, numbered according to SEQ ID NO: 9200. 429. The AAV particle of any one of embodiments 1-428, wherein the antibody molecule comprises: (i) a heavy chain variable region comprising the HCDR1, HCDR2, and HCDR3 sequences of any one of the anti-tau antibody molecules described herein (e.g., an antibody molecule listed in Tables 9-19); and / orVTJ-4010PC (i) a light chain variable region comprising the LCDR1, LCDR2, and LCDR3 sequences of any one of the anti-tau antibody molecules described herein (e.g., an antibody molecule listed in Tables 9-19). 430. The AAV particle of any one of embodiments 1-429, wherein the antibody molecule comprises a heavy chain variable region comprising HCDR1, HCDR2, and HCDR3, and a light chain variable region comprising LCDR1, LCDR2, and LCDR3, of any one of the anti-tau antibody molecules described herein (e.g., an antibody molecule listed in Tables 9-19); optionaly wherein at least one, two, three, four, five or al of the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and / or LCDR3 comprises at most one, two, or three substitutions (e.g., conservative amino acid substitutions) in a CDR relative to the CDR sequences of any one of the anti-tau antibody molecules described herein (e.g., an antibody molecule listed in Tables 9-19). 431. The AAV particle of any one of embodiments 1-430, wherein the antibody molecule comprises: (i) a heavy chain variable region (VH) comprising the amino acid sequence of the VH of any one of the anti-tau antibody molecules described herein (e.g., the VH sequence of an antibody molecule listed in Tables 9-19), or an amino acid sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to the VH sequence of any one of the anti-tau antibody molecules described herein (e.g., the VH sequence of an antibody molecule listed in Tables 9-19), or an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications, to the amino acid sequence of the VH of any of the anti-tau antibody molecules described herein (e.g., the VH sequence of an antibody molecule listed in Tables 9-19); and / or (i) a light chain variable region (VL) comprising the amino acid sequence of the VL of any one of the anti-tau antibody molecules described herein (e.g., the VL sequence of an antibody molecule listed in Tables 9-19), or an amino acid sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to the VL sequence of any one of the anti-tau antibody molecules described herein (e.g., the VL sequence of an antibody molecule listed in Tables 9-19), or an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications, to the amino acid sequence of the VL of any of the anti-tau antibody molecules described herein (e.g., the VL sequence of an antibody molecule listed in Tables 9-19).VTJ-4010PC 432. The AAV particle of any one of embodiments 1-431, wherein the antibody molecule comprises the VH region and the VL region of any one of the anti-tau antibody molecule described herein (e.g., the VH and VL region sequences of an antibody molecule listed in Tables 9-19). 433. The AAV particle of any one of embodiments 1-432, wherein the antibody molecule comprises the HCDR1, HCDR2, and / or HCDR3 sequences, and / or LCDR1, LCDR2, and / or LCDR3 sequences of Ab1, Ab2, Ab3, Ab4, Ab5, V0022, V0004, V0009, V0023, V0024, V0052, IPN002, AT8, PT3, UCB, PT76, PHF1, or C10.2. 434. The AAV particle of any one of embodiments 1-408, wherein the antibody moleculecomprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1555, 1556, 1557, 1568, RVS, and1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and1566, respectively; optionaly wherein, the antibody moleculeis a humanized antibody. 435. The AAV particle of any one of embodiments 1-408, wherein the antibody moleculecomprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1555, 1556, 1557, 1568, RVS, and1566, respectively; orVTJ-4010PC (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and1566, respectively; optionaly wherein: (i) the VH comprises an amino acid sequence comprising one, two, three, four, five, six, seven, eight, nine, or al of: an amino acid other than Q at position 5, P at position 7, T at position 9, L at position 11, V at position 12, N at position 19, L at position 20, K at position 67, A at position 68, and / or S at position 76, numbered according to SEQ ID NO: 1562; and / or (i) the VL comprises and amino acid sequence comprising one, two, or al of: an amino acid other than D at position 17, Q at position 18, and / or G at position 68, numbered according to SEQ ID NO: 1573. 436. The AAV particle of any one of embodiments 1-408, wherein the antibody moleculecomprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1555, 1556, 1557, 1568, RVS, and1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and1566, respectively; optionaly wherein: (i) the VH comprises an amino acid sequence comprising one, two, three, four, five, six, seven, eight, or al of: a V at position 5, an S at position 7, an A at position 9, a V at position 11, a K at position 12, a K at position 19, a V at position 20, an R at position 67, and / or a V at position 68, numbered according to SEQ ID NO: 1562; and / or (i) the VL comprises and amino acid sequence comprising one, two, or al of: Q or E at position 17, P or R at position 18, and / or S at position 68, numbered according to SEQ ID NO: 1573.VTJ-4010PC 437. The AAV particle of any one of embodiments 1-408, wherein the antibody moleculecomprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1555, 1556, 1557, 1568, RVS, and1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and1566, respectively; and optionaly wherein: (i) the VH comprises an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 67-71; and / or (i) the VL comprises an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 72-76. 438. The AAV particle of any one of embodiments 1-408 or 434-437, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively. 439. The AAV particle of any one of embodiments 1-408 or 434-438, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively. 440. The AAV particle of any one of embodiments 1-408 or 434-439, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1555, 1556, 1557, 1568, RVS, and 1566, respectively. 441. The AAV particleof any one of embodiments 1-408 or 434-440, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively.VTJ-4010PC 442. The AAV particle of any one of embodiments 1-408 or 434-441, wherein the VH comprises an amino acid sequence comprising one, two, three, four, five, six, seven, eight, nine, or al of: an amino acid other than Q at position 5, P at position 7, T at position 9, L at position 11, V at position 12, N at position 19, L at position 20, K at position 67, A at position 68, and / or S at position 76, numbered according to SEQ ID NO: 1562. 443. The AAV particle of any one of embodiments 1-408 or 434-442, wherein the VH comprises: (a) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or al of: an amino acid other than Q at position 5; an amino acid other than Q at position 6; an amino acid other than P at position 7; an amino acid other than T at position 9; an amino acid other than L at position 11; an amino acid other than V at position 12; an amino acid other than S at position 16; an amino acid other than N at position 19; an amino acid other than L at position 20; an amino acid other than I at position 48; an amino acid other than K at position 67; an amino acid other than A at position 68; an amino acid other than L at position 70; an amino acid other than S at position 76; an amino acid other than T at position 77; an amino acid other than V at position 79; an amino acid other than F at position 80; an amino acid other than I at position 81; an amino acid other than Q at position 82; an amino acid other than T at position 87; an amino acid other than S at position 91; and / or an amino acid other than S at position 113, numbered according to SEQ ID NO: 1562; (b) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or al of: an amino acid other than Q at position 5; an amino acid other than P at position 7; an amino acid other than T at position 9; an amino acid other than L at position 11; an amino acid other than V at position 12; an amino acid other than S at position 16; an amino acid other than N at position 19; an amino acid other than L at position 20; an amino acid other than K at position 38; an amino acid other than K at position 67; an amino acid other than A at position 68; an amino acid other than L at position 70; an amino acid other than S at position 76; an amino acid other than T at position 77; an amino acid other than V at position 79; an amino acid other than F at position 80; an amino acid other than I at position 81; an amino acid other than Q at position 82; an amino acid other than T at position 87; an amino acid other than E at position 89; and / or an amino acid other than S at position 113, numbered according to SEQ ID NO: 1562; (c) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or al of: an amino acid other than Q at position 5; an amino acid other than P at position 7; an amino acid other than T at position 9; an amino acid other than L at position 11; an amino acid other than V at position 12; an amino acidVTJ-4010PC other than P at position 14; an amino acid other than S at position 16; an amino acid other than N at position 19; an amino acid other than L at position 20; an amino acid other than K at position 38; an amino acid other than E at position 39; an amino acid other than R at position 40; an amino acid other than H at position 43; an amino acid other than K at position 67; an amino acid other than A at position 68; an amino acid other than T at position 71; an amino acid other than V at position 72; an amino acid other than H at position 73; an amino acid other than K at position 74; an amino acid other than S at position 76; an amino acid other than S at position 84; and / or an amino acid other than S at position 113, numbered according to SEQ ID NO: 1562; (d) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or al of: an amino acid other than Q at position 1; an amino acid other than Q at position 5; an amino acid other than P at position 7; an amino acid other than T at position 9; an amino acid other than L at position 11; an amino acid other than V at position 12; an amino acid other than N at position 19; an amino acid other than L at position 20; an amino acid other than K at position 67; an amino acid other than A at position 68; an amino acid other than L at position 70; an amino acid other than S at position 76; an amino acid other than V at position 79; an amino acid other than F at position 80; an amino acid other than I at position 81; an amino acid other than Q at position 82; an amino acid other than S at position 85; an amino acid other than E at position 89, an amino acid other than S at position 113; and / or an amino acid other than T at position 115, numbered according to SEQ ID NO: 1562; or (e) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or al of: an amino acid other than Q at position 5; an amino acid other than P at position 7; an amino acid other than T at position 9; an amino acid other than L at position 11; an amino acid other than V at position 12; an amino acid other than S at position 16; an amino acid other than N at position 19; an amino acid other than L at position 20; an amino acid other than H at position 43; an amino acid other than I at position 48; an amino acid other than K at position 67; an amino acid other than A at position 68; an amino acid other than L at position 70; an amino acid other than S at position 76; an amino acid other than T at position 77; an amino acid other than T at position 87; and / or an amino acid other than S at position 91, numbered according to SEQ ID NO: 1562. 444. The AAV particle of any one of embodiments 1-408 and 434-443, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or al of: an amino acid other than Q at position 5; an amino acid other than P at position 7; an amino acid other than T at position 9; an amino acid other than L at position 11; an amino acid other than V at position 12; an amino acid other than P atVTJ-4010PC position 14; an amino acid other than S at position 16; an amino acid other than N at position 19; an amino acid other than L at position 20; an amino acid other than K at position 38; an amino acid other than E at position 39; an amino acid other than R at position 40; an amino acid other than H at position 43; an amino acid other than K at position 67; an amino acid other than A at position 68; an amino acid other than T at position 71; an amino acid other than V at position 72; an amino acid other than H at position 73; an amino acid other than K at position 74; an amino acid other than S at position 76; an amino acid other than S at position 84; and / or an amino acid other than S at position 113, numbered according to SEQ ID NO: 1562. 445. The AAV particle of any one of embodiments 1-408 or 434-443, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or al of: an amino acid other than Q at position 5; an amino acid other than Q at position 6; an amino acid other than P at position 7; an amino acid other than T at position 9; an amino acid other than L at position 11; an amino acid other than V at position 12; an amino acid other than S at position 16; an amino acid other than N at position 19; an amino acid other than L at position 20; an amino acid other than I at position 48; an amino acid other than K at position 67; an amino acid other than A at position 68; an amino acid other than L at position 70; an amino acid other than S at position 76; an amino acid other than T at position 77; an amino acid other than V at position 79; an amino acid other than F at position 80; an amino acid other than I at position 81; an amino acid other than Q at position 82; an amino acid other than T at position 87; an amino acid other than S at position 91; and / or an amino acid other than S at position 113, numbered according to SEQ ID NO: 1562. 446. The AAV particle of any one of embodiments 1-408 or 434-443, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or al of: an amino acid other than Q at position 1; an amino acid other than Q at position 5; an amino acid other than P at position 7; an amino acid other than T at position 9; an amino acid other than L at position 11; an amino acid other than V at position 12; an amino acid other than N at position 19; an amino acid other than L at position 20; an amino acid other than K at position 67; an amino acid other than A at position 68; an amino acid other than L at position 70; an amino acid other than S at position 76; an amino acid other than V at position 79; an amino acid other than F at position 80; an amino acid other than I at position 81; an amino acid other than Q at position 82; an amino acid other than S at position 85; an amino acid other than E at position 89, anVTJ-4010PC amino acid other than S at position 113; and / or an amino acid other than T at position 115, numbered according to SEQ ID NO: 1562. 447. The AAV particle of any one of embodiments 1-408 or 434-443, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or al of: an amino acid other than Q at position 5; an amino acid other than P at position 7; an amino acid other than T at position 9; an amino acid other than L at position 11; an amino acid other than V at position 12; an amino acid other than S at position 16; an amino acid other than N at position 19; an amino acid other than L at position 20; an amino acid other than H at position 43; an amino acid other than I at position 48; an amino acid other than K at position 67; an amino acid other than A at position 68; an amino acid other than L at position 70; an amino acid other than S at position 76; an amino acid other than T at position 77; an amino acid other than T at position 87; and / or an amino acid other than S at position 91, numbered according to SEQ ID NO: 1562. 448. The AAV particle of any one of embodiments 1-408 or 434-447, wherein the VH comprises an amino acid sequence comprising one, two, three, four, five, six, seven, eight, or al of: a V at position 5, an S at position 7, an A at position 9, a V at position 11, a K at position 12, a K at position 19, a V at position 20, an R at position 67, and / or a V at position 68, numbered according to SEQ ID NO: 1562. 449. The AAV particle of any one of embodiments 1-408 or 434-448, wherein the VH comprises: (a) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or al of: V at position 5; E at position 6; S at position 7; A at position 9; V at position 11; K at position 12; A at position 16; K at position 19; V at position 20; M at position 48; R at position 67; V at position 68; I at position 70; A at position 76; S at position 77; A at position 79; Y at position 80; M at position 81; E at position 82; R at position 87; T at position 91; and / or T at position 113, numbered according to SEQ ID NO: 1562; (b) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or al of: V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; A at position 16; K at position 19; V at position 20; R at position 38; R at position 67; V at position 68; M at position 70; I at position 76; S at position 77; A at position 79; Y at position 80; M at position 81; E at position 82; R at position 87; D at position 89; and / or L at position 113, numbered according to SEQ ID NO: 1562; (c) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or al of: V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; S at position 14; A at position 16; K at position 19; V at position 20; R at position 38; Q at position 39; A at position 40; Q at position 43; R atVTJ-4010PC position 67; V at position 68; I at position 71; R at position 72; D at position 73; T at position 74; T at position 76; T at position 84; and / or L at position 113, numbered according to SEQ ID NO: 1562; (d) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or al of: E at position 1; V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; K at position 19; V at position 20; R at position 67; V at position 68; M at position 70; I at position 76; A at position 79; Y at position 80; M at position 81; E at position 82; R at position 85; D at position 89, L at position 113; and / or S at position 115, numbered according to SEQ ID NO: 1562; or (e) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or al of: V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; A at position 16; K at position 19; V at position 20; Q at position 43; M at position 48; R at position 67; V at position 68; M at position 70; T at position 76; S at position 77; R at position 87; and / or T at position 91, numbered according to SEQ ID NO: 1562. 450. The AAV particle of any one of embodiments 1-408, 434-444, 448, or 449434-443, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or al of: V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; S at position 14; A at position 16; K at position 19; V at position 20; R at position 38; Q at position 39; A at position 40; Q at position 43; R at position 67; V at position 68; I at position 71; R at position 72; D at position 73; T at position 74; T at position 76; T at position 84; and / or L at position 113, numbered according to SEQ ID NO: 1562. 451. The AAV particle of any one of embodiments 1-408, 434-443, 445, 448, or 449, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or al of: V at position 5; E at position 6; S at position 7; A at position 9; V at position 11; K at position 12; A at position 16; K at position 19; V at position 20; M at position 48; R at position 67; V at position 68; I at position 70; A at position 76; S at position 77; A at position 79; Y at position 80; M at position 81; E at position 82; R at position 87; T at position 91; and / or T at position 113, numbered according to SEQ ID NO: 1562. 452. The AAV particle of any one of embodiments 1-408, 434-443, 446, 448, or 449, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or al of: E at position 1; V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; K at position 19; V at position 20; R at position 67; V at position 68; M at position 70; I at position 76; A at position 79; Y at position 80; M at position 81; E at position 82; R at position 85; D at position 89, L at position 113; and / or S at position 115, numbered according to SEQ ID NO: 1562.VTJ-4010PC 453. The AAV particle of any one of embodiments 1-408, 434-443, or 447-449, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or al of: V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; A at position 16; K at position 19; V at position 20; Q at position 43; M at position 48; R at position 67; V at position 68; M at position 70; T at position 76; S at position 77; R at position 87; and / or T at position 91, numbered according to SEQ ID NO: 1562. 454. The AAV particle of any one of embodiments 1-408 or 434-453, wherein the VL comprises and amino acid sequence comprising one, two, or al of: an amino acid other than D at position 17, Q at position 18, and / or G at position 68, numbered according to SEQ ID NO: 1573. 455. The AAV particle of any one of embodiments 1-408 or 434-454, wherein the VL comprises: (a) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or al of: an amino acid other than T at position 7; an amino acid other than S at position 14; an amino acid other than D at position 17; an amino acid other than Q at position 18; an amino acid other than L at position 42; an amino acid other than K at position 44; an amino acid other than K at position 50; an amino acid other than G at position 68; an amino acid other than L at position 88; an amino acid other than F at position 92; and / or an amino acid other than G at position 105, numbered according to SEQ ID NO: 1573; (b) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or al of: an amino acid other than V at position 2; an amino acid other than T at position 7; an amino acid other than P at position 12; an amino acid other than S at position 14; an amino acid other than L at position 15; an amino acid other than D at position 17; an amino acid other than Q at position 18; an amino acid other than K at position 50; an amino acid other than G at position 68; an amino acid other than L at position 88; an amino acid other than F at position 92; an amino acid other than G at position 105; and / or an amino acid other than L at position 109, numbered according to SEQ ID NO: 1573; (c) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or al of: an amino acid other than V at position 2; an amino acid other than L at position 11; an amino acid other than T at position 14; an amino acid other than D at position 17; an amino acid other than Q at position 18; an amino acid other than L at position 42; an amino acid other than K at position 44; an amino acid other than S at position 48; an amino acid other than K at position 50; an amino acid other than G at position 68; an amino acid other than S at position 72; an amino acid other than S at position 81; an amino acid other than L at position 88; and / or an amino acid other than G at position 105, numbered according to SEQ ID NO: 1573;VTJ-4010PC (d) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or al of: an amino acid other than V at position 2; an amino acid other than V at position 3; an amino acid other than T at position 7; an amino acid other than S at position 14; an amino acid other than D at position 17; an amino acid other than Q at position 18; an amino acid other than L at position 42; an amino acid other than K at position 44; an amino acid other than K at position 50; an amino acid other than L at position 51; an amino acid other than G at position 68; and / or an amino acid other than L at position 88, numbered according to SEQ ID NO: 1573; or (e) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or al of: an amino acid other than D at position 1; an amino acid other than V at position 2; an amino acid other than M at position 4; an amino acid other than T at position 7; an amino acid other than L at position 9; an amino acid other than S at position 10; an amino acid other than P at position 12; an amino acid other than V at position 13; an amino acid other than L at position 15; an amino acid other than D at position 17; an amino acid other than Q at position 18; an amino acid other than S at position 20; an amino acid other than I at position 21; an amino acid other than S at position 48; an amino acid other than V at position 63; an amino acid other than G at position 68; an amino acid other than S at position 72; an amino acid other than K at position 79; an amino acid other than R at position 82; an amino acid other than V at position 83; an amino acid other than A at position 85; and / or an amino acid other than G at position 89, numbered according to SEQ ID NO: 1573. 456. The AAV particle of any one of embodiments 1-408 or 434-455, wherein the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or al of: an amino acid other than V at position 2; an amino acid other than T at position 7; an amino acid other than P at position 12; an amino acid other than S at position 14; an amino acid other than L at position 15; an amino acid other than D at position 17; an amino acid other than Q at position 18; an amino acid other than K at position 50; an amino acid other than G at position 68; an amino acid other than L at position 88; an amino acid other than F at position 92; an amino acid other than G at position 105; and / or an amino acid other than L at position 109, numbered according to SEQ ID NO: 1573. 457. The AAV particle of any one of embodiments 1-408 or 434-453, wherein the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or al of: an amino acid other than T at position 7; an amino acid other than S at position 14; an amino acid other than D at position 17; an amino acid other than Q at position 18; an amino acid other than L at position 42; an amino acid other than K at position 44; an amino acid other than K at position 50; an amino acid other than G at position 68; an amino acid other than L at positionVTJ-4010PC 88; an amino acid other than F at position 92; and / or an amino acid other than G at position 105, numbered according to SEQ ID NO: 1573. 458. The AAV particle of any one of embodiments 1-408 or 434-453, wherein the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or al of: an amino acid other than V at position 2; an amino acid other than L at position 11; an amino acid other than T at position 14; an amino acid other than D at position 17; an amino acid other than Q at position 18; an amino acid other than L at position 42; an amino acid other than K at position 44; an amino acid other than S at position 48; an amino acid other than K at position 50; an amino acid other than G at position 68; an amino acid other than S at position 72; an amino acid other than S at position 81; an amino acid other than L at position 88; and / or an amino acid other than G at position 105, numbered according to SEQ ID NO: 1573. 459. The AAV particle of any one of embodiments 1-408 or 434-458, wherein the VL comprises and amino acid sequence comprising one, two, or al of: Q or E at position 17, P or R at position 18, and / or S at position 68, numbered according to SEQ ID NO: 1573 460. The AAV particle of any one of embodiments 1-408 or 434-459, wherein the VL comprises: (a) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or al of: S at position 7; T at position 14; Q at position 17; P at position 18; Q at position 42; R at position 44; R at position 50; S at position 68; V at position 88; Y at position 92; and / or Q at position 105, numbered according to SEQ ID NO: 1573; (b) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or al of: I at position 2; S at position 7; S at position 12; T at position 14; P at position 15; Q at position 17; P at position 18; Q at position 50; S at position 68; V at position 88; Y at position 92; Q at position 105; and / or V at position 109, numbered according to SEQ ID NO: 1573; (c) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or al of: I at position 2; S at position 11; T at position 14; Q at position 17; P at position 18; Q at position 42; R at position 44; P at position 48; R at position 50; S at position 68; A at position 72; N at position 81; V at position 88; and / or Q at position 105, numbered according to SEQ ID NO: 1573; (d) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or al of: I at position 2; E at position 3; S at position 7; T at position 14; Q at position 17; P at position 18; Q at position 42; R at position 44; R at position 50; R at position 51; S at position 68; and / or V at position 88, numbered according to SEQ ID NO: 1573; orVTJ-4010PC (e) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or al of: E at position 1; I at position 2; L at position 4; S at position 7; A at position 9; T at position 10; S at position 12; L at position 13; P at position 15; E at position 17; R at position 18; T at position 20; L at position 21; A at position 48; I at position 63; S at position 68; P at position 72; T at position 79; S at position 82; L at position 83; P at position 85; and / or A at position 89, numbered according to SEQ ID NO: 1573. 461. The AAV particle of any one of embodiments 1-408, 434-456, 459, or 460, wherein the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or al of: I at position 2; S at position 7; S at position 12; T at position 14; P at position 15; Q at position 17; P at position 18; Q at position 50; S at position 68; V at position 88; Y at position 92; Q at position 105; and / or V at position 109, numbered according to SEQ ID NO: 1573. 462. The AAV particle of any one of embodiments 1-408, 434-455, 457, 459, or 460, wherein the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or al of: S at position 7; T at position 14; Q at position 17; P at position 18; Q at position 42; R at position 44; R at position 50; S at position 68; V at position 88; Y at position 92; and / or Q at position 105, numbered according to SEQ ID NO: 1573. 463. The AAV particle of any one of embodiments 1-408, 434-455, or 457-460, wherein the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or al of: I at position 2; S at position 11; T at position 14; Q at position 17; P at position 18; Q at position 42; R at position 44; P at position 48; R at position 50; S at position 68; A at position 72; N at position 81; V at position 88; and / or Q at position 105, numbered according to SEQ ID NO: 1573. 464. The AAV particle of any one of embodiments 1-408 or 434-463, wherein: (i) the VH comprises one, two, three, or four framework regions, e.g., one, two, three, or al of a FRH1, FRH2, FRH3, and / or FRH4; optionaly wherein the VH comprises from N-terminus to C- terminus, FRH1-CDRH1-FRH2-CDRH2-FRH3-CDRH3-FRH4; and / or (i) the VL comprises one, two, three, or four framework regions, e.g., one, two, three, or al of a FRL1, FRL2, FRL3, and / or FRL4; optionaly wherein the VL comprises from N terminus to C-terminus, FRL1-CDRL1-FRL2-CDRL2-FRL3-CDRL3-FRL4. 465. The AAV particle of embodiment 464, wherein:VTJ-4010PC (a) (i) the FRH1 coresponds to positions 1-25 of a heavy chain variable region, numbered according to any one of SEQ ID NOs: 1562 or 67-71; the FRH2 corresponds to positions 36-49, numbered according to any one of SEQ ID NOs: 1562 or 67-71; the FRH3 coresponds to positions 67-96, numbered according to any one of SEQ ID NOs: 1562B or 67A-71A; and / or the FRH4 corresponds to positions 108-118, numbered according to any one of SEQ ID NOs: 1562 or 67-71; or (i) the FRH1 corresponds to positions 1-30 of a heavy chain variable region, numbered according to any one of SEQ ID NOs: 1562 or 67-71; the FRH2 corresponds to positions 36-49, numbered according to any one of SEQ ID NOs: 1562 or 67-71; the FRH3 coresponds to positions 67-98, numbered according to any one of SEQ ID NOs: 1562 or 67-71; and / or the FRH4 corresponds to positions 108-118, numbered according to any one of SEQ ID NOs: 1562 or 67-71; and / or (b) the FRL1 coresponds to positions 1-23 of a light chain variable region, numbered according to any one of SEQ ID NOs: 72-76 or 1573B; the FRL2 corresponds to positions 40-54 of a light chain variable region, numbered according to any one of SEQ ID NOs: 72-76 or1573; the FRL3 corresponds to positions 62-93 of a light chain variable region, numbered according to any one of SEQ ID NOs: 72-76 or1573; and / or the FRL4 corresponds to positions 103-112, numbered according to any one of SEQ ID NOs: 72-76 or1573. 466. The AAV particle of any one of embodiments 408 or 434-465, wherein (a) the VH comprises one, two, three, or al of: (i) a FRH1 comprising amino acids 1-25 or 1-30 of any one of SEQ ID NOs: 67- 71 (optionaly any one of SEQ ID NOs: 67 or 69-71); an amino acid sequence comprising one, two, three but no more than four modifications (e.g., substitutions, e.g., conservative substitutions) relative to amino acids 1-25 or 1-30 of any one of SEQ ID NOs: 67-71 (optionaly any one of SEQ ID NOs: 67 or 69-71); or an amino acid sequence comprising one, two, three, but no more than four different amino acids relative to amino acids 1-25 or 1-30 of any one of SEQ ID NOs: 67-71 (optionaly any one of SEQ ID NOs: 67 or 69-71); (i) a FRH2 comprising amino acids 36-49 of any one of SEQ ID NOs: 67- 71 (optionaly any one of SEQ ID NOs: 67 or 69-71); an amino acid sequence comprising one, two, three but no more than four modifications (e.g., substitutions, e.g., conservative substitutions) relative to amino acids 36-49 of any one of SEQ ID NOs: 67-71 (optionaly any one of SEQ ID NOs: 67 or 69-71); or an amino acid sequence comprising one, two, three, but no more than four diferentVTJ-4010PC amino acids relative to amino acids 36-49 of any one of SEQ ID NOs: 67A-71A (optionaly any one of SEQ ID NOs: 67 or 69-71); (ii) a FRH3 comprising amino acids 67-96 or 67-98 of any one of SEQ ID NOs: 67-71 (optionaly any one of SEQ ID NOs: 67 or 69-71); an amino acid sequence comprising one, two, three but no more than four modifications (e.g., substitutions, e.g., conservative substitutions) relative to amino acids 67-96 or 67-98 of any one of SEQ ID NOs: 67-71 (optionaly any one of SEQ ID NOs: 67 or 69-71); or an amino acid sequence comprising one, two, three, but no more than four different amino acids relative to amino acids 67-96 or 67-98 of any one of SEQ ID NOs: 67-71 (optionaly any one of SEQ ID NOs: 67 or 69-71); and / or (iv) a FRH4 comprising amino acids 108-118 of any one of SEQ ID NOs: 67-71 (optionaly any one of SEQ ID NOs: 67 or 69-71); an amino acid sequence comprising one, two, three but no more than four modifications (e.g., substitutions, e.g., conservative substitutions) relative to amino acids 108-118 of any one of SEQ ID NOs: 67-71 (optionaly any one of SEQ ID NOs: 67 or 69-71); or an amino acid sequence comprising one, two, three, but no more than four diferent amino acids relative to amino acids 108-118 of any one of SEQ ID NOs: 67-71 (optionaly any one of SEQ ID NOs: 67 or 69-71); and / or (b) the VL comprises one, two, three or al of: (i) a FRL1 comprising amino acids 1-23 of any one of SEQ ID NOs: 72-76 (optionaly any one of SEQ ID NOs: 72-74); an amino acid sequence comprising one, two, three but no more than four modifications (e.g., substitutions, e.g., conservative substitutions) relative to amino acids 1-23 of any one of SEQ ID NOs: 72-76 (optionaly any one of SEQ ID NOs: 72-74); or an amino acid sequence comprising one, two, three but no more than four different amino acids relative to amino acids 1-23 of any one of SEQ ID NOs: 72-76 (optionaly any one of SEQ ID NOs: 72-74); (i) a FRL2 comprising amino acids 40-54 of any one of SEQ ID NOs: 72-76 (optionaly any one of SEQ ID NOs: 72-74); an amino acid sequence comprising one, two, three but no more than four modifications (e.g., substitutions, e.g., conservative substitutions) relative to amino acids 40-54 of any one of SEQ ID NOs: 72-76 (optionaly any one of SEQ ID NOs: 72-74); or an amino acid sequence comprising one, two, three but no more than four different amino acids relative to amino acids 40-54 of any one of SEQ ID NOs: 72-76 (optionaly any one of SEQ ID NOs: 72-74);VTJ-4010PC (ii) a FRL3 comprising amino acids 62-93 of any one of SEQ ID NOs: 72-76 (optionaly any one of SEQ ID NOs: 72-74); an amino acid sequence comprising one, two, three but no more than four modifications (e.g., substitutions, e.g., conservative substitutions) relative to amino acids 62-93 of any one of SEQ ID NOs: 72-76 (optionaly any one of SEQ ID NOs: 72-74); or an amino acid sequence comprising one, two, three but no more than four different amino acids relative to amino acids 62-93 of any one of SEQ ID NOs: 72-76 (optionaly any one of SEQ ID NOs: 72-74); and / or (iv) a FRL4 comprising amino acids 103-112 of any one of SEQ ID NOs: 72-76 (optionaly any one of SEQ ID NOs: 72-74); an amino acid sequence comprising one, two, three but no more than four modifications (e.g., substitutions, e.g., conservative substitutions) relative to amino acids 103-112 of any one of SEQ ID NOs: 72-76 (optionaly any one of SEQ ID NOs: 72-74); or an amino acid sequence comprising one, two, three but no more than four different amino acids relative to amino acids 103-112 of any one of SEQ ID NOs: 72-76 (optionaly any one of SEQ ID NOs: 72-74). 467. The AAV particle of any one of embodiments 1-408 or 434-466, wherein the: (i) the VH does not comprise one, two, three, or al of a FRH1 comprising amino acids 1-25 or 1- 30 of SEQ ID NO: 1562; a FRH2 comprising amino acids 36-49 of SEQ ID NO: 1562B; an FRH3 comprising amino acids 67-96 or 67-98 of SEQ ID NO: 1562; and / or a FRH4 comprising amino acids 108-118 of SEQ ID NO: 1562; and / or (i) the VL does not comprise one, two, three, or al of a FRL1 comprising amino acids 1-23 of SEQ ID NO: 1573; a FRL2 comprising amino acids 40-54 of SEQ ID NO: 1573; an FRL3 comprising amino acids 62-93 of SEQ ID NO: 1573B; and / or a FRL4 comprising amino acids 103-112 of SEQ ID NO: 1573. 468. The AAV particle of any one of embodiments 1-408 or 434-467, wherein VH comprises the amino acid sequence of any one of SEQ ID NOs: 67-71; or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 67-71. 469. The AAV particle of any one of embodiments 1-408 or 434-468, wherein the VH comprises an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 modifications,VTJ-4010PC e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of any one of SEQ ID NOs: 67-71. 470. The AAV particle of any one of embodiments 1-408 or 434-469, wherein the VH comprises an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NOs: 67-71. 471. The AAV particle of any one of embodiments 1-408, 434-444, 448-450, or 454-470, wherein VH comprises the amino acid sequence of SEQ ID NO: 69A; or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 69. 472. The AAV particle of any one of embodiments 1-408, 434-444, 448-450, or 454-471, wherein the VH comprises an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 69. 473. The AAV particle of any one of embodiments 1-408, 434-444, 448-450, or 454-472, wherein the VH comprises an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 diferent amino acids relative to the amino acid sequence of SEQ ID NO: 69. 474. The AAV particle of any one of embodiments 1-408, 434-443, 445, 448, 449, 451, or 454-470, wherein VH comprises: (i) the amino acid sequence of SEQ ID NO: 67A; or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 67; (i) an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 67; or (ii) an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 diferent amino acids relative to the amino acid sequence of SEQ ID NO: 67. 475. The AAV particle of any one of embodiments 1-408, 434-443, 446, 448, 449, 452, or 454-470, wherein VH comprises:VTJ-4010PC (i) the amino acid sequence of SEQ ID NO: 70; or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 70; (i) an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 70; or (ii) an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 diferent amino acids relative to the amino acid sequence of SEQ ID NO: 70. 476. The AAV particle of any one of embodiments 1-408, 434-443, 448, 449, or 453-470, wherein VH comprises: (i) the amino acid sequence of SEQ ID NO: 71; or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 71; (i) an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 71; or (ii) an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 diferent amino acids relative to the amino acid sequence of SEQ ID NO: 71. 477. The AAV particle of any one of embodiments 1-408 or 434-476, wherein VL comprises the amino acid sequence of any one of SEQ ID NOs: 72-76; or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 72-76. 478. The AAV particle of any one of embodiments 1-408 or 434-477, wherein the VL comprises an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of any one of SEQ ID NOs: 72-76. 479. The AAV particle of any one of embodiments 1-408 or 434-478, wherein the VL comprises an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 different amino acids relative to the amino acid sequence of any one of SEQ ID NOs: 72-76.VTJ-4010PC 480. The AAV particle of any one of embodiments 1-408, 434-456, 459-461, or 464-479, wherein VL comprises the amino acid sequence of SEQ ID NO: 73; or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 73. 481. The AAV particle of any one of embodiments 1-408, 434-456, 459-461, or 464-480, wherein the VL comprises an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO:73. 482. The AAV particle of any one of embodiments 1-408, 434-456, 459-461, or 464-481, wherein the VL comprises an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 diferent amino acids relative to the amino acid sequence of SEQ ID NO: 73. 483. The AAV particle of any one of embodiments 1-408, 434-455, 457, 459, 460, 462, or 464-479, wherein VL comprises: (i) the amino acid sequence of SEQ ID NO: 72; or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 72; (i) an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 72; (ii) an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 diferent amino acids relative to the amino acid sequence of SEQ ID NO: 72. 484. The AAV particle of any one of embodiments 1-408, 434-455, 457-460, or 463-479, wherein VL comprises: (i) the amino acid sequence of SEQ ID NO: 74; or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 74; (i) an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 74; (ii) an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 diferent amino acids relative to the amino acid sequence of SEQ ID NO: 74.VTJ-4010PC 485. The AAV particle of any one of embodiments 1-408 or 434-484, wherein: (a) the VH comprises the amino acid sequence of any one of SEQ ID NOs: 67-71, or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 67-71; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of any one of SEQ ID NOs: 67-71; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NOs: 67-71; and (b) the VL comprises the amino acid sequence of any one of SEQ ID NOs: 72-76; or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 72-76; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of any one of SEQ ID NOs: 72-76; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 diferent amino acids relative to the amino acid sequence of any one of SEQ ID NOs: 72-76. 486. The AAV particle of any one of embodiments 1-408 or 434-485, wherein: (a) the VH comprises the amino acid sequence of any one of SEQ ID NOs: 67 or 69-71, or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 67 or 69-71; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of any one of SEQ ID NOs: 67 or 69-71; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NOs: 67 or 69-71; and (b) the VL comprises the amino acid sequence of any one of SEQ ID NOs: 72-74; or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 72-74; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of any one of SEQ ID NOs: 72-74; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 diferent amino acids relative to the amino acid sequence of any one of SEQ ID NOs: 72-74.VTJ-4010PC 487. The AAV particle of any one of embodiments 1-408 or 434-486, wherein: (a) the VH comprises the amino acid sequence of any one of SEQ ID NOs: 67-71, or an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 67-71; and (b) the VL comprises the amino acid sequence of any one of SEQ ID NOs: 72-76; or an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 72-76. 488. The AAV particle of any one of embodiments 1-408 or 434-487, wherein: (a) the VH comprises the amino acid sequence of any one of SEQ ID NOs: 67 or 69-71, or an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 67 or 69-71; and (b) the VL comprises the amino acid sequence of any one of SEQ ID NOs: 72-74; or an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 72-74. 489. The AAV particle of any one of embodiments 1-408 or 434-488, wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 67, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 67; and the VL comprises the amino acid sequence of SEQ ID NO: 72, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 72; (i) the VH comprises the amino acid sequence of SEQ ID NO: 67, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 67; and the VL comprises the amino acid sequence of SEQ ID NO: 73, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 73; (ii) the VH comprises the amino acid sequence of SEQ ID NO: 67, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 67; and the VL comprises the amino acid sequence of SEQ ID NO: 74, or an amino acid sequenceVTJ-4010PC at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 74; (iv) the VH comprises the amino acid sequence of SEQ ID NO: 67, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 67; and the VL comprises the amino acid sequence of SEQ ID NO: 75, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 75; (v) the VH comprises the amino acid sequence of SEQ ID NO: 67, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 67; and the VL comprises the amino acid sequence of SEQ ID NO: 76, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 76; (vi) the VH comprises the amino acid sequence of SEQ ID NO: 68, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 68; and the VL comprises the amino acid sequence of SEQ ID NO: 72, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 72; (vi) the VH comprises the amino acid sequence of SEQ ID NO: 68, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 68; and the VL comprises the amino acid sequence of SEQ ID NO: 73, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 7; (vii) the VH comprises the amino acid sequence of SEQ ID NO: 68, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 68; and the VL comprises the amino acid sequence of SEQ ID NO: 74, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 74; (ix) the VH comprises the amino acid sequence of SEQ ID NO: 68, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 68; and the VL comprises the amino acid sequence of SEQ ID NO: 75, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 75;VTJ-4010PC (x) the VH comprises the amino acid sequence of SEQ ID NO: 68, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 68; and the VL comprises the amino acid sequence of SEQ ID NO: 76, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 76; (xi) the VH comprises the amino acid sequence of SEQ ID NO: 69, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 69; and the VL comprises the amino acid sequence of SEQ ID NO: 72, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 72; (xi) the VH comprises the amino acid sequence of SEQ ID NO: 69, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 69; and the VL comprises the amino acid sequence of SEQ ID NO: 73, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 73; (xii) the VH comprises the amino acid sequence of SEQ ID NO: 69, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 69; and the VL comprises the amino acid sequence of SEQ ID NO: 74, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 74; (xiv) the VH comprises the amino acid sequence of SEQ ID NO: 69, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 69; and the VL comprises the amino acid sequence of SEQ ID NO: 75, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 75; (xv) the VH comprises the amino acid sequence of SEQ ID NO: 69, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 69; and the VL comprises the amino acid sequence of SEQ ID NO: 76, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 76; (xvi) the VH comprises the amino acid sequence of SEQ ID NO: 70, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQVTJ-4010PC ID NO: 70; and the VL comprises the amino acid sequence of SEQ ID NO: 72, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 72; (xvi) the VH comprises the amino acid sequence of SEQ ID NO: 70, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 70; and the VL comprises the amino acid sequence of SEQ ID NO: 73, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 73; (xvii) the VH comprises the amino acid sequence of SEQ ID NO: 70, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 70; and the VL comprises the amino acid sequence of SEQ ID NO: 74, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 74; (xix) the VH comprises the amino acid sequence of SEQ ID NO: 70, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 70; and the VL comprises the amino acid sequence of SEQ ID NO: 75, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 75; (xx) the VH comprises the amino acid sequence of SEQ ID NO: 70, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 70; and the VL comprises the amino acid sequence of SEQ ID NO: 76, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 76; (xxi) the VH comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:71; and the VL comprises the amino acid sequence of SEQ ID NO: 72, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 72; (xxi) the VH comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 71; and the VL comprises the amino acid sequence of SEQ ID NO: 73, or an amino acid sequenceVTJ-4010PC at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 73; (xxii) the VH comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 71; and the VL comprises the amino acid sequence of SEQ ID NO: 74, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 74; (xxiv) the VH comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 71; and the VL comprises the amino acid sequence of SEQ ID NO: 75, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 75; or (xv) the VH comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 71; and the VL comprises the amino acid sequence of SEQ ID NO: 76, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 76. 490. The AAV particle of any one of embodiments 1-408, 434-444, 448-450, 454-456, 459-461, 464-471, 477-482, or 485-489, wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 69, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 69; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 69; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NO:69; and (i) the VL comprises the amino acid sequence of SEQ ID NO: 73, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:73; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 73; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NO: 73.VTJ-4010PC 491. The AAV particle of any one of embodiments 1-408, 434-444, 448-450, 454-456, 459-461, 464-471, 477-482, or 485-490, wherein the VH comprises the amino acid sequence of SEQ ID NO: 69 and the VL comprises the amino acid sequence of SEQ ID NO: 73. 492. The AAV particle of any one of embodiments 1-408, 434-443, 445, 448, 449, 451, 454, 455, 457, 459, 460, 462, 464-470, 474, 477-479, 483, or 485-48944-46, 50, or 52-56, wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 67, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 67; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 67; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NO:67; and (i) the VL comprises the amino acid sequence of SEQ ID NO: 72, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:72; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 72; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NO: 72. 493. The AAV particle of any one of embodiments 1-408, 434-443, 446, 448, 449, 452, 454, 455, 457, 459, 460, 462, 464-470, 475, 477-479, 483, or 485-489, wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 70, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 70; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 70; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NO:70; and (i) the VL comprises the amino acid sequence of SEQ ID NO: 72, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:72; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence ofVTJ-4010PC SEQ ID NO: 72; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NO: 72. 494. The AAV particle of any one of embodiments 1-408, 434-443, 447-449, 453-456, 464-470, 476-482, or 485-489, wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 71; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 71; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NO:71; and (i) the VL comprises the amino acid sequence of SEQ ID NO: 73, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:73; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 73; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NO: 73. 495. The AAV particle of any one of embodiments 1-408, 434-443, 447-449, 453-455, 458-460, 463-470, 476-479, or 484-489, wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 71; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 71; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NO:71; and (i) the VL comprises the amino acid sequence of SEQ ID NO: 74, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:74; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 74; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NO: 74.VTJ-4010PC 496. The AAV particle of any one of embodiments 1-408 or 434-495, wherein: (i) the nucleotide sequence encoding the VH comprises the nucleotide sequence of any one of SEQ ID NOs: 156-160, or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto; and / or (i) the nucleotide sequence encoding the VL comprises the nucleotide sequence of any one of SEQ ID NOs: 161-165; or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto. 497. The AAV particle of any one of embodiments 1-408 or 434-496, wherein: (i) the nucleotide sequence encoding the VH comprises the nucleotide sequence of any one of SEQ ID NOs: 156 or 158-160, or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto; and / or (i) the nucleotide sequence encoding the VL comprises the nucleotide sequence of any one of SEQ ID NOs: 161-163; or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto. 498. The AAV particle of any one of embodiments 1-408 or 434-444, 448-450, 454-456, 458-461, 464- 471, 477-482, 485-491, 496, or 497, wherein: (i) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO:158, or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto; and / or (i) the nucleotide sequence encoding the VL comprises the nucleotide sequence of any one of SEQ ID NO: 162; or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto. 499. The AAV particle of any one of embodiments 1-408, 434-443, 445, 448, 449, 451, 454, 455, 457, 459, 460, 462, 464-470, 474, 477-479, 483, 485-489, 492, 496, or 497, wherein: (i) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO:156, or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto; and / orVTJ-4010PC (i) the nucleotide sequence encoding the VL comprises the nucleotide sequence of any one of SEQ ID NO: 161; or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto. 500. The AAV particle of any one of embodiments 1-408, 434-443, 446, 448, 449, 452, 454, 455, 457, 459, 460, 462, 464-470, 475, 477-479, 483, 485-489, 493, 496, or 497, wherein: (i) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO:159, or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto; and / or (i) the nucleotide sequence encoding the VL comprises the nucleotide sequence of any one of SEQ ID NO: 161; or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto. 501. The AAV particle of any one of embodiments 1-408, 434-443, 447-449, 453-456, 458-460, 463-470, 466-482, 484-489, or 494-497, wherein: (i) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO:160, or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto; and / or (i) the nucleotide sequence encoding the VL comprises the nucleotide sequence of any one of SEQ ID NO: 162 or163; or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto. 502. The AAV particle of any one of embodiments 1-408 or 434-501, which does not comprise the amino acid sequence of SEQ ID NO: 1562 and / or the amino acid sequence of SEQ ID NO: 1573. 503. The AAV particle of any one of embodiments 1-408, wherein the antibody moleculecomprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and1566, respectively;VTJ-4010PC (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1555, 1556, 1557, 1568, RVS, and1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and1566, respectively; and optionaly wherein: (i) the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or al of: V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; S at position 14; A at position 16; K at position 19; V at position 20; R at position 38; Q at position 39; A at position 40; Q at position 43; R at position 67; V at position 68; I at position 71; R at position 72; D at position 73; T at position 74; T at position 76; T at position 84; and / or L at position 113, numbered according to SEQ ID NO: 1562; and (i) the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or al of: I at position 2; S at position 7; S at position 12; T at position 14; P at position 15; Q at position 17; P at position 18; Q at position 50; S at position 68; V at position 88; Y at position 92; Q at position 105; and / or V at position 109, numbered according to SEQ ID NO: 1573. 504. The AAV particle of any one of embodiments 1-408, wherein the antibody moleculecomprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1555, 1556, 1557, 1568, RVS, and1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and1566, respectively; and optionaly wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 69, or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 69; and / orVTJ-4010PC (i) the VL comprises the amino acid sequence of SEQ ID NO: 73, or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO:73. 505. The AAV particle of any one of embodiments 1-408, wherein the antibody moleculecomprises a VH regioncomprising the amino acid sequence of SEQ ID NO: 69, and a VL region comprising the amino acid sequence of SEQ ID NO: 73. 506. The AAV particle of any one of embodiments 1-408, wherein the antibody moleculecomprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1555, 1556, 1557, 1568, RVS, and1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and1566, respectively; and optionaly wherein: (i) the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or al of: V at position 5; E at position 6; S at position 7; A at position 9; V at position 11; K at position 12; A at position 16; K at position 19; V at position 20; M at position 48; R at position 67; V at position 68; I at position 70; A at position 76; S at position 77; A at position 79; Y at position 80; M at position 81; E at position 82; R at position 87; T at position 91; and / or T at position 113, numbered according to SEQ ID NO: 1562; (i) the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or al of: S at position 7; T at position 14; Q at position 17; P at position 18; Q at position 42; R at position 44; R at position 50; S at position 68; V at position 88; Y at position 92; and / or Q at position 105, numbered according to SEQ ID NO: 1573.VTJ-4010PC 507. The AAV particle of any one of embodiments 1-408, wherein the antibody moleculecomprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1555, 1556, 1557, 1568, RVS, and1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and1566, respectively; optionaly wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 67, or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 67; and / or (i) the VL comprises the amino acid sequence of SEQ ID NO: 72, or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO:72. 508. The AAV particle of any one of embodiments 1-408, wherein the antibody moleculecomprises a VH region comprising the amino acid sequence of SEQ ID NO: 67, and a VL region comprising the amino acid sequence of SEQ ID NO: 72. 509. The AAV particle of any one of embodiments 1-408, wherein the antibody moleculecomprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1555, 1556, 1557, 1568, RVS, and1566, respectively; orVTJ-4010PC (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and1566, respectively; optionaly wherein: (i) the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or al of: E at position 1; V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; K at position 19; V at position 20; R at position 67; V at position 68; M at position 70; I at position 76; A at position 79; Y at position 80; M at position 81; E at position 82; R at position 85; D at position 89, L at position 113; and / or S at position 115, numbered according to SEQ ID NO: 1562; and (i) the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or al of: S at position 7; T at position 14; Q at position 17; P at position 18; Q at position 42; R at position 44; R at position 50; S at position 68; V at position 88; Y at position 92; and / or Q at position 105, numbered according to SEQ ID NO: 1573. 510. The AAV particle of any one of embodiments 1-408, wherein the antibody moleculecomprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1555, 1556, 1557, 1568, RVS, and1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and1566, respectively; optionaly wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 70, or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 70; and / or (i) the VL comprises the amino acid sequence of SEQ ID NO: 72, or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO:72.VTJ-4010PC 511. The AAV particle of any one of embodiments 1-408, wherein the antibody moleculecomprises a VH regioncomprising the amino acid sequence of SEQ ID NO: 70, and a VL region comprising the amino acid sequence of SEQ ID NO: 72. 512. The AAV particle of any one of embodiments 1-408, wherein the antibody moleculecomprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1555, 1556, 1557, 1568, RVS, and1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and1566, respectively; optionaly wherein: (i) the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or al of: V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; A at position 16; K at position 19; V at position 20; Q at position 43; M at position 48; R at position 67; V at position 68; M at position 70; T at position 76; S at position 77; R at position 87; and / or T at position 91, numbered according to SEQ ID NO: 1562; and (i) the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or al of: I at position 2; S at position 7; S at position 12; T at position 14; P at position 15; Q at position 17; P at position 18; Q at position 50; S at position 68; V at position 88; Y at position 92; Q at position 105; and / or V at position 109, numbered according to SEQ ID NO: 1573. 513. The AAV particle of any one of embodiments 1-408, wherein the antibody moleculecomprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively;VTJ-4010PC (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1555, 1556, 1557, 1568, RVS, and1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and1566, respectively; optionaly wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO:71; and / or (i) the VL comprises the amino acid sequence of SEQ ID NO: 73, or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO:73. 514. The AAV particle of any one of embodiments 1-408, wherein the antibody moleculecomprises a VH regioncomprising the amino acid sequence of SEQ ID NO: 71, and a VL region comprising the amino acid sequence of SEQ ID NO: 73. 515. The AAV particle of any one of embodiments 1-408, wherein the antibody molecule comprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1555, 1556, 1557, 1568, RVS, and1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and1566, respectively; optionaly wherein: (i) the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or al of: V at position...

Claims

VTJ-4010PC We claim:

1. An AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to human tau, wherein the AAV capsid variant comprises an amino acid sequence having the folowing formula: [N1]-[N2]-[N3], wherein: (i) [N1] comprises X1, X2, and X3, wherein at least one of X1, X2, or X3 is G; (i) [N2] comprises the amino acid sequence of SPH; and (ii) [N3] comprises X4, X5, and X6, wherein at least one of X4, X5, or X6 is a basic amino acid, e.g., a K or R; wherein [N1]-[N2]-[N3] is present in hypervariable loop IV; and wherein the AAV capsid variant comprises an amino acid sequence at least 95% identical to the amino acid sequence of positions 203-736 of SEQ ID NO:

138.

2. The AAV particle of claim 1, wherein [N3] comprises SKA, KSG, ARM, VKS, ASR, VKI, KKN, VRM, RKA, KTS, KFG, KIG, KLG, KTT, KTY, KYG, SKD, SKP, TRG, VRG, KRG, GAR, KSA, KSR, SKL, SRA, SKR, SLR, SRG, SSR, FLR, SKW, SKS, WKA, VRR, SKV, SKT, SKG, GKA, TKA, NKA, SKL, SKN, AKA, KTG, KSL, KSE, KSV, KSW, KSN, KHG, KSQ, KSK, KLW, WKG, KMG, KMA, or RSG.

3. The AAV particle of claim 1 or 2, wherein [N2]-[N3] comprises SPHSKA (SEQ ID NO: 941), SPHKSG (SEQ ID NO: 946), SPHARM (SEQ ID NO: 947), SPHVKS (SEQ ID NO: 948), SPHASR (SEQ ID NO: 949), SPHVKI (SEQ ID NO: 950), SPHKKN (SEQ ID NO: 954), SPHVRM (SEQ ID NO: 955), SPHRKA (SEQ ID NO: 956), SPHKFG (SEQ ID NO: 957), SPHKIG (SEQ ID NO: 958), SPHKLG (SEQ ID NO: 959), SPHKTS (SEQ ID NO: 963), SPHKTT (SEQ ID NO: 964), SPHKTY (SEQ ID NO: 965), SPHKYG (SEQ ID NO: 966), SPHSKD (SEQ ID NO: 967), SPHSKP (SEQ ID NO: 968), SPHTRG (SEQ ID NO: 972), SPHVRG (SEQ ID NO: 973), SPHKRG (SEQ ID NO: 974), SPHGAR (SEQ ID NO: 975), SPHKSA (SEQ ID NO: 977), SPHKSR (SEQ ID NO: 951), SPHSKL (SEQ ID NO: 960), SPHSRA (SEQ ID NO: 969), SPHSKR (SEQ ID NO: 978), SPHSLR (SEQ ID NO: 952), SPHSRG (SEQ ID NO: 961), SPHSSR (SEQ ID NO: 970), SPHFLR (SEQ ID NO: 979), SPHSKW (SEQ ID NO: 953), SPHSKS (SEQ ID NO: 962) SPHWKA (SEQ ID NO: 971), SPHVRR (SEQ ID NO: 980), SPHSKT (SEQ ID NO: 1704), SPHSKG (SEQ ID NO: 1705), SPHGKA (SEQ ID NO: 1706), SPHNKA (SEQ ID NO: 1707), SPHSKN (SEQ ID NO: 1708), SPHAKA (SEQ ID NO: 1709), SPHSKV (SEQ ID NO: 1710), SPHKTG (SEQ ID NO: 1711), SPHTKA (SEQ ID NO: 1712), SPHKSL (SEQ ID NO: 1713), SPHKSE (SEQ ID NO: 1714), SPHKSV (SEQ ID NO: 1715), SPHKSW (SEQ ID NO: 1716), SPHKSN (SEQ ID NO: 1717), SPHKHG (SEQ IDVTJ-4010PC NO: 1718), SPHKSQ (SEQ ID NO: 1719), SPHKSK (SEQ ID NO: 1720), SPHKLW (SEQ ID NO: 1721), SPHWKG (SEQ ID NO: 1722), SPHKMG (SEQ ID NO: 1723), SPHKMA (SEQ ID NO: 1724), or SPHRSG (SEQ ID NO: 976).

4. The AAV particle of any one of claims 1-3, wherein [N1] comprises GSG, GHD, VSG, GQD, CSG, GRG, CSH, GQS, GSH, RVG, GSC, GLL, GDD, GHE, GNY, MSG, RNG, TSG, ISG, GPG, ESG, SSG, GNG, ASG, NSG, LSG, GGG, KSG, HSG, GTG, PSG, GSV, RSG, GIG, WSG, DSG, IDG, GLG, DAG, DGG, MEG, ENG, GSA, KNG, KEG, AIG, GYD, GHG, GRD, GND, GPD, GMG, GQV, GHN, GHP, or GHS.

5. The AAV particle of any one of claims 1-4, wherein [N1]-[N2]-[N3] comprises: (i) GSGSPHSKA (SEQ ID NO: 1671), GHDSPHKSG (SEQ ID NO: 1672), GSGSPHARM (SEQ ID NO: 3983), GSGSPHVKS (SEQ ID NO: 3984), GQDSPHKSG (SEQ ID NO: 3985), GSGSPHASR (SEQ ID NO: 3986), GSGSPHVKI (SEQ ID NO: 3987), GSGSPHKKN (SEQ ID NO: 3988), GSGSPHVRM (SEQ ID NO: 3989), VSGSPHSKA (SEQ ID NO: 3990), CSGSPHSKA (SEQ ID NO: 3991), GSGSPHRKA (SEQ ID NO: 3992), CSGSPHKTS (SEQ ID NO: 3993), CSHSPHKSG (SEQ ID NO: 3994), GQSSPHRSG (SEQ ID NO: 3995), GRGSPHASR (SEQ ID NO: 3996), GRGSPHSKA (SEQ ID NO: 3997), GSGSPHKFG (SEQ ID NO: 3998), GSGSPHKIG (SEQ ID NO: 3999), GSGSPHKLG (SEQ ID NO: 4000), GSGSPHKTS (SEQ ID NO: 4001), GSGSPHKTT (SEQ ID NO: 4002), GSGSPHKTY (SEQ ID NO: 4003), GSGSPHKYG (SEQ ID NO: 4004), GSGSPHSKD (SEQ ID NO: 4005), GSGSPHSKP (SEQ ID NO: 4006), GSGSPHTRG (SEQ ID NO: 4007), GSGSPHVRG (SEQ ID NO: 4008), GSHSPHKRG (SEQ ID NO: 4009), GSHSPHKSG (SEQ ID NO: 4010), VSGSPHASR (SEQ ID NO: 4011), VSGSPHGAR (SEQ ID NO: 4012), VSGSPHKFG (SEQ ID NO: 4013), GHDSPHKRG (SEQ ID NO: 4014), GDDSPHKSG (SEQ ID NO: 4015), GHESPHKSA (SEQ ID NO: 4016), GHDSPHKSA (SEQ ID NO: 4017), GNYSPHKIG (SEQ ID NO: 4018), GHDSPHKSR (SEQ ID NO: 4019), GSGSPHSKL (SEQ ID NO: 4020), GSGSPHSRA (SEQ ID NO: 4021), GSGSPHSKR (SEQ ID NO: 4022), GSGSPHSLR (SEQ ID NO: 4023), GSGSPHSRG (SEQ ID NO: 4024), GSGSPHSSR (SEQ ID NO: 4025), RVGSPHSKA (SEQ ID NO: 4026), GSCSPHRKA (SEQ ID NO: 4027), GSGSPHFLR (SEQ ID NO: 4028), GSGSPHSKW (SEQ ID NO: 4029), GSGSPHSKS (SEQ ID NO: 4030), GLLSPHWKA (SEQ ID NO: 4031), GSGSPHVRR (SEQ ID NO: 4032), GSGSPHSKV (SEQ ID NO: 4033), MSGSPHSKA (SEQ ID NO: 4034), RNGSPHSKA (SEQ ID NO: 4035), TSGSPHSKA (SEQ ID NO: 4036), ISGSPHSKA (SEQ ID NO: 4037), GPGSPHSKA (SEQ ID NO: 4038), GSGSPHSKT (SEQ ID NO: 4039), ESGSPHSKA (SEQ IDVTJ-4010PC NO: 4040), SSGSPHSKA (SEQ ID NO: 4041), GNGSPHSKA (SEQ ID NO: 4042), ASGSPHSKA (SEQ ID NO: 4043), NSGSPHSKA (SEQ ID NO: 4044), LSGSPHSKA (SEQ ID NO: 4045), GGGSPHSKA (SEQ ID NO: 4046), KSGSPHSKA (SEQ ID NO: 4047), GGGSPHSKS (SEQ ID NO: 4048), GSGSPHSKG (SEQ ID NO: 4049), HSGSPHSKA (SEQ ID NO: 4050), GTGSPHSKA (SEQ ID NO: 4051), PSGSPHSKA (SEQ ID NO: 4052), GSVSPHGKA (SEQ ID NO: 4053), RSGSPHSKA (SEQ ID NO: 4054), GSGSPHTKA (SEQ ID NO: 4055), GIGSPHSKA (SEQ ID NO: 4056), WSGSPHSKA (SEQ ID NO: 4057), DSGSPHSKA (SEQ ID NO: 4058), IDGSPHSKA (SEQ ID NO: 4059), GSGSPHNKA (SEQ ID NO: 4060), GLGSPHSKS (SEQ ID NO: 4061), DAGSPHSKA (SEQ ID NO: 4063), DGGSPHSKA (SEQ ID NO: 4064), MEGSPHSKA (SEQ ID NO: 4065), ENGSPHSKA (SEQ ID NO: 4066), GSASPHSKA (SEQ ID NO: 4067), GNGSPHSKS (SEQ ID NO: 4068), KNGSPHSKA (SEQ ID NO: 4069), KEGSPHSKA (SEQ ID NO: 4070), AIGSPHSKA (SEQ ID NO: 4071), GSGSPHSKN (SEQ ID NO: 4072), GSGSPHAKA (SEQ ID NO: 4073), GHDSPHKIG (SEQ ID NO: 4074), GYDSPHKSG (SEQ ID NO: 4075), GHESPHKSG (SEQ ID NO: 4076), GHDSPHKTG (SEQ ID NO: 4077), GRGSPHKRG (SEQ ID NO: 4078), GQDSPHKSG (SEQ ID NO: 3985), GHDSPHKSL (SEQ ID NO: 4079), GHGSPHSKA (SEQ ID NO: 4080), GHDSPHKSE (SEQ ID NO: 4082), VSGSPHSKA (SEQ ID NO: 3990), GRDSPHKSG (SEQ ID NO: 4083), GNDSPHKSV (SEQ ID NO: 4084), GQDSPHKIG (SEQ ID NO: 4085), GHDSPHKSV (SEQ ID NO: 4086), GPDSPHKIG (SEQ ID NO: 4087), GPDSPHKSG (SEQ ID NO: 4088), GHDSPHKSW (SEQ ID NO: 4089), GHDSPHKSN (SEQ ID NO: 4090), GMGSPHSKT (SEQ ID NO: 4091), GHDSPHKHG (SEQ ID NO: 4092), GQVSPHKSG (SEQ ID NO: 4093), GDDSPHKSV (SEQ ID NO: 4094), GHNSPHKSG (SEQ ID NO: 4095), GNGSPHKRG (SEQ ID NO: 4096), GHDSPHKYG (SEQ ID NO: 4097), GHDSPHKSQ (SEQ ID NO: 4487), GNDSPHKIG (SEQ ID NO: 4488), GHDSPHKSK (SEQ ID NO: 4489), GHDSPHKLW (SEQ ID NO: 4490), GHPSPHWKG (SEQ ID NO: 4491), GHDSPHKMG (SEQ ID NO: 4492), GHDSPHKMA (SEQ ID NO: 4493), or GHSSPHRSG (SEQ ID NO: 4494); or (i) GSGSPHSKA (SEQ ID NO: 1671), GHDSPHKSG (SEQ ID NO: 1672), or VSGSPHSKA (SEQ ID NO: 3990).

6. The AAV particle of any one of claims 1-5, which further comprises: (i) [N0], wherein [N0] comprises TIN, TEN, TER, SMN, TIM, YLS, GLS, MPE, MEG, MEY, AEW, CEW, ANN, IPE, ADM, IEY, ADY, IET, MEW, CEY, RIN, MEI, LEY, ADW, IEI, DIM, FEQ, MEF, CDQ, LPE, IEN, MES, AEI, VEY, IIN, TSN, IEV, MEM, AEV, MDA, VEW, AEQ, LEW, MEL, MET, MEA, IES, MEV, CEI, ATN, MDG, QEV, ADQ, NMN, IEM, ISN, TGN, QQQ, HDW, IEG, TII,VTJ-4010PC TFP, TEK, EIN, TVN, TFN, SIN, TSY, ELH, AIN, SVN, TDN, TFH, TVH, TSS, TID, TCN, NIN, TEH, AEM, AIK, TDK, TFK, SDQ, TEI, NTN, TET, SIK, TEL, TEA, TAN, TIY, TFS, TES, TTN, TED, TNN, EVH, TIS, TVR, TDR, TIK, NHI, TIP, ESD, TDL, TVP, TVI, AEH, NCL, TVK, NAD, TIT, NCV, TIR, NAL, VIN, TIQ, TEF, TRE, QGE, SEK, NVN, GGE, EFV, SDK, TEQ, EVQ, TEY, NCW, TDV, SDI, NSI, NSL, EVV, TEP, SEL, TWQ, TEV, AVN, GVL, TLN, TEG, TRD, NAI, AEN, AET, ETA, or NNL; and / or (i) [N4], wherein [N4] comprises QNQQ (SEQ ID NO: 4496), WNQQ (SEQ ID NO: 4497), QYYV (SEQ ID NO: 4498), RRQQ (SEQ ID NO: 4499), GCGQ (SEQ ID NO: 4508), LRQQ (SEQ ID NO: 4509), RNQQ (SEQ ID NO: 4510), VNQQ (SEQ ID NO: 4511), FRLQ (SEQ ID NO: 4512), FNQQ (SEQ ID NO: 4513), LLQQ (SEQ ID NO: 4514), SNQQ (SEQ ID NO: 4515), RLQQ (SEQ ID NO: 4516), LNQQ (SEQ ID NO: 4517), QRKL (SEQ ID NO: 4518), LRRQ (SEQ ID NO: 4519), QRLR (SEQ ID NO: 4520), QRRL (SEQ ID NO: 4521), RRLQ (SEQ ID NO: 4522), RLRQ (SEQ ID NO: 4523), SKRQ (SEQ ID NO: 4524), QLYR (SEQ ID NO: 4525), QLTV (SEQ ID NO: 4526), QNKQ (SEQ ID NO: 4527), KNQQ (SEQ ID NO: 4528), QKQQ (SEQ ID NO: 4529), QTQQ (SEQ ID NO: 4530), QNHQ (SEQ ID NO: 4531), QHQQ (SEQ ID NO: 4532), QNQH (SEQ ID NO: 4533), QHRQ (SEQ ID NO: 4534), LTQQ (SEQ ID NO: 4536), QNQW (SEQ ID NO: 4541), QNTH (SEQ ID NO: 4542), RRRQ (SEQ ID NO: 4543), QYQQ (SEQ ID NO: 4544), QNDQ (SEQ ID NO: 4546), QNRH (SEQ ID NO: 4547), RDQQ (SEQ ID NO: 4548), PNLQ (SEQ ID NO: 4549), HVRQ (SEQ ID NO: 4550), PNQH (SEQ ID NO: 4551), HNQQ (SEQ ID NO: 4552), QSQQ (SEQ ID NO: 4553), QPAK (SEQ ID NO: 4554), QNLA (SEQ ID NO: 4555), QNQL (SEQ ID NO: 4556), QGQQ (SEQ ID NO: 4557), LNRQ (SEQ ID NO: 4558), QNPP (SEQ ID NO: 4559), QNLQ (SEQ ID NO: 4560), QDQE (SEQ ID NO: 4561), QDQQ (SEQ ID NO: 4562), HWQQ (SEQ ID NO: 4563), PNQQ (SEQ ID NO: 4564), PEQQ (SEQ ID NO: 4565), QRTM (SEQ ID NO: 4566), LHQH (SEQ ID NO: 4567), QHRI (SEQ ID NO: 4568), QYIH (SEQ ID NO: 4569), QKFE (SEQ ID NO: 4570), QFPS (SEQ ID NO: 4571), QNPL (SEQ ID NO: 4572), QAIK (SEQ ID NO: 4573), QNRQ (SEQ ID NO: 4574), QYQH (SEQ ID NO: 4575), QNPQ (SEQ ID NO: 4576), QHQL (SEQ ID NO: 4577), QSPP (SEQ ID NO: 4578), QAKL (SEQ ID NO: 4579), KSQQ (SEQ ID NO: 4580), QDRP (SEQ ID NO: 4581), QNLG (SEQ ID NO: 4582), QAFH (SEQ ID NO: 4583), QNAQ (SEQ ID NO: 4584), HNQL (SEQ ID NO: 4585), QKLN (SEQ ID NO: 4586), QNVQ (SEQ ID NO: 4587), QAQQ (SEQ ID NO: 4588), QTPP (SEQ ID NO: 4589), QPPA (SEQ ID NO: 4590), QERP (SEQ ID NO: 4591), QDLQ (SEQ ID NO: 4592), QAMH (SEQ ID NO: 4593), QHPS (SEQ ID NO: 4594), PGLQ (SEQ ID NO: 4595), QGIR (SEQ ID NO: 4596), QAPA (SEQ ID NO: 4597), QIPP (SEQ ID NO: 4598), QTQL (SEQ ID NO: 4599), QAPS (SEQ ID NO: 4600), QNTY (SEQ ID NO: 4601), QDKQ (SEQ ID NO: 4602), QNHL (SEQ ID NO: 4603), QIGM (SEQ ID NO: 4604), LNKQ (SEQ ID NO: 4605), PNQL (SEQ ID NO: 4606), QLQQ (SEQ ID NO: 4607), QRMS (SEQ ID NO: 4608),VTJ-4010PC QGIL (SEQ ID NO: 4609), QDRQ (SEQ ID NO: 4610), RDWQ (SEQ ID NO: 4611), QERS (SEQ ID NO: 4612), QNYQ (SEQ ID NO: 4613), QRTC (SEQ ID NO: 4614), QIGH (SEQ ID NO: 4615), QGAI (SEQ ID NO: 4616), QVPP (SEQ ID NO: 4617), QVQQ (SEQ ID NO: 4618), LMRQ (SEQ ID NO: 4619), QYSV (SEQ ID NO: 4620), QAIT (SEQ ID NO: 4621), QKTL (SEQ ID NO: 4622), QLHH (SEQ ID NO: 4623), QNI (SEQ ID NO: 4624), QGHH (SEQ ID NO: 4625), QSKV (SEQ ID NO: 4626), QLPS (SEQ ID NO: 4627), IGKQ (SEQ ID NO: 4628), QAIH (SEQ ID NO: 4629), QHGL (SEQ ID NO: 4630), QFMC (SEQ ID NO: 4631), QNQM (SEQ ID NO: 4632), QHLQ (SEQ ID NO: 4633), QPAR (SEQ ID NO: 4634), QSLQ (SEQ ID NO: 4635), QSQL (SEQ ID NO: 4636), HSQQ (SEQ ID NO: 4637), QMPS (SEQ ID NO: 4638), QGSL (SEQ ID NO: 4639), QVPA (SEQ ID NO: 4640), HYQQ (SEQ ID NO: 4641), QVPS (SEQ ID NO: 4642), RGEQ (SEQ ID NO: 4643), PGQQ (SEQ ID NO: 4644), LEQQ (SEQ ID NO: 4645), QNQS (SEQ ID NO: 4646), QKVI (SEQ ID NO: 4647), QNND (SEQ ID NO: 4648), QSVH (SEQ ID NO: 4649), QPLG (SEQ ID NO: 4650), HNQE (SEQ ID NO: 4651), QIQQ (SEQ ID NO: 4652), QVRN (SEQ ID NO: 4653), PSNQ (SEQ ID NO: 4654), QVGH (SEQ ID NO: 4655), QRDI (SEQ ID NO: 4656), QMPN (SEQ ID NO: 4657), RGLQ (SEQ ID NO: 4658), PSLQ (SEQ ID NO: 4659), QRDQ (SEQ ID NO: 4660), QAKG (SEQ ID NO: 4661), QSAH (SEQ ID NO: 4662), QSTM (SEQ ID NO: 4663), QREM (SEQ ID NO: 4664), QYRA (SEQ ID NO: 4665), QRQQ (SEQ ID NO: 4666), QWQQ (SEQ ID NO: 4667), QRMN (SEQ ID NO: 4668), GDSQ (SEQ ID NO: 4669), QKIS (SEQ ID NO: 4670), PSMQ (SEQ ID NO: 4671), SPRQ (SEQ ID NO: 4672), MEQQ (SEQ ID NO: 4673), QYQN (SEQ ID NO: 4674), QIRQ (SEQ ID NO: 4675), QSVQ (SEQ ID NO: 4676), RSQQ (SEQ ID NO: 4677), QNKL (SEQ ID NO: 4678), QIQH (SEQ ID NO: 4680), PRQQ (SEQ ID NO: 4681), HTQQ (SEQ ID NO: 4682), QRQH (SEQ ID NO: 4683), RNQE (SEQ ID NO: 4684), QSKQ (SEQ ID NO: 4685), QNQP (SEQ ID NO: 4686), QSPQ (SEQ ID NO: 4687), QTRQ (SEQ ID NO: 4688), QNLH (SEQ ID NO: 4689), QNQE (SEQ ID NO: 4690), LNQP (SEQ ID NO: 4691), QNQD (SEQ ID NO: 4692), QNLL (SEQ ID NO: 4693), QLVI (SEQ ID NO: 4694), RTQE (SEQ ID NO: 4695), QTHQ (SEQ ID NO: 4696), QDQH (SEQ ID NO: 4697), QSQH (SEQ ID NO: 4698), VRQQ (SEQ ID NO: 4699), AWQQ (SEQ ID NO: 4700), QSVP (SEQ ID NO: 4701), QNIQ (SEQ ID NO: 4702), LDQQ (SEQ ID NO: 4703), PDQQ (SEQ ID NO: 4704), ESQQ (SEQ ID NO: 4705), QRQL (SEQ ID NO: 4706), QIV (SEQ ID NO: 4707), QKQS (SEQ ID NO: 4708), QSHQ (SEQ ID NO: 4709), QFVV (SEQ ID NO: 4710), QSQP (SEQ ID NO: 4711), QNEQ (SEQ ID NO: 4712), INQQ (SEQ ID NO: 4713), RNRQ (SEQ ID NO: 4714), RDQK (SEQ ID NO: 4715), QWKR (SEQ ID NO: 4716), ENRQ (SEQ ID NO: 4717), QTQP (SEQ ID NO: 4718), QKQL (SEQ ID NO: 4719), RNQL (SEQ ID NO: 4720), ISIQ (SEQ ID NO: 4721), QTVC (SEQ ID NO: 4722), QQIM (SEQ ID NO: 4723), LNHQ (SEQ ID NO: 4724), QNQA (SEQ ID NO: 4725), QMIH (SEQ ID NO: 4726), RNHQ (SEQ ID NO: 4727), or QKMN (SEQ ID NO: 4728).VTJ-4010PC 7. The AAV particle of claim 6, wherein [N0]-[N1]-[N2]-[N3]-[N4] comprises: (i) the amino acid sequence of any one of SEQ ID NOs: 2242-2886; or (i) TENVSGSPHSKAQNQQ (SEQ ID NO: 2283), TERVSGSPHSKAQNQQ (SEQ ID NO: 2272), TINGSGSPHSKAQNQQ (SEQ ID NO: 2242), or TINGHDSPHKSGQNQQ (SEQ ID NO: 2243).

8. The AAV particle of claim 6 or 7, wherein: (i) [N0] is present at amino acids 450-452, numbered according to SEQ ID NO: 981, 982, or 138; (i) [N1] is present at amino acids 453-455, numbered according to SEQ ID NO: 981, 982, or 138; (ii) [N2] is present at amino acids 456-458, numbered according to SEQ ID NO: 981 or 982; (iv) [N3] is present at amino acids 459-461, numbered according to SEQ ID NO: 981 or 982; (v) [N4] is present at amino acids 462-465, numbered according to SEQ ID NO: 981 or 982; and / or (vi) [N0]-[N1]-[N2]-[N3]-[N4] is present at amino acids 450-465, numbered according to SEQ ID NO: 981 or 982.

9. An AAV capsid particle comprising an AAV capsid variant and a nucleic acid encoding a polynucleotide that targets human SOD1, wherein the AAV capsid variant comprises: (i) the amino acid sequence of SPHSKA (SEQ ID NO: 941) in hypervariable loop IV; and (i) an amino acid sequence at least 95% identical to the amino acid sequence of positions 203- 736 of SEQ ID NO:

138.

10. The AAV particle of claim 9, wherein the amino acid sequence of SPHSKA (SEQ ID NO: 941) is present immediately subsequent to amino acid 455, numbered according to SEQ ID NO:

981.

11. The AAV particle of claim 9 or 10, wherein the AAV capsid variant further comprises the amino acid E at position 451, numbered according to SEQ ID NO:

981.

12. The AAV particle of any one of claims 9-11, wherein the AAV capsid variant comprises the amino acid V at position 453, numbered according to SEQ ID NO: 981.VTJ-4010PC 13. The AAV particle of any one of claims 9-12, wherein the AAV capsid variant comprises the amino acid R at position 452, numbered according to SEQ ID NO:

981.

14. The AAV particle of any one of claims 1-13, wherein the AAV capsid variant comprises: (i) an amino acid sequence at least 95% or at least 98% identical to amino acids 203-742 of SEQ ID NOs: 981, 36, or 4500; (i) an amino acid sequence at least 95% or at least 98% identical to amino acids 138-742 of SEQ ID NOs: 981, 36, or 4500; and / or (ii) an amino acid sequence at least 95% or at least 98% identical to the amino acid sequence of SEQ ID NOs: 981, 36, or 4500.

15. The AAV particle of any one of claims 1-14, wherein the AAV capsid variant comprises: (i) the amino acid sequence of amino acids 203-742 of SEQ ID NOs: 981, 36, or 4500; (i) the amino acid sequence of amino acids 138-742 of SEQ ID NOs: 981, 36, or 4500; and / or (ii) the amino acid sequence of SEQ ID NOs: 981, 36, or 4500.

16. An AAV capsid particle comprising an AAV capsid variant and a nucleic acid encoding a polynucleotide that targets human SOD1, wherein the AAV capsid variant comprises: (i) the amino acid sequence of HDSPHK (SEQ ID NO: 2) in hypervariable loop IV; and (i) an amino acid sequence at least 95% identical to the amino acid sequence of positions 203- 736 of SEQ ID NO:

138.

17. The AAV particle of claim 16, wherein the amino acid sequence of HDSPHK (SEQ ID NO: 2) is present immediately subsequent to amino acid 453, numbered according to SEQ ID NO:

982.

18. The AAV particle of any one of claims 1-9, 16, or 17, wherein the AAV capsid variant comprises: (i) an amino acid sequence at least 95% or at least 98% identical to amino acids 203-742 of SEQ ID NOs: 982, 37, or 4505; (i) an amino acid sequence at least 95% or at least 98% identical to amino acids138-742 of SEQ ID NOs: 982, 37, or 4505; and / or (ii) an amino acid sequence at least 95% or at least 98% identical to the amino acid sequence of SEQ ID NOs: 982, 37, or 4505.VTJ-4010PC 19. The AAV particle of any one of claims 1-9 or 16-18, wherein the AAV capsid variant comprises: (i) the amino acid sequence of amino acids 203-742 of SEQ ID NOs: 982, 37, or 4505; (i) the amino acid sequence of amino acids 138-742 of SEQ ID NOs: 982, 37, or 4505; and / or (ii) the amino acid sequence of SEQ ID NOs: 982, 37, or 4505.

20. The AAV particle of any one of claims 1-19, wherein hypervariable loop IV comprises amino acids 449-460, numbered according to SEQ ID NO:

138.

21. The AAV particle of any one of claims 1-20, wherein the AAV capsid variant: (i) has an increased tropism for a CNS cel or tissue, e.g., a brain cel, brain tissue, spinal cord cel, or spinal cord tissue, relative to the tropism of a reference sequence comprising the amino acid sequence of SEQ ID NO: 138; (i) transduces a brain region (e.g., a putamen, caudate, hippocampus, thalamus, substantia nigra, motor cortex, frontal cortex, temporal cortex, cerebral cortex, dentate nucleus, and / or Lateral Geniculate Nucleus (LGN), optionaly wherein the level of transduction is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, or 65-fold greater as compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay, e.g., an immunohistochemistry assay or a qPCR assay, e.g., as described in Example 2 or 6; (ii) is enriched at least about 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, or 210-fold, in the brain compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1 or 4; (iv) has increased tropism for a CNS cel or tissue, e.g., a brain cel, brain tissue, spinal cord cel, or spinal cord tissue, of at least two to three species, e.g., a non-human primate and rodent (e.g., Macaca fascicularis, Chlorocebus sabaeus, Calithrix jacchus, and / or mouse (e.g., BALB / c mice, C57Bl / 6 mice, and / or CD-1 outbred mice), relative to the tropism of a reference sequence comprising the amino acid sequence of SEQ ID NO: 138; (v) is enriched at least about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100-fold, in the brain of at least two to three species, e.g., a non-human primate and rodent (e.g., Macaca fascicularis, Chlorocebus sabaeus, Calithrix jacchus, and / or mouse (e.g., BALB / c mice, C57Bl / 6 mice, and / or CD-1 outbred mice), compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1 or 4;VTJ-4010PC (vi) delivers an increased level of a payload to a brain region, optionaly wherein the level of the payload is increased by at least 5, 10, 15, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, or 70-fold, as compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay, e.g., a qRT-PCR or a qPCR assay (e.g., as described in Example 1), optionaly wherein the brain region is a midbrain region (e.g., the hippocampus or thalamus), frontal cortex, temporal cortex, motor cortex, cerebral cortex, caudate, putamen, dentate nucleus, substantia nigra, or the brainstem; (vi) delivers an increased level of viral genomes to a brain region, optionaly wherein the level of viral genomes is increased by at least 5, 10, 15, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50-fold, as compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay, e.g., a qRT-PCR or a qPCR assay (e.g., as described in Example 1), optionaly wherein the brain region is a putamen, caudate, hippocampus, thalamus, substantia nigra, motor cortex, frontal cortex, temporal cortex, cerebral cortex, dentate nucleus, and / or Lateral Geniculate Nucleus (LGN)); (vii) is enriched at least about 5, 10, 15, 20, 25, 30, or 35-fold, in the spinal cord compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 2, optionaly wherein the region of the spinal cord is a thoracic spinal cord region, cervical spinal cord region, C5 ventral horn region, lumbar spinal cord region, or L5 ventral horn region; (ix) shows preferential transduction in a brain region relative to the transduction in the dorsal root ganglia (DRG) and / or the liver; and / or (x) is capable of transducing neuronal cels and / or non-neuronal cels (e.g., astrocytes).

22. The isolated AAV particle of any one of claims 1-21, wherein the antibody molecule: (i) binds to the N-terminal region or an epitope within the N-terminal region of a human tau protein, (i) binds to the mid-domain region or an epitope within the mid-domain region of a human tau protein, (ii) binds to the C-terminal region or an epitope within the C-terminal region of a human tau protein, (iv) binds to the microtubule-binding domain or an epitope within the microtubule-binding domain of a human tau protein, (v) binds to a region that overlaps with the N-terminal domain and the mid-domain of a human tau protein,VTJ-4010PC (vi) binds to a region that overlaps with the mid-domain and the microtubule-binding domain of a human tau protein, or (vi) binds to a region that overlaps with the mid-domain and the C-terminal domain of a human tau protein.

23. The isolated AAV particle of any one of claims 1-22, wherein the antibody molecule comprises a heavy chain variable region (VH) comprising an HC CDR1, an HC CDR2, and an HC CDR3, and a light chain variable region (VL) comprising an LC CDR1, an LC CDR2, and an LC CDR3, wherein: (i) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1631, 1551, and 1552, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1632, 1633, and 1566, respectively; (i) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of X1X2WMH (X1 is R or I; X2 is Y or F) and SEQ ID NOs: 1635 and 1552, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1636, 1633, and 1566, respectively; or (ii) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1637, 1638, and 1557, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1639, 1569, and 1566, respectively, wherein the antibody binds to a region of a human tau protein comprising residues 409-436, numbered according to SEQ ID NO: 9200.

24. The isolated AAV particle of any one of claims 1-23, wherein the antibody molecule comprises a heavy chain variable region (VH) comprising an HC CDR1, an HC CDR2, and an HC CDR3, and a light chain variable region (VL) comprising an LC CDR1, an LC CDR2, and an LC CDR3, wherein: (i) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1553, 1554, and 1552, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1567, 1565, and 1566, respectively; (i) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1576, 1577, and 1552, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1585, 1565, and 1566, respectively; or (ii) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1594, 1595, and 1552, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1601, 1602, and 1566, respectively.VTJ-4010PC 25. The isolated AAV particle of any one of claims 1-22, wherein the antibody molecule comprises a heavy chain variable region (VH) comprising an HC CDR1, an HC CDR2, and an HC CDR3, and a light chain variable region (VL) comprising an LC CDR1, an LC CDR2, and an LC CDR3, wherein: (i) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1503, 1504, and 1502, respectively; and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1514, 1515, and 1516, respectively; (i) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1528, 1529, and 1527, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1539, 1540, and 1541, respectively; (ii) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1611, 1612, and 1610, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1621, 1622, and 1623, respectively; or (iv) the HC CDR1, HC CDR2, and HC CDR3 comprise the amino acid sequence of any of the HC CDR sequences of Tables 9-16; and the LC CDR1, LC CDR2, LC CDR3 comprise the amino acid sequence of any of the LC CDR sequences of Tables 9-16.

26. The isolated AAV particle of any one of claims 1-24, wherein: (i) the VH of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 69, 67, 70, 71, 1562, 1583, or 1599 or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; (i) the VH of the antibody molecule comprises an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications of the amino acid sequence of SEQ ID NO: 69, 67, 70, 71, 1562, 1583, or 1599; or (ii) the VH of the antibody molecule comprises an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 158, 156, 159, 160, 1563, 1584, or 1600, or a nucleotide sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto.

27. The isolated AAV particle of any one of claims 1-22 or 25, wherein: (i) the VH of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1512, 1537, or 1619 or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto;VTJ-4010PC (i) the VH of the antibody molecule comprises an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications of the amino acid sequence of SEQ ID NO: 1512, 1537, or 1619; (ii) the VH of the antibody molecule comprises an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 1513, 1538, or 1620, or a nucleotide sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; or (iv) the VH of the antibody molecule comprises an amino acid sequence of any VH provided in Tables 9-16, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; or an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications of the amino acid sequence of any VH provided in Tables 9-16.

28. The isolated AAV particle of any one of claims 1-24 or 26, wherein: (i) the VL of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 73, 72, 74, 1573, 1591, or 1606, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; (i) the VL of the antibody molecule comprises an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications of the amino acid sequence of SEQ ID NO: 73, 72, 74, 1573, 1591, or 1606; or (ii) the VL of the antibody molecule comprises an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 162, 161, 163, 1574, 1592, or 1607, or a nucleotide sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto.

29. The isolated AAV particle of any one of claims 1-22, 25, or 27, wherein: (i) the VL of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1523, 1548, or 1629, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; (i) the VL of the antibody molecule comprises an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications of the amino acid sequence of SEQ ID NO: 1523, 1548, or 1629; (ii) the VL of the antibody molecule comprises an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 1524, 1549, or 1630, or a nucleotide sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; orVTJ-4010PC (iv) the VL of the antibody molecule comprises the amino acid sequence of any VL provided in Tables 9-16, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; or an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications of the amino acid sequence of any VL provided in Tables 9-16.

30. The isolated AAV particle of any one of claims 1-24, 26, or 28, wherein: (i) the VH of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 69 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the VL of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 73 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof; (i) the VH of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 67 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the VL of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 72 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof; (ii) the VH of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 70 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the VL of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 72 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof; (iv) the VH of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 71 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the VL of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 73 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof; (v) the VH of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 71 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequenceVTJ-4010PC identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the VL of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 74 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof; or (vi) the VH of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1562 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the VL of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1573 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof.

31. The isolated AAV particle of any one of claims 1-22, 25, 27, or 29, wherein: (i) the VH of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1512 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the VL of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1523 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof; (i) the VH of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1537 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the VL of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1548 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof; (ii) the VH of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1583 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the VL of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1591 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof; (iv) the VH of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1559 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequenceVTJ-4010PC identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the VL of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1606 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof; or (v) the VH of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1619 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the VL of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1629 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof.

32. The isolated AAV particle of any one of claims 1-24, 26, 28, or 30, wherein the antibody molecule comprises: (i) a VH encoded by the nucleotide sequence of SEQ ID NO: 158, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 158; and a VL encoded by the nucleotide sequence of SEQ ID NO: 162, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 162; (i) a VH encoded by the nucleotide sequence of SEQ ID NO: 156, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 156; and a VL encoded by the nucleotide sequence of SEQ ID NO: 161, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 161; (ii) a VH encoded by the nucleotide sequence of SEQ ID NO: 159, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 159; and a VL encoded by the nucleotide sequence of SEQ ID NO: 161, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 161; (iv) a VH encoded by the nucleotide sequence of SEQ ID NO: 160, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 160; and a VL encoded by the nucleotide sequence of SEQ ID NO: 162, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 162; (v) a VH encoded by the nucleotide sequence of SEQ ID NO: 160, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 160; and a VLVTJ-4010PC encoded by the nucleotide sequence of SEQ ID NO: 163, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 163; or (vi) a VH encoded by the nucleotide sequence of SEQ ID NO: 1563, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1563; and a VL encoded by the nucleotide sequence of SEQ ID NO: 1574, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1574.

33. The isolated AAV particle of any one of claims 1-22, 25, 27, 29, or 31, wherein the antibody molecule comprises: (i) a VH encoded by the nucleotide sequence of SEQ ID NO: 1513, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1513; and a VL encoded by the nucleotide sequence of SEQ ID NO: 1524, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1524; (i) a VH encoded by the nucleotide sequence of SEQ ID NO: 1538, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1538; and a VL encoded by the nucleotide sequence of SEQ ID NO: 1549, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1549; (ii) a VH encoded by the nucleotide sequence of SEQ ID NO: 1584, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1584; and a VL encoded by the nucleotide sequence of SEQ ID NO: 1592, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1592; (iv) a VH encoded by the nucleotide sequence of SEQ ID NO: 1600, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1600; and a VL encoded by the nucleotide sequence of SEQ ID NO: 1607, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1607; or (v) a VH encoded by the nucleotide sequence of SEQ ID NO: 1620, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1620; and a VL encoded by the nucleotide sequence of SEQ ID NO: 1630, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1630.VTJ-4010PC 34. The isolated AAV particle of any one of claims 1-22, wherein the antibody molecule comprises a heavy chain variable region (VH) comprising an HC CDR1, an HC CDR2, and an HC CDR3, and a light chain variable region (VL) comprising an LC CDR1, an LC CDR2, and an LC CDR3, wherein: (i) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1188, 1189, and 1190, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1195, 1196, and 1197, respectively; (i) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1220, 1221, and 1222, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1226, DVS, and 1228, respectively; (ii) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1239, 1207, and 1240, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1195, KIS, and 1212, respectively; (iv) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1206, 1207, and 1208, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1195, KIS, and 1212, respectively; (v) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1188, 1248, and 1249, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1253, KDS, and 1255, respectively; (vi) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1401, 1402, and 1403, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1406, WAS, and 1407, respectively; or (vi) the HCDR1, HCDR2, and / or HCDR3 sequences, and / or LCDR1, LCDR2, and / or LCDR3 sequences of any one of (i)-(vi), with at most one, two, or three substitutions (e.g., conservative amino acid substitutions) in each CDR.

35. The isolated AAV particle of any one of claims 1-22 and 34, wherein: (i) the VH of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1202, 1235, 1244, 1216, 1260, or 1411, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; (i) the VH of the antibody molecule comprises an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications of the amino acid sequence of SEQ ID NO: 1202, 1235, 1244, 1216, 1260, or 1411;VTJ-4010PC (ii) the VH of the antibody molecule comprises an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 1204, 1237, 1246, 1218, 1263, or 1413, or a nucleotide sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; or (iv) the VH of the antibody molecule comprises an amino acid sequence of any VH provided in Tables 17-19, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; or an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications of the amino acid sequence of any VH provided in Tables 17- 19.

36. The isolated AAV particle of any one of claims 1-22, 34, or 35, wherein: (i) the VL of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1203, 1236, 1245, 1217, 1261, or 1412, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; (i) the VL of the antibody molecule comprises an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications of the amino acid sequence of SEQ ID NO: 1203, 1236, 1245, 1217, 1261, or 1412; (ii) the VL of the antibody molecule comprises an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 1205, 1238, 1247, 1219, 1264, or 1414, or a nucleotide sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; or (iv) the VL of the antibody molecule comprises the amino acid sequence of any VL provided in Tables 17-19, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; or an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications of the amino acid sequence of any VL provided in Tables 17-19.

37. The isolated AAV particle of any one of claims 1-22 or 34-36, wherein: (i) the VH of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1202 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the VL of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1203 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof; (i) the VH of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1235 orVTJ-4010PC an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the VL of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1236 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof; (ii) the VH of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1244 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the VL of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1245 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof; (iv) the VH of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1216 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the VL of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1217 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof; (v) the VH of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1260 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the VL of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1261 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof; or (vi) the VH of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1411 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the VL of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 1412 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof.

38. The isolated AAV particle of any one of claims 1-22 or 34-37, wherein the antibody molecule comprises:VTJ-4010PC (i) a VH encoded by the nucleotide sequence of SEQ ID NO: 1204, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1204; and a VL encoded by the nucleotide sequence of SEQ ID NO: 1205, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1205; (i) a VH encoded by the nucleotide sequence of SEQ ID NO: 1237, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1237; and a VL encoded by the nucleotide sequence of SEQ ID NO: 1238, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1238; (ii) a VH encoded by the nucleotide sequence of SEQ ID NO: 1246, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1246; and a VL encoded by the nucleotide sequence of SEQ ID NO: 1247, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1247; (iv) a VH encoded by the nucleotide sequence of SEQ ID NO: 1218, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1218; and a VL encoded by the nucleotide sequence of SEQ ID NO: 1219, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1219; (v) a VH encoded by the nucleotide sequence of SEQ ID NO: 1263, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1263; and a VL encoded by the nucleotide sequence of SEQ ID NO: 1264, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1264; or (vi) a VH encoded by the nucleotide sequence of SEQ ID NO: 1413, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1413; and a VL encoded by the nucleotide sequence of SEQ ID NO: 1414, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 1414.

39. The isolated AAV particle of any one of claims 1-38, wherein the antibody molecule is a ful length antibody, a bispecific antibody, an Fab, an F(ab')2, an Fv, a single chain Fv fragment (scFv), a diabody, a single chain antibody, an intrabody, a nanobody, or a camelid antibody.

40. The isolated AAV particle of any one of claims 1-39, wherein the antibody molecule comprises:VTJ-4010PC (i) a heavy chain constant region selected from human IgG1, human IgG2, human IgG3, human IgG4, murine IgG1, murine IgG2a, murine IgG2b, murine IgG2c, and murine IgG3; and / or a light chain constant region selected from the light chain constant regions of kappa or lambda, (i) a human IgG4 constant region, comprising an amino acid other than serine at position 228 according to EU numbering; or (ii) a human IgG4 constant region, comprising a serine to proline substitution (e.g., mutation) at position 228 according to EU numbering.

41. The isolated AAV particle of any one of claims 1-40, wherein the antibody molecule comprises: (i) a heavy chain constant region comprising the amino acid sequence of any one of SEQ ID NOs: 1457-1459, 1461-1464, 1470, 1472-1474, 1483, or 1486, or a sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to any one of SEQ ID NOs: 1457-1459, 1461-1464, 1470, 1472- 1474, 1483, or 1486, an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications, to the amino acid sequence of any one of SEQ ID NOs: 1457-1459, 1461-1464, 1470, 1472-1474, 1483, or 1486, or an amino acid sequence of a heavy chain constant region provided in Table 20; and / or (i) a light chain constant region (CL) comprising the amino acid sequence of any one of SEQ ID NOs: 1465, 1467-1469, 1475-1480, 1485, or 1491, or a sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to any one of SEQ ID NOs: 1465, 1467-1469, 1475-1480, 1485, or 1491, or an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications, to the amino acid sequence of any one of SEQ ID NOs: 1465, 1467-1469, 1475- 1480, 1485, or 1491, or an amino acid sequence of a light chain constant region provided in Table 20.

42. The isolated AAV particle of any one of claims 1-24, 26, 28, 30, 32, or 39-41, wherein: (i) the heavy chain of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 172, 170, 173, 174, 8, or 65, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; (i) the heavy chain of the antibody molecule comprises an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications of the amino acid sequence of SEQ ID NO: 172, 170, 173, 174, 8, or 65; (ii) the heavy chain of the antibody molecule comprises an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 182, 180, 183, 184, 10, or 191, or a nucleotide sequence having atVTJ-4010PC least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; or (iv) the heavy chain of the antibody molecule comprises an amino acid sequence of any heavy chain provided in Tables 13-16, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; or an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications of the amino acid sequence of any heavy chain provided in Tables 13-16.

43. The isolated AAV particle of any one of claims 1-24, 26, 28, 30, 32, or 39-42, wherein: (i) the light chain of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 176, 175, 177, 78, or 66, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; (i) the light chain of the antibody molecule comprises an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications of the amino acid sequence of SEQ ID NO: 176, 175, 177, 78, or 66; (ii) the light chain of the antibody molecule comprises an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 186, 185, 187, 80 or 193, or a nucleotide sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; or (iv) the light chain of the antibody molecule comprises the amino acid sequence of any light chain provided in Tables 13-16, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; or an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications of the amino acid sequence of any light chain provided in Tables 13-16.

44. The isolated AAV particle of any one of claims 1-24, 26, 28, 30, 32, or 39-43, wherein: (i) the heavy chain of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 172 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the light chain of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 176 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof; (i) the heavy chain of the antibody molecule comprises the amino acid sequence of SEQ ID NO:VTJ-4010PC 170 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the light chain of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 175 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof; (ii) the heavy chain of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 173 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the light chain of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 175 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof; (iv) the heavy chain of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 174 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the light chain of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 176 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof; or (v) the heavy chain of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 174 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof, and the light chain of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 177 or an amino acid sequence either having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto or having at least one, two or three modifications, but not more than 10 modifications thereof.

45. The isolated AAV particle of any one of claims 1-24, 26, 28, 30, 32, or 39-44, wherein the antibody molecule comprises: (i) a heavy chain encoded by the nucleotide sequence of SEQ ID NO: 182, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 182; and aVTJ-4010PC light chain encoded by the nucleotide sequence of SEQ ID NO: 186, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 186; (i) a heavy chain encoded by the nucleotide sequence of SEQ ID NO: 180, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 180; and a light chain encoded by the nucleotide sequence of SEQ ID NO: 185, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 185; (ii) a heavy chain encoded by the nucleotide sequence of SEQ ID NO: 183, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 183; and a light chain encoded by the nucleotide sequence of SEQ ID NO: 185, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 185; (iv) a heavy chain encoded by the nucleotide sequence of SEQ ID NO: 184, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 184; and a light chain encoded by the nucleotide sequence of SEQ ID NO: 186, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 186; or (v) a heavy chain encoded by the nucleotide sequence of SEQ ID NO: 184, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO: 184; and a light chain encoded by the nucleotide sequence of SEQ ID NO: 187, or a nucleotide sequence having at least 90% (e.g., 95, 96, 97, 98, or 99%) sequence identity to SEQ ID NO:

187.

46. The isolated AAV particle of any one of claims 1-45, further comprising a viral genome comprising a promoter operably linked to the nucleic acid comprising the transgene encoding the antibody molecule, wherein the promoter comprises a tissue specific promoter or a ubiquitous promoter.

47. The isolated AAV particle of claim 46, wherein the promoter comprises: (i) a chicken β-actin (CBA) promoter and / or its derivative CAG, an EF-1a promoter, a CMV immediate-early enhancer and / or promoter, a β glucuronidase (GUSB) promoter, a ubiquitin C (UBC) promoter, a neuron-specific enolase (NSE), a platelet-derived growth factor (PDGF) promoter, a platelet- derived growth factor B-chain (PDGF-β) promoter, an intercelular adhesion molecule 2 (ICAM-2) promoter, a synapsin (Syn) promoter, a methyl-CpG binding protein 2 (MeCP2) promoter, a Ca2+ / calmodulin-dependent protein kinase I (CaMKI) promoter, a metabotropic glutamate receptor 2 (mGluR2) promoter, a neurofilament light (NFL) or heavy (NFH) promoter, a β-globin minigene nβ2 promoter, a preproenkephalin (PPE) promoter, an enkephalin (Enk) and excitatory amino acid transporterVTJ-4010PC 2 (EAAT2) , a glial fibrilary acidic protein (GFAP) promoter, a myelin basic protein (MBP) promoter, a cardiovascular promoter (e.g., αMHC, cTnT, and CMV-MLC2k), a liver promoter (e.g., hAAT, TBG), a skeletal muscle promoter (e.g., desmin, MCK, C512) or a fragment, e.g., a truncation, or a functional variant thereof; or (i) the nucleotide sequence of any one of SEQ ID NOs: 9000, 9001, 9003, 9004, 9008, 9009, 9011-9020, GCATG , CGTGAG , GT, GCTCCGGT, or GTAAG, or a nucleotide sequence at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identical thereto or any of the sequences provided in Table 8.

48. The isolated AAV particle of claim 46 or 47, wherein the viral genome further comprises an enhancer, optionaly wherein the enhancer is a CMV immediate-early (CMVie) enhancer.

49. The isolated AAV particle of any one of claims 46-48, wherein the viral genome further comprises: (i) a polyadenylation (polyA) signal region, optionaly wherein the polyA signal region comprises the nucleotide sequence of any of SEQ ID NO: 1138, or a nucleotide sequence with at least 95% identity thereto; (i) an ITR sequence, optionaly wherein: (a) the ITR sequence is positioned 5’ relative to the encoded payload and / or the ITR sequence is positioned 3’ relative to the encoded; and / or (b) the ITR sequence comprises a nucleotide sequence of SEQ ID NO: 1126 or 1139, or a nucleotide sequence with at least 80%, 85%, 90%, or 95% sequence identity thereto; (ii) at least 1, 2, or 3 intron regions, optionaly wherein the intron region comprises the nucleotide sequence of SEQ ID NO: 1129, or a nucleotide sequence with at least 95% identity thereto; (iv) at least 1, 2, or 3 exon regions; optionaly wherein each exon region independently encodes a VH, VL, heavy chain constant region, light chain constant region, heavy chain, or light chain of the antibody molecule, e.g., an antibody molecule or constant region provided in any one of Tables 9-20, or a nucleotide sequence with at least 95% identity thereto; and / or (v) a Kozak sequence, optionaly wherein the Kozak sequence comprises the nucleotide sequence of GCCGCCACCATG (SEQ ID NO: 9021) or GAGGAGCCACC (SEQ ID NO: 9022).

50. The isolated AAV particle of any one of claims 46-49, wherein the viral genome further comprises a nucleotide sequence encoding at least 1-5 copies of an miR binding site, e.g., at least 1, 2, 3, 4, or 5VTJ-4010PC copies, optionaly wherein the at least 1-5 copies of the encoded miR binding sites are continuous, e.g., not separated by a spacer; or are separated by a spacer (optionaly wherein the spacer comprises the nucleotide sequence of GATAGTTA).

51. The isolated AAV particle of claim 50, wherein the encoded miR binding site comprises a miR183 binding site, a miR122 binding site, a miR-1 binding site, a miR-142-3p, or a combination thereof, optionaly wherein: (i) the encoded miR183 binding site comprises the nucleotide sequence of SEQ ID NO: 1497, or a nucleotide sequence having at least 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity thereto; or a nucleotide sequence having at least one, two, three, four, five, six, or seven modifications, but no more than ten modifications of SEQ ID NO: 1497; (i) the encoded miR122 binding site comprises the nucleotide sequence of SEQ ID NO: 1494, or a nucleotide sequence having at least 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity thereto; or a nucleotide sequence having at least one, two, three, four, five, six, or seven modifications, but no more than ten modifications of SEQ ID NO: 1494; (ii) the encoded miR-1 binding site comprises the nucleotide sequence of SEQ ID NO: 4679, or a nucleotide sequence having at least 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity thereto; or a nucleotide sequence having at least one, two, three, four, five, six, or seven modifications, but no more than ten modifications of SEQ ID NO: 4679; and / or (iv) the encoded miR-142-3p binding site comprises the nucleotide sequence of SEQ ID NO: 1496, or a nucleotide sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity thereto; or a nucleotide sequence having at least one, two, three, four, five, six, or seven modifications, but no more than ten modifications of SEQ ID NO: 1496.

52. The isolated AAV particle of any one of claims 46-51, wherein the viral genome comprises in 5’ to 3’ order: (i) a 5’ adeno-associated (AAV) ITR, optionaly wherein the 5’ AAV ITR comprises the nucleotide sequence of SEQ ID NO: 1126, or a nucleotide sequence at least 95% identical thereto; (i) a CMVie enhancer, optionaly wherein the CMVie enhancer comprises the nucleotide sequence of SEQ ID NO: 1127, or a nucleotide sequence at least 95% identical thereto;VTJ-4010PC (ii) a CBA promoter or functional variant thereof, optionaly wherein the CBA promoter or functional variant thereof comprises the nucleotide sequence of SEQ ID NO: 1128, or a nucleotide sequence at least 95% identical thereto; (iv) an intron, optionaly wherein the intron comprises the nucleotide sequence of SEQ ID NO: 1129, or a nucleotide sequence at least 95% identical thereto; (v) a nucleotide sequence encoding a signal sequence, optionaly wherein the nucleotide sequence encoding the signal sequence comprises the nucleotide sequence of SEQ ID NO: 1130, or a nucleotide sequence at least 95% identical thereto; (vi) a transgene encoding a heavy chain variable region (VH) of the antibody molecule, wherein the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 1131 or a nucleotide sequence at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) identical thereto; (vi) a nucleotide sequence encoding an IgG1 heavy chain constant region, optionaly wherein the nucleotide sequence encoding the IgG1 heavy chain constant region comprises the nucleotide sequence of SEQ ID NO: 1132, or a nucleotide sequence at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) identical thereto; (vii) a furin cleavage site, optionaly wherein the furin cleavage site comprises the nucleotide sequence of SEQ ID NO: 1133, or a nucleotide sequence at least 95% identical thereto; (ix) a T2A linker, optionaly wherein the T2A linker comprises the nucleotide sequence of SEQ ID NO: 1134, or a nucleotide sequence at least 95% identical thereto; (x) a nucleotide sequence encoding a signal sequence, optionaly wherein the nucleotide sequence encoding the signal sequence comprises the nucleotide sequence of SEQ ID NO: 1135, or a nucleotide sequence at least 95% identical thereto; (xi) a transgene encoding a light chain variable region (VL) of the antibody molecule, wherein the nucleotide sequence encoding the VL comprises the nucleotide sequence of SEQ ID NO: 1136 or a nucleotide sequence at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) identical thereto; (xi) a nucleotide sequence encoding an IgG kappa light chain constant region, optionaly wherein the nucleotide sequence encoding the IgG kappa light chain constant region comprises the nucleotide sequence of SEQ ID NO: 1137, or a nucleotide sequence at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) identical thereto; (xii) a polyA signal region, optionaly wherein the polyA signal region comprises the nucleotide sequence of SEQ ID NO: 1138, or a nucleotide sequence at least 95% identical thereto; andVTJ-4010PC (xiv) a 3’ AAV ITR, optionaly wherein the 3’ AAV ITR comprises the nucleotide sequence of SEQ ID NO: 1139, or a nucleotide sequence at least 95% identical thereto.

53. The isolated AAV particle of any one of claims 46-52, wherein the viral genome comprises the nucleotide sequence of SEQ ID NO: 1125, or a nucleotide sequence at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) identical thereto.

54. The isolated AAV particle of any one of claims 46-53, wherein the viral genome: (i) is single stranded; (i) further comprises a nucleic acid encoding a capsid protein, e.g., a structural protein, wherein the capsid protein comprises a VP1 polypeptide, a VP2 polypeptide, and / or a VP3 polypeptide, optionaly wherein the VP1 polypeptide, the VP2 polypeptide, and / or the VP3 polypeptide are encoded by at least one Cap gene; and / or (ii) further comprises a nucleic acid encoding a Rep protein, e.g., a non-structural protein, wherein the Rep protein comprises a Rep78 protein, a Rep68, Rep52 protein, and / or a Rep40 protein. optionaly wherein the Rep78 protein, the Rep68 protein, the Rep52 protein, and / or the Rep40 protein are encoded by at least one Rep gene.

55. A cel comprising the isolated AAV particle of any one of claims 1-54, optionaly wherein the cel is a mammalian cel, e.g., an HEK293 cel, an insect cel, e.g., an Sf9 cel, or a bacterial cel.

56. A method of making the isolated AAV particle of any one of claims 1-54, the method comprising (i) providing a host cel comprising the viral genome; and (i) incubating the host cel under conditions suitable to enclose the viral genome in the AAV capsid variant; thereby making the isolated AAV particle.

57. A pharmaceutical composition comprising the isolated AAV particle of any one of claims 1-54, and a pharmaceuticaly acceptable excipient.VTJ-4010PC 58. A method of delivering an antibody molecule which binds to human tau to a subject, comprising administering an efective amount of the pharmaceutical composition of claim 57 or the isolated AAV particle of any one of claims 1-54, thereby delivering the antibody molecule to the subject.

59. The method of claim 58, wherein the subject has, has been diagnosed with having, or is at risk of having: (i) a disease associated with tau expression or activity; (i) a neurological disorder (e.g., a neurodegenerative disorder); (ii) a tau-related disease (e.g., a tauopathy).

60. A method of treating a subject having or diagnosed with having a disease associated with human tau expression or activity comprising administering an effective amount of the pharmaceutical composition of claim 57 or the isolated AAV particle of any one of claims 1-54, thereby treating the disease associated with human tau expression in the subject.

61. A method of treating a subject having or diagnosed with having a neurological disorder (e.g., a neurodegenerative disorder), comprising administering an efective amount of the pharmaceutical composition of claim 57 or the isolated AAV particle of any one of claims 1-54, thereby treating the neurodegenerative disorder in the subject.

62. A method of treating a subject having or diagnosed with having a tauopathy, comprising administering an efective amount of the pharmaceutical composition of claim 57 or the isolated AAV particle of any one of claims 1-54, thereby treating the tauopathy in the subject.

63. The method of any one of claims 59-62, wherein the disease associated with tau expression or activity, the neurological disorder (e.g., neurodegenerative disorder), or tauopathy comprises Alzheimer’s disease (AD), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration (FTLD), frontotemporal dementia (FTD), chronic traumatic encephalopathy (CTE), progressive Supranuclear Palsy (PSP), Down’s syndrome, Pick’s disease, corticobasal degeneration (CBD), corticobasal syndrome, amyotrophic lateral sclerosis (ALS), prion diseases, Creutzfeldt-Jakob disease (CJD), multiple system atrophy, tangle-only dementia, or progressive subcortical gliosis.VTJ-4010PC 64. The method of any one of claims 58-63, wherein the AAV particle is administered to the subject: (i) intravenously, intracerebraly, via intrathalamic (ITH) administration, intramuscularly, intrathecaly, intracerebroventricularly, via intraparenchymal administration, via focused ultrasound (FUS), e.g., coupled with the intravenous administration of microbubbles (FUS-MB), or MRI-guided FUS coupled with intravenous administration, via intra-cisterna magna injection (ICM), or via dual ITH and ICM administration; or (i) via intravenous administration, optionaly wherein the intravenous administration is via focused ultrasound (FUS), e.g., coupled with the intravenous administration of microbubbles (FUS-MB), or MRI-guided FUS coupled with intravenous administration.

65. The method of any one of claims 58-64, further comprising administration of an additional therapeutic agent and / or therapy suitable for treatment or prevention of the disease associated with tau expression or activity, a neurological disorder (e.g., a neurodegenerative disorder), or a tauopathy, optionaly wherein the additional therapeutic agent comprises enzyme replacement therapy (ERT) (e.g., imiglucerase, velaglucerase alfa, or taliglucerase alfa); substrate reduction therapy (SRT) (e.g., eliglustat or miglustat), blood transfusion, levodopa, carbidopa, Safinamide, dopamine agonists (e.g., pramipexole, rotigotine, or ropinirole), anticholinergics (e.g., benztropine or trihexyphenidyl), cholinesterase inhibitors (e.g., rivastigmine, donepezil, or galantamine), an N-methyl-d-aspartate (NMDA) receptor antagonist (e.g., memantine), or a combination thereof.

66. The pharmaceutical composition of claim 57 or the isolated AAV particle of any one of claims 1-54, for use in the manufacture of a medicament.

67. The pharmaceutical composition of claim 57 or the isolated AAV particle of any one of claims 1-54, for use in the treatment of a disease associated with tau expression or activity, a neurological disorder (e.g., a neurodegenerative disorder), or a tauopathy.

68. Use of the pharmaceutical composition of claim 57 or the isolated AAV particle of any one of claims 1-54, in the manufacture of a medicament for the treatment of a disease associated with tau expression or activity, a neurological disorder (e.g., a neurodegenerative disorder), or a tauopathy.

Images